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ABSTRACT
QUADRUPEDAL GAIT IN HUMANS:
IDENTIFICATION AND PARTIAL
CHARACTERIZATION OF A NOVEL GENE WD
REPEAT DOMAIN 81 (WDR81 )
Süleyman smail Gülsüner
Ph.D. in Molecular Biology and Genetics
Supervisor: Prof. Dr. Tayfun Özçelik
November, 2011
Identication of disease genes responsible for cerebellar phenotypes provides
mechanistic insights into the development of cerebellum. Neural pathways in-
volved in bipedal gait in humans is not completely understood. Cerebellar ataxia,
mental retardation, and disequilibrium syndrome (CAMRQ) is a rare neurode-
velopmental disorder accompanied by quadrupedal gait, dysarthric speech and
cerebellar hypoplasia. A large consanguineous family exhibiting this rare disor-
der was investigated in this study. Disease locus was mapped to a 7.1 Mb region
on chromosome 17p by genetic analysis. Targeted capture and massively parallel
DNA sequencing using the DNA of three aected and two carrier individuals en-
abled the identication of a novel variant, p.P856L, in a predicted transcript of
WD repeat domain 81 gene (WDR81 ). Several exclusion lters including segrega-
tion analysis, identication of rare polymorphisms, extended pedigree screen and
bioinformatics evaluation was performed. Expression analysis revealed highest
levels of transcripts in cerebellum and corpus callosum. In mouse brain Wdr81
RNA was observed in cerebellum, especially in Purkinje cell layer. The major
structural abnormalities of the patients were atrophy of superior, middle and in-
ferior cerebellar peduncles and corpus callosum. These ndings are compatible
with the expression pattern of the gene. Analysis of the developing mouse brain
revealed that, the expression pattern of the gene was correlated with those in-
volved in neuronal dierentiation. This study was one of the rst examples of
the utility of next generation sequencing in discovery of genes associated with
Mendelian phenotypes.
Keywords: Quadrupedal locomotion, CAMRQ2, Unertan syndrome, next gener-
ation sequencing.
iv
ÖZET
NSANDA EL-AYAK ÜZERNDE YÜRÜME:
WD REPEAT DOMAIN 81 (WDR81 ) GEN'NN
TANIMLANMASI VE KISM KARAKTERZASYONU
Süleyman smail Gülsüner
Moleküler Biyoloji ve Genetik, Doktora
Tez Yöneticisi: Prof. Dr. Tayfun Özçelik
Kasm, 2011
Serebellar ataksi, mental retardasyon ve dengesizlik sendromu (CAMRQ) in-
sanda el-ayak üzerinde yürüme, dizartrik konu³ma ve serebellar hipoplazi ile gi-
den nadir bir sinir geli³imsel hastalktr. Bu çal³mada, bu hastalktan etkilen-
mi³ akraba evlili§i bulunan geni³ bir aile incelenmi³tir. Ba§lant incelemeleri ve
homozigotluk haritalamas ile hastalk lokusu kromozom 17p13.1-13.3 üzerinde
bulunan 7.1 Mb'lk bir bölgeye haritalanm³tr. Fenotipten sorumlu mutasyonu
saptamak için, hastalk lokusu üç adet etkilenmi³ birey ve iki adet ta³ycnn
DNA örnekleri kullanlarak dizi yakalama mikrodizinleri ile yakalanm³ ve yeni
nesil DNA dizilemesi ile dizilenmi³tir. Aile içi yaylm incelemeleri, nadir polimor-
zmlerin belirlenmesi, geni³letilmi³ soya§acnn taranmas ve tahmin araçlar gibi
birçok süzgeç kullanlarak, WD repeat domain 81 (WDR81 ) geninin tahmini
ifade varyantnda p.P856L mutasyonu tanmlanm³tr. fade incelemeleri insan
beyninde en yüksek ifadenin serebellum ve korpus kallozumda oldu§unu göster-
mi³tir. Fare beyin dokularnda yaplan incelemelerde Wdr81 RNA's serebel-
lumda, özellikle Purkinje hücrelerinde gözlenmi³tir. Hastalarda saptanan belirgin
yapsal bozukluklar üst, orta ve alt serebellar pedünküller ve korpus kallosumda
saptanm³tr ve bu genin ifade paterni ile uyumludur. Geli³en fare beyni ifade
mikrodizin incelemeleri sonucu, genin embyonik günler arasndaki ifade pater-
ninin nöronal farklla³mada yer alan genlere paralel oldu§u belirlenmi³tir. Bu
çal³ma Mendel kaltm gösteren hastalklarda sorumlu genin bulunmas amaçl
yeni nesil dizileme teknolojilerinin kullanlmasnn ilk örneklerinden biridir.
Anahtar sözcükler : El-ayak üzerinde yürüme, CAMRQ2, Ünertan sendromu, yeni
nesil dizileme.
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Chapter 1
Introduction
1.1 Quadrupedal Locomotion in Humans
The life of humankind begins with walking on all fours and continue with upright
posture (bipedal locomotion).[1] Human bipedal locomotion is unique among liv-
ing primates. Although comprehensive studies provided valuable information
about walking and upright posture [1, 2, 3, 4, 5], mechanistic insights into the
developmental processes and their genetic determinants are poorly understood.
Functional brain imaging studies of healthy individuals suggested that, cerebral
cortex, occipital cortex, basal ganglia and cerebellum are the crucial brain regions
that control locomotor activities.[6, 7]
The cerebellum has a particular role in timing and controlling of complex
patterns of muscle movements, and important for balance and bipedal locomo-
tion. Developmental disorders of the cerebellum aecting gait and locomotion are
rare and genetically heterogeneous. These clinical traits are characterized by loss
of balance and motor coordination. Hereditary syndromes involving cerebellar
abnormalities are of interest since they provide functional insights into regula-
tion, maintenance and organization of the motor system.[8] Cerebellar ataxia,
mental retardation, and disequilibrium syndrome (CAMRQ) is a genetically het-
erogeneous disease characterized by cerebellar hypoplasia, mental retardation,
1
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Family B
Figure 1.1: Pedigree of family B. Six of the 19 children of a rst cousin marriage
are aected by CAMRQ2.
dysarthric speech and quadrupedal locomotion. The syndrome was rst described
by Tan [9] in a large consanguineous family named family B (Figure 1.1). The
rst family was initially studied and the disease locus was mapped to a 7.1 Mb
region on chromosome 17p (CAMRQ2, MIM 613227).[10] Subsequent analysis of
the family using next generation sequencing of the entire disease locus, conser-
vation analysis, presence of polymorphic stop codons in the variant sites, and
genotyping of the control group and ethnically matched healthy individuals lead
to the discovery of a missense mutation in WD repeat protein 81 (WDR81 ).[11]
1.1.1 Families described in Turkey
The rst family described in the literature with quadrupedal gait is Family B.
It consists of six aected and 13 healthy children who are the product of a con-
sanguineous marriage (Figure 1.1).[9] Family B lives in south-eastern Turkey.
The main characteristics of the aected individuals are cerebellar hypoplasia,
dysarthric speech, mental retardation, truncal ataxia and quadrupedal locomo-
tion. The pedigree shows an autosomal recessive mode of inheritance. The index
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case is now a 33 years old man. He is mentally retarded based on Mini Mental
State Examination Test. Another brother and a sister are bipedal and they have
similar neurological ndings with a milder degree of mental retardation. All af-
fected individuals can move around freely. In resting state, patients are able to
stand upright, but they quickly returned to the quadrupedal position for walk-
ing. Aected individuals have dysarthric speech with limited vocabulary. They
can understand and respond to simple questions in their own language and can
express their basic needs.[9, 10]
During the course of our studies three additional families have been identied
in Turkey with slightly dierent clinical characteristics (Table 1). Family A is a
consanguineous family from south-eastern Turkey with seven aected individuals
(Figure 1.2). Family D is another consanguineous family from western Turkey
with 3 aected individuals (Figure 1.3).[12, 13] Initial genetic analysis identied
a nonsense mutation (p.R257X) and a single nucleotide deletion (c.2339delT) in
Very Low Density Lipoprotein Receptor (VLDLR) gene in these families respec-
tively (CAMRQ1 [MIM 224050]).[12]
Another consanguineous family aected by CAMRQ is residing in southern
Turkey (Family C). The disease is observed in four individuals in three branches
of the pedigree (Figure 1.4).[14] One of the aected individuals is bipedal ataxic
albeit exhibiting quadrupedal locomotion in childhood. The other aected indi-
vidual was also a quadruped, but he completely lost his ambulation now. Re-
maining two aected individuals exhibit quadrupedal locomotion. Both aected
individuals had severe mental retardation and mild cerebellar hypoplasia. The
initial genetic mapping studies and sequence analysis exclude the previously re-
ported gene loci in this family.[15]
1.2 Cerebellum and Motor Coordination
In the last million years of evolution the size of the cerebellum and cerebral
cortex dramatically increased. Through out evolution, cerebellum enable both
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Figure 1.2: Pedigree of family A.
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Figure 1.3: Pedigree of family D.
Table 1.1: Clinical characteristics of families.[12]
Family A Family B Family C Family D
Locus 9p24 17p Not 9p or 17p 9p24
Gene VLDLR WDR81  VLDLR
Gait Quadrupedal Quadrupedal Quadrupedal Quadrupedal
Speech Dysarthric Dysarthric Dysarthric Dysarthric
Hyptonia    
B.c.n. Normal Cvs defect Pvs defect Not done
M.r. Profound Severe to profound Profound Profound
Ambulation Delayed Delayed Delayed Delayed
T. ataxia Severe Severe Severe Severe
Low. leg ref. Hyperactive Hyperactive Hyperactive Hyperactive
Up. ext. ref. Vivid Vivid Vivid Vivid
Tremor Very rare Mild Present Absent
Pes-planus Present Present Present Present
Seizures Very rare Rare Rare Absent
Strabismus Present Present Present Present
Inf. cereb. Hypoplasia Hypoplasia Mild hypoplasia Hypoplasia
Inf. vermis Absent Absent Normal Absent
Cort. gyri M.s. M.s. M.s. M.s.
Corp. col. Normal Reduced Normal Normal
Abbreviations used in this table: B.c.n., barany caloric nystagmus; M.r., mental retardation; T. ataxia, truncal
ataxia; Low. leg ref., lower leg reexes; Up. ext. ref., Upper extremity reexes; Inf. cereb., inferior cerebellum;
Cor., cortical; Corp. col., corpus callosum; Cvs, Central vestibular system; Pvs, Peripheral vestibular system.
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Figure 1.4: Pedigree of family C.
motor and mental capabilities, which provided humans great advantages in adap-
tation. Another adaptive advantage could be the possible role of the cerebellum
in combining motor function of articulation to the mental functions that controls
language and speak.[16] However, the hypothesis of the linguistic processing by
the cerebellum has not been yet elucidated. Most of the knowledge regarding the
functions of the cerebellum has been obtained from damaged cerebellar struc-
tures and brain imaging studies. Recent improvements in mouse genetics, brain
imaging techniques, and genomic approaches have led to the identication of
several genes underlying human cerebellar malformations.[17] Hence, those stud-
ies have accelerated our understanding of the development and functions of the
cerebellum.
Cerebellum is essential for normal motor function. It coordinates timing,
progression, and intensity of motor movements. It plays critical roles, espe-
cially in rapid movements like typing, running and talking. Complete loss of
the cerebellum does not cause complete loss of the muscle movements, but total
incoordination of these activities. Functionally, cerebellum is placed in a central
position between the output signals of motor system to peripheral muscles and
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Figure 1.5: Adjustment of motor system. (The picture of the cerebellum in this
gure is taken and modied from Purves et. al [19] with permission).
input signals from peripheral organs to central nervous system (Figure 1.5). Sen-
sory signals such as, rate of movement, forces that act on the movement and the
current position of the extremities send information to cerebellum. In addition,
cerebellum compares two signals; motor signals of the desired movement and sen-
sory signals from actualized movement. If the result is not favoured, cerebellum
sends correction signals to the motor system, and motor system replies by in-
creasing or decreasing the activation of targeted muscles.[18] The cerebellum also
plans the next sequential movement, and directs the cerebral cortex while the
rst movement is still active.
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1.2.1 Anatomical and functional areas of the cerebellum
Cerebellum is located in the bottom of the brain, and is divided into three anatom-
ical regions: the anterior lobe, the posterior lobe and the uccolonoduler lobe.
These lobes divide the organ from top to bottom in humans. The uccolonoduler
lobe is often called as vestibulocerebellum and has distinct functions and connec-
tions. It controls the body equilibrium together with the vestibular system.[20]
Remaining anterior and posterior lobes are functionally organized along the lon-
gitudinal axis. From the posteroinferior view, cerebellum is divided into two
hemispheres by a narrow strip called vermis. Each side of the vermis consists of
two large cerebellar hemispheres, and each hemisphere is divided into interme-
diate and lateral zones (Figure 1.6). As in other brain regions, a topographical
body is represented in the cerebellum. Axial body, hips, shoulders and necks
lie in the vermis. The distal part of the body -limbs, hands and feet- lie in the
intermediate zones of the cerebellar hemispheres. These regions receive aerent
nerve signals from the respective body parts and corresponding topographical
motor areas of the brain. The intermediate zone of the hemispheres are also
known as spinocerebellum and responsible for the adjustment of body and limb
movements.[18] The lateral zone does not represent any topographical body sec-
tion. It constitutes the cerebrocerebellum and this region receives signals from
the cerebral cortex and sends output mainly to ventrolateral thalamus and red
nuclei. It plays crucial roles in planning the next sequential movements.[21]
1.2.2 Cellular components
Cerebellar cell types, cell layers, axon types and tracts are the major components
of the cerebellum. There are three major types of cell in the cerebellum; Purkinje
cells, deep nuclei cells and granule cells. One purkinje cell and a deep nucleus
constitutes a functional unit. Cerebellar cortex has three cell layers; the molecular
layer, Purkinje cell layer and granule cell layer. The cerebellar deep nuclei, which
sends the output signals to the nervous system are located under these cortical
layers (Figure 1.7). Mossy bers and the climbing bers are the major tracts of
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Figure 1.6: Functional and anatomical parts of the cerebellum. (The picture
of cerebellum in this gure is taken and modied from Purves et. al [19] with
permission).
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cerebellar circuitry.[18]
Cerebellar cortex consists of nearly 30 million functional units. Deep nuclei
cells are under the inuence of both excitatory and inhibitory signals. The exci-
tatory signals arise from the connections of aerent bers coming from dierent
brain regions and body parts. Mossy bers and climbing bers are the two types
of aerent inputs. Climbing bers arise from inferior olivaris of medulla. They
make contacts with deep nuclei cells and extend to the molecular layer of cere-
bellar cortex to make synapses with dentrites and soma of Purkinje cells. Each
climbing ber makes contact with ve to ten Purkinje cells. The mossy bers
arise from all other bers that come from multiple sources and make contact with
deep nuclei cells. In contrast to climbing bers, mossy bers reach to the granule
layer and make synapses with thousands of granule cells. These granule cells
send small axons to molecular layer and they divide in two branches to constitute
parallel bers. In the molecular layer, thousands of parallel bers make synapses
with Purkinje cells.[18, 20]
As summarized in Figure 1.7 deep nuclei cells are always activated by climbing
and mossy bers. Purkinje cells are also activated by those bers and send
inhibitory signals to deep nuclei cells. When motor system is activated, the deep
nuclei cells are inhibited by Purkinje cells after a short delay with a negative
feedback signal. This negative feedback mechanism prevent the muscle movement
from over reaction and oscillation.
Besides from Purkinje, deep nuclei and granular cells, there are three types
of additional cells located in the cerebellum. These are the stellate and basket
cells in the molecular layer, and Golgi cells under the parallele bers. All three
types of cells are activated by parallele bers. Stellate and basket cells then send
inhibitory signals to Purkinje cells by lateral inhibition to sharpen the signals. In
contrast, golgi cells inhibit granule cells, and provide ne-tuning of movements
and prevents errors.
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Figure 1.7: Neuronal circuit of the cerebellum. (Copyright Elsevier 2011. From
Guyton et. al. 2006 [18] with permission).
1.2.3 Neuronal circuits of the cerebellum
As mentioned above, the major functional units of the cerebellum are Purkinje
and deep nuclei cells. They receive input signals from various sources. In cere-
bellum, input signals arise from two major sources: 1) Aerent pathways from
dierent brain regions and 2) Aerent sensory tracts from peripheral parts of the
body. The rst pathway activates deep nuclei cells and results in an increased
output from these cells. Then, Purkinje cells balance the activation by negative
feed-back. The peripheral sensory pathway provides information about position,
rate of movement and the forces against movement. This information is used
to adjust the movement by increasing and decreasing the activation signals from
deep nuclei cells.
1.2.3.1 Aerent pathways from brain
There are four major pathways, which send signals from various brain regions to
the cerebellum:
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Figure 1.8: Principal aerent tracts to the cerebellum. (Copyright Elsevier 2011.
From Guyton et. al. 2006 [18] with permission).
 The Corticopontocerebellar pathway originates from the cerebral motor, pre-
motor and somatosensory cortices. They terminate in the lateral parts of
the opposite cerebellar hemispheres by pontocerebellar tracts.
 The olivocerebellar bers arise from cerebral motor cortex, basal ganglia,
reticular formation and spinal cord. They reach to all parts of the cerebel-
lum, after passing the inferior olive.
 The vestibulocerebellar tract originates from the vestibular apparatus and
vestibular nuclei of the brain stem and terminate at the uccolonoduler
lobe.
 The reticulocerebellar bers extend to the vermis from the reticular forma-
tion of the brain stem.
1.2.3.2 Aerent pathways from periphery
Two major tracts by which cerebellum receives sensory signals from peripheral
body regions are the dorsal and the ventral spinocerebellar tracts (Figure 1.9).
The most rapid conduction in nervous system occurs at the spinocerebellar tracts
by which the cerebellum is informed of the rapid changes in the muscle movements
instantaneously.
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Figure 1.9: Spinocerebellar tracts. (Copyright Elsevier 2011. From Guyton et.
al. 2006 [18] with permission).
 Dorsal spinocerebellar tract carries the signals that originate mainly from
muscle spindles. Signals from tactile receptors of the skin, joint receptors,
somatic receptors and golgi tendon organs are also transmitted through the
dorsal spinocerebellar tract. The signals arise from these peripheral parts
of the body to inform the cerebellum about the degree of muscle contrac-
tion and tension of the tendons, position of the body parts, rates of the
movements, and the forces against the movements. Dorsal spinocerebellar
tract reaches to the intermediate zones of the cerebellum and the vermis by
passing through the inferior peduncle.
 Ventral spinocerebellar tract transmits information from the motor signals
which arrive to the anterior horns of the spinal cord. The signals reach both
sides of the cerebellum by passing through superior peduncle.
1.2.3.3 Eerent pathways
All eerent signals received by the cerebellum arrive at one of the cerebellar nuclei
and its associated area in the cerebellar cortex. After a fraction of time, cerebellar
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nucleus receives inhibitory signals from the cerebellar cortex as mentioned above.
By this balancing system, adjusted output signals leave the cerebellum and spread
through other regions of the brain. There are three major eerent pathways that
originate from three dierent deep cerebellar nuclei (Figure 1.10).
 Fastigial nucleus : Signals from the vermis are transferred to the medulla
and pons by passing through the fastigial nucleus. This pathway works
together with vestibular nuclei and equilibrium apparatus to control body
equilibrium. This circuit also helps coordinate the attitudes associated with
posture of the body together with reticular formation.
 Interposed nucleus : The signals from intermediate regions of the hemi-
spheres are transmitted to the ventroanterior and ventrolateral nuclei of
the thalamus  ! cerebral cortex  ! midline structures of the thalamus
 ! basal ganglia  ! reticular formation and red nuclei of the brain stem.
This pathway mainly contributes to the coordination of the reciprocal con-
tractions of the antagonist and agonist muscles in the peripheral parts of
the extremities.
 Dentate nucleus : Cerebellum helps coordinate sequential movements
through pathways arising from lateral hemispheres. These signals exit from
the dentate nucleus and reach to the cerebral cortex by passing ventrolateral
and ventroanterior nuclei of the thalamus.
1.3 Dysfunction of Cerebellum and Ataxias
The major consequences of cerebellar dysfunction are motor related and vary
based on the localization of the damage.[20] One of the important aspects of
cerebellar dysfunction is that, if the deep nuclei cells are not damaged, the un-
damaged parts of the cerebellum can compensate for motor functions in slow
movements.[18] One of the most important symptoms of cerebellar diseases is
ataxia.[20] The term is generally used to indicate uncoordinated movement. The
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Figure 1.10: Eerent tracts to the cerebellum. (Copyright Elsevier 2011. From
Guyton et. al. 2006 [18] with permission).
most common causes of ataxia are, damaging of cerebellar and spinal structures,
atrophy of cells in the cerebellum or its connections and cerebellar degeneration.
The diseases accompanied by ataxia can be divided into three groups as i.
acquired ataxias, ii. inherited ataxias and iii. degenerative ataxias. Acquired
ataxias are mostly caused by traumatic events, strokes and intoxications. The
most common form of toxic ataxia is caused by alcohol induced degeneration
of the cerebellum.[22] Degenerative ataxias consist of multiple system atrophy
(MSA) and idiopathic late-onset cerebellar ataxia (ILOCA).[22] MSA is the most
common cause of the nonhereditary degenerative ataxia.[23]
Hereditary ataxias are caused by defective genes and follow the characteris-
tics of Mendelian inheritance. These diseases are characterized by degeneration
of the cerebellum and spinocerebellar tracts. Various symptoms in central and
peripheral nervous system can accompany ataxias.[24]
Clinical presentation of dierent inherited ataxias caused by dierent genes
may show signicant similarities including histopathological ndings. Therefore,
it is dicult to make a classication based on clinical ndings.[25] Thus, it is pre-
ferred to group inherited ataxias according to mode of inheritance as autosomal
dominant, autosomal recessive, X-linked and mitochondrial.[26] Common genetic
causes of autosomal recessive ataxias are summarized in Table 1.2
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Table 1.2: Summary of common autosomal recessive ataxia syndromes.[22]
Type Protein Locus
Degenerative ataxias
Friedreich ataxia Frataxin 9q13
Charlevoix-Saguenay spastic ataxia Sacsin 13q12
Mitochondrial recessive ataxic syndrome (MIRAS) Polymerase 
Marinesco-Sjogren syndrome SILI 5q32
Congenital ataxias
Joubert syndrome (JBTS) AHII, Nephrocystin-6 11p12, 12q21
Cayman ataxia Cayataxin 19p13.3
Metabolic ataxias
Ataxia with isolated vitamin E deciency (AVED) a-TTP 8q13
Refsum's disease Phytanoyl-CoA hydroxylase 10pter-p11.2
Niemann-Pick type C NPC1 protein 18q11-121
Ataxias with DNA repair defects
Ataxia telangiectasia ATM 11q22.3
Ataxia with oculomotor apraxia Aprataxin, Senataxin 9p13, 9q34
Spinocerebellar ataxia with axonal neuropathy
(SCAN1)
Tyrosyl-DNA phosphodiesterase 114q31
There is no specic treatment for ataxias. Current therapies generally aim to
diminish disease severity.
1.4 Disease Gene Identication in Autosomal Re-
cessive Disorders
Consanguinity has been recognized as a risk factor for rare diseases since the
beginning of the previous century. Garrod reported notable excess of consan-
guineous marriages among the parents of alkaptonuria patients in 1902.[27] This
phenomenon was later described with Mendelian inheritance. A consanguineous
marriage is dened as the union of individuals descended from the same ancestor.
Consanguinity refers to the amount of shared genetic material between individu-
als. The most common form of consanguineous marriage is between rst degree
cousins. In theory, such a couple shares 1=8 of their genetic material inherited
from a common ancestor. Descendents of a consanguineous marriage inherit half
of these shared alleles and 1=16 of their loci are homozygous. Therefore, assem-
bly of two recessive disease alleles is more frequently observed in such families.
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Figure 1.11: Prevalence of consanguineous marriages. (http://www.consang.
net, with permission of A.H. Bittles).
Rate of consanguineous marriages in a population directly aects the frequency
of recessive diseases. With the increasing levels of consanguineous marriages,
the frequency of individuals aected by a recessive disorder is proportional to
the frequency of disease allele. However, in randomly mating populations the
frequency of aected individuals is proportional to the square of the frequency
of the disease allele.[28] In some populations more than 50% of the marriages
are consanguineous.[29] Highest levels of consanguineous marriages are observed
in Suudi Arabia, Pakistan and southern and eastern rims of the Mediterranean
basin (Figure 1.11, please see http://consang.net for further information).
In consanguineous families with recessive disorders, the regions adjacent to
the disease causing mutation will preferentially be identical by descent leading to
a stretch of homozygosity. Therefore, homozygosity mapping has the potential
to identify the disease locus even in a single small consanguineous family.[30] In
the presence of high density SNP genotyping data, detecting shared homozygous
regions provides a powerful strategy.[31]
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Table 1.3: Candidate gene prioritization tools.
GeneSeeker[32] Expression and phenotypic data from
mouse and human.
http://www.cmbi.ru.nl/GeneSeeker
Prioritizer[33] Based on KEGG [34], Reactome [35], and
HPRD [36] data.
http://www.prioritizer.nl
DGP[37] Based on protein sequence properties
(protein length, conservation, phyloge-
netic relationship and paralogy pat-
terns).
http://cgg.ebi.ac.uk/services/dgp
PROSPECTR[38]Based on sequence features (gene length,
protein length, and homology).
http://www.genetics.med.ed.ac.uk/
prospectr
SUSPECTS[39] Combinatory approach using InterPro
data, GO terms and expression data with
the PROSPECTR classier.
http://www.genetics.med.ed.ac.uk/
suspects
The rate limiting step of disease gene identication studies lies between map-
ping of the disease locus and identication of the mutation. The disease locus
could be several megabases long and contain hundreds of genes. Comprehensive
analysis of the whole locus is time consuming and expensive. Publicly available
data derived from experimental analysis and advances on bioinformatics tools en-
able to combine positional cloning and functional prediction approaches. Several
tools have been developed to prioritize the candidate genes by their probability
of involvement in a disease phenotype (Table 1.3).
However, candidate gene prioritization for the identication of the culprit
gene could be complicated by the presence of hypothetical and/or uncharacterised
genes in a given interval. Lack of functional information on a particular protein
or pathway may further complicate the situation. In such cases a brute-force
approach is required to identify the disease causing mutation. Availability of tar-
geted capture of the genome and next generation sequencing approaches greatly
facilitated disease gene identication studies.[40, 41, 42] On average, sequencing
the whole exome of an individual yields 20,000 variants. More then 95% of those
variants are known polymorphisms detected in healthy populations. The major
challenge of this technology is pinpointing the disease causing variant among the
many rare and neutral variants. Identifying the disease causing mutation among
those variants depends on the estimation of the deleteriousness of variants. As
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Figure 1.12: Classication of the variants according to functional regions.
in the candidate gene prioritization approach, several methods can be applied to
prioritize causal variants.[43, 44]
Identication of a disease gene depends on several steps of ltering and strati-
cation. First variants that are not compatible with the inheritance of the disease
could be excluded. Segregation analysis of the variants in the family members
and population screening are the primary steps for the exclusion of neutral vari-
ants. Identication of the same or dierent mutations in other families who are
aected by the disease is the most powerful step. [44] However, in several recessive
conditions the phenotypes could be extremely rare.[11] The second step in such
instances is based on the stratication of the variants according to their functional
impacts (Figure 1.12). By using publicly available curated databases, role of the
genes in biological pathways or their interactions with genes that are known to
cause similar phenotypes can be identied as in the candidate gene approaches
(Table 1.3). In addition, several tools have been developed to predict the impact
of the mutation. Most of these approaches use conservation as the measure of
deleteriousness. The most preferable tools are summarized in Table 1.4.
1.5 Outline of the Thesis
In the next chapter, overview of the methods used in this study is given. The
clinical description of the aected family and results of MRI studies were initially
described in Chapter 3. Then, genetic analysis of the disease locus and results of
the candidate gene sequencing approaches to nd the culprit gene are discussed.
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Table 1.4: Deleteriousness prediction tools for variants.
Tool Method Web address
DNA sequence based
phastCons [45] Evol http://compgen.bscb.cornell.edu/
phast/
GERP [46] Evol http://mendel.stanford.edu/
SidowLab/downloads/gerp/index.
html
phyloP [47] Evol http://compgen.bscb.cornell.edu/
phast/
Protein sequence based
MAPP [48] Evol, biochem http://mendel.stanford.edu/
SidowLab/downloads/MAPP/
PhD-SNP [49] Evol, biochem http://gpcr2.biocomp.unibo.it/
~emidio/PhD-SNP/PhD-SNP_Help.html
SIFT [50] Evol, biochem http://sift.bii.a-star.edu.sg/
PANTHER [51] Evol, biochem http://www.pantherdb.org/
MutationTaster [52] Evol, biochem, str http://www.mutationtaster.org/
polyPhen [53] Evol, biochem, str http://genetics.bwh.harvard.edu/
pph2/
SNAP [54] Evol, biochem, str http://www.rostlab.org/services/
SNAP/
SNPs3D [55] Evol, biochem, str http://www.snps3d.org/
Abbreviations used in this table: Evol, Evolutionary; biochem, biochemical; str, structural.
In remaining parts of the Chapter 3, targeted next generation sequencing ap-
proach and initial identication and partial characterization of the disease gene
will be described. Finally we conclude the thesis with Chapter 4.
Chapter 2
Materials and Methods
2.1 Recruitment of the Family and Control group
Family B from Turkey, aicted by cerebellar ataxia, mental retardation, and
disequilibrium syndrome (CAMRQ), was investigated in this study. Ancestors
of the Family B migrated from a village of Syria to Turkey in early 1950s. Ap-
proximately 240 individuals spanning seven generations could be ascertained and
blood samples were obtained from 177 individuals belonging to ve generations.
Approximately 549 individuals, who were not aected and did not have any
family history about movement disorders, were enrolled in the study as control
group. Two cohorts were used to investigate presence of candidate mutations
in the unrelated individuals with similar phenotypes. The rst cohort consisted
of 58 patients with cerebellar phenotypes with or without quadrupedal locomo-
tion. The second cohort of 750 patients had structural cortical malformations or
degenerative neurological disorders.
All clinical investigations performed were compatible with the Helsinki Dec-
laration (http://www.wma.net). The study was approved by institutional re-
view boards of Bilkent, Hacettepe, Ba³kent and Çukurova Universities (deci-
sions BEK02, 28.08.2008; TBK08/4, 22.04.2008; KA07/47, 02.04.2007 and 21/3,
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08.11.2005, respectively). Written informed consent forms were obtained from
the all participants prior to the study.
Functional brain imaging studies were performed by National Research Center
for Magnetic Resonance (UMRAM), Bilkent University, Ankara, Turkey. A total
of 18 participants were subjected to the study. Six of the participants were from
the aected family, including the carrier father (05-981), one female sibling who
is homozygous for the wild type allele (10-033) and four aected siblings (05-984,
05-986, 05-987, 05-988). Remaining seven male and seven female individuals were
age and sex matched controls without signs of any neurological phenotype and
movement disorders. Prior to scanning, family members were sedated in order to
eliminate movements. Sedation was performed by using intravenous midazolam
(2mg per subject), which was followed by propofol (120mg) and fentanyl (50mg).
2.2 DNA and RNA Samples
Peripheral blood samples of aected and healthy individuals were taken by venop-
uncture, collected in K3-EDTA containing tubes and transferred to the laboratory
with cold chain conditions. They were separated into 1.5 µL aliquots in eppendorf
tubes and stored at  80.
2.2.1 DNA isolation from blood samples
DNA were isolated from 200 µL of peripheral whole blood samples using
NucleospinTM Blood Kit (Macherey-Nagel Inc., PA, USA) according to the pro-
tocol from the manufacturer. For the next generation sequencing experiments,
Phenol-Chloroform DNA extraction method [56] was used to obtain high quality
and high concentration of DNA. Quality and quantity of the DNA was mea-
sured by using NanoDropTM ND-1000 UV-Vis Spectrophotometer (NanoDrop,
DE, USA) and PicoGreen method [57]. DNA quantities and qualities were veri-
ed by densitometric agarose gel electrophoresis.
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2.2.2 RNA isolation and cDNA synthesis
RNA samples were isolated with Trizol reagent (Invitrogen, CA, USA) using
1mL of fresh peripheral blood samples of the patients, the carriers and healthy
individuals according to manufacturer's protocol. Commercially available total
RNA from dierent human tissues were obtained to analyse the expression pat-
tern of the disease causing gene (Clontech, CA, USA and Agilent Technologies,
CA, USA). Qualities and concentrations of the RNA samples were measured by
using NanoDropTM ND-1000 UV-Vis Spectrophotometer (NanoDrop, DE, USA)
and Agilent Bioanalyzer 2100 (Agilent Technologies, CA, USA). cDNA was pre-
pared from 1µg DNaseI (Fermentas, NY, USA) digested RNA samples using
First Strand cDNA Synthesis kit (MBI Fermentas, NY, USA). Random hexamer
primers were used in cDNA synthesis reactions.
2.3 Genetic Mapping
2.3.1 Pedigree construction and analysis
Medical and familial histories of Family B were obtained from healthy members of
the family. For the construction of an extended pedigree, 177 relatives of Family
B were visited and family and medical histories were obtained from each individ-
ual. Pedigrees of each family were drawn on site. Haplopainter [58] and Inkscape
(http://inkscape.org/) softwares were used to construct the extended pedi-
gree. Pedigree analysis were performed according to characteristics of Mendelian
diseases.[59]
2.3.2 Array based genotyping
Two obligate carrier parents, three healthy and six aected siblings were selected
for whole-genome single nucleotide polymorphism (SNP) genotyping. GeneChip
10K Xba Aymetrix arrays (Aymetrix Inc, CA, USA) were used to genotype
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11 individuals according to manufacturer's recommendations. Normalization of
the raw data and genotype calling were performed by Aymetrix Genotype Con-
sole Software v2.1 (Aymetrix Inc, CA, USA). SNP genotype data were used to
perform parametric linkage analysis and homozygosity mapping.
Furthermore, two aected individuals (05-984, 05-987) were genotyped using
high resolution Illumina 300 Duo v2 BeadChip (Illumina Inc, CA, USA). Images
were normalized and genotypes were called using Bead Studio (Illumina Inc, CA,
USA). Illumina data were used to conrm homozygous regions and to calculate
next generation data statistics as mentioned in sections 2.3.4 and 2.5.3.
Mendelian errors, missing genotype rates, sex and inbreeding statistics were
calculated by using PLINK whole genome association analysis toolset v1.07.[60]
2.3.3 Genetic linkage analyses
Merlin V1.01 software [61] was used to perform parametric linkage analysis. PED,
MAP and DAT les were generated from genotype data. PED les consisted
of the pedigree structure and the genotype data of each individual. DAT les
contains labels and orders of SNPs and the location of aection status in PED
les. MAP les indicate the chromosomal locations and cM distance information
of each marker. Contents of these les are summarized in Figure 2.1. A model
le was prepared to input the inheritance model. Analysis was performed using
standard Merlin parameters for parametric linkage analysis.
2.3.4 Homozygosity mapping and haplotype analysis
The anking DNA regions harbouring the disease causing mutations segregate
with the phenotype in the pedigrees of the families aected by monogenic dis-
eases. Genetic linkage analysis is a powerful approach to identify the critical
region segregating with the disease. However, signicant linkage can be reached
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Figure 2.1: Contents of linkage les.
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on the availability of large informative pedigrees. In an aected child of a consan-
guineous marriage, the anking region spanning the disease causing mutation is
almost homozygous by descent. In the presence of high density SNP genotyping
data, detecting the shared homozygous regions provides a powerful strategy in
the identication of the region which contains the disease causing mutation in a
recessive condition.[31]
Homozygosity mapping analysis was performed to identify the shared homozy-
gous regions in the aected individuals of the family B and to verify the candidate
locus determined by linkage analysis. Since there were not any suitable software
for homozygosity mapping, homozygous regions in 10K SNP data were detected
by using a custom Perl script (algorithm summarized in Figure 2.2). In addition,
regions were analysed with a spread sheet software visually. While 10K SNP mi-
croarrays contain only 10,204 SNPs with a mean inter-marker spacing of 258 Kb,
a total of 318,238 SNPs with a mean inter-marker spacing of 8 Kb are printed
on Illumina 300 Duo microarrays. Thus, two DNA of aected individuals were
genotyped by using Illumina 300 Duo v2 BeadChip and the data were used to
analyse unrepresented regions and to conrm the minimal critical region. Illu-
mina SNP data was analysed by using HomozygosityMapper software [62]. Since
it is expected to observe genotype errors in a high throughput microarray data
and false heterozygotes can cause overlooking of homozygous blocks, analyses
were repeated with dierent numbers of heterozygotes allowed in a homozygous
window.
To verify and saturate the candidate locus, the family was further genotyped
with polymorphic microsatellite markers (STR)(Appendix A). Then, the candi-
date region was visually analysed by constructing the haplotypes of the family
with the genotype information obtained from STR analysis and SNP genotyping.
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Figure 2.2: Homozygosity mapping algorithm. A Perl script was developed to
detect shared homozygous regions in aected individuals.
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2.4 Candidate Gene Analysis
2.4.1 Candidate gene prediction
The disease locus identied by linkage and homozygosity mapping analysis could
contain a large number of genes. In the absence of high throughput sequencing
technologies, selection and sequencing of the candidate genes within the disease
interval is the the rate-limiting step of disease gene identication. Availability
of experimental data and advances on bioinformatics tools enable to combine
positional cloning and functional prediction approaches. The main aim of these
approaches is prioritize the genes by their probability of involvement in a disease
phenotype.
In an attempt to identify candidate genes in the minimal critical region, a
combined bioinformatics approach was conducted and three dierent screening
strategies were employed. These are systems biology techniques, bipartite distri-
bution predictions and hybrid techniques.
 Systems biology techniques: VLDLR is the rst gene implicated in
CAMRQ. The protein encoded by VLDLR is involved in Reelin pathway
as a receptor of Reln to regulate Dab1 tyrosine phosphorylation and mi-
crotubule function in neurons. Therefore, rst, experimentally validated
proteins that are interacting with VLDLR up to 3 connection levels were
identied by using APID (Agile Protein Interaction DataAnalyzer)[63]. Sec-
ond, corresponding genes of those proteins were fetched from ENSEMBL
database (http://www.ensembl.org). Then, a subset o genes located in
the critical region encoding the proteins which are interacting with VLDLR
are determined. In addition, genes of the Reelin pathway were reviewed by
using the GeneAssistTM Pathway Atlas.
 Bipartite distribution predictions: All genes within the disease locus
were analysed for their probability of being involved in a hereditary disease
using two dierent tools. DGP tool (Disease Gene Prediction)[37], uses pa-
rameters -conservation, phylogenetic extent, protein length and paralogy-
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that have been shown to follow specic trends in the already known disease
genes. The second tool, Prospectr (PRiOrization by Sequence & Phylo-
genetic Extent of CandidaTe Regions)[64] ranks candidate genes with se-
quence features, sharing interpro domains, GO terms or similar expression
proles with any given gene or group of genes responsible for similar phe-
notypes. For both tools, VLDLR and other genes responsible for cerebellar
hypoplasia were used as model genes.
 Hybrid techniques: The third tool, SUSPECTS prioritizes disease genes
using a combination of genotype-phenotype mapping method based on
disease-gene-associated keywords from InterPro and GO, and expression
libraries. This tool uses the PROSPECTR Boolean classier.[65]
2.4.1.1 Trinucleotide repeat containing genes
A variety of neurological disorders, including several forms of mental retardation,
fragile X syndrome, Huntington's disease, Friedreich's ataxia and the inherited
ataxias, have been characterized based on the presence of unstable expansions of
trinucleotides.[66, 67] Hence, a bioinformatics approach was developed to predict
the possible genes which have the probability of harbouring trinucleotide repeat
expansion mutations.
For that purpose, previously reported disease causing nucleotide repeat mu-
tations were determined (Table 2.1).[68, 69] Then, sequence data of 5' and
3' untranslated regions (UTR), exons, introns and 5' and 3' anking regions
of the genes within the disease locus was obtained from ENSEMBL database
(http://www.ensembl.org). A Perl script was developed to scan and report the
position information of the nucleotide motifs in the sequence data sets.
2.4.2 Mutation search
Selected candidate genes were screened by sequencing all coding regions by con-
ventional Sanger method. Regions with nucleotide repeat motifs were amplied
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Table 2.1: Genes and diseases with trinucleotide repeat expansion
[Genes and diseases with trinucleotide repeat expansion.]
Gene Disease Repeat Repeat location
AR SBMA CAG Coding region
ARX X-linked MR GCG Coding region
ATN1 DRPLA CAG Coding region
ATXN1 SCA1 CAG Coding region
ATXN10 SCA10 ATTCT Intron
ATXN2 SCA2 CAG Coding region
ATXN3 SCA3 CAG Coding region
ATXN7 SCA7 CAG Coding region
ATXN8 SCA8 CTG / CAG UTRs, coding region
CACNA1A SCA6 CAG Coding region
DM1 DM1 CTG 3'UTR
FMR1 FMR1 CGG 5'UTR
FMR1 FXTAS CGG 5'UTR
FMR2 FMR2 GCC 5'UTR
FXN FRDA GAA Intron
HTT HD CAG Coding region
JPH3 HDL2 CTG 3'UTR, coding region
PABPN1 OPMD GCG Coding region
PPP2R2B SCA12 CAG Promoter, 5'UTR
TBP SCA17 CAG Coding region
ZNF9 DM2 CTG Intron
Abbreviations of disease names: DM, myotonic dystrophy; DRPLA, dentatorubral-pallidoluysian atrophy; FMR,
fragile X mental retardation syndrome; FRDA, Friedreich's ataxia; FXTAS, fragile X tremor ataxia syndrome;
HD, Huntington's disease; HDL2, Huntington's disease-like 2; MR, mental retardation; OPMD, oculopharyngeal
muscular dystrophy; SBMA, spinal and bulbar muscular atrophy; SCA, spinocerebellar ataxia.
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and analysed by gel electrophoresis using the DNA of aected and healthy indi-
viduals.
2.4.2.1 Primers
PCR primers for all consensus splice sites and exons of the candidate genes were
designed by using web based Primer3 software (http://frodo.wi.mit.edu/).
All primers were veried by in-silico PCR (http://genome.ucsc.edu/cgi-bin/
hgPcr) and BLAT (http://genome.ucsc.edu/cgi-bin/hgBlat) tools. Primers
were purchased from Iontek Inc. (Istanbul, Turkey).
2.4.2.2 PCR conditions
75-150 ng of DNA samples were used as template for polymerase chain reaction
(PCR). The optimal PCR conditions consisted of 2.5µL PCR buer (10X), 1.5µL
MgCl2 (25 mM), 0.3µL dNTPs (10mM), 1µL (10pmol/µL) from each primer and
0.2µL Taq DNA Polymerase (5U/µL) (MBI Fermentas, NY, USA). PCR reaction
volumes were adjusted to 25 µL with ddH20 in standart reactions. When necessary,
nal volume was increased up to 50µL. Reactions were performed in TechneTM
TC-512 thermal cycler. Reaction conditions were 5 min initial denaturation at
94, followed by 35 cycles of 94 for 30 sec, 56 - 64 for 30 sec and 72 for
30 sec and 5 min nal extension at 72. PCR conditions were optimized when
necessary by addition of PCR additives (DMSO, BSA) and by changing reaction
conditions.
2.4.2.3 Agarose gel electrophoresis
Agarose (Basica LE, EU) was dissolved in 1X TAE buer with a nal percentage
of 1%. 30 ng/µL ethidium bromide was used as uorescent tag. PCR products
were mixed with 6X loading dye solution prior to loading onto agarose gel. pUC
Mix Marker 8 and Mass Ruler DNA Ladder (MBI Fermentas, NY, USA) were
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Figure 2.3: DNA Markers used in this study. Sizes of the fragments were shown.
MassRuler DNA Ladder: 10µL per lane, 1% agarose gel, 1X TAE 7 V/cm, 45
minutes. pUC Mix Marker 8: 0.5µg per lane, 1.7% agarose gel, 1X TBE, 5 V/cm,
1.5 hours. (http://www.fermentas.com/en/support/printed-media).
used as DNA markers (Figure 2.3). Electrophoresis running times and voltages
were determined according to the size of PCR amplicons. Gels were visually
analysed and images were captured by using GelDoc imaging system (Bio-Rad,
CA, USA) and MultiAnalyst software version 1.1 (Bio-Rad, CA, USA).
2.4.2.4 Polyacrylamide gel electrophoresis (PAGE)
10X TAE and 10% Ammonium persulfate was mixed with 30% acry-
lamide:bisacrylamide solution (29:1) and TEMED was added to the solution.
10µL of each sample was loaded into gels. Gels were run at 15 W for 2-4 hours
according to the length of the gel. Then, they were stained with EtBr for 10 min
and destained in ddH20 for 5 min. Gels were visually analysed and imaged by
using GelDoc imaging system (Bio-Rad, CA, USA) and MultiAnalyst software
version 1.1 (Bio-Rad, CA, USA).
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2.4.2.5 Sequencing reactions
PCR products were puried by using MinEluteTM 96 UF PCR Purication Kit
(Qiagen, MD, USA). Puried products were sequenced using forward and reverse
primers on an ABI 3130 XL capillary sequencing instrument (Applied Biosys-
tems). Purication and sequencing steps were carried out by Refgen Corp.
(Ankara, Turkey).
2.4.2.6 Data analysis
Raw sequence data les were obtained as AB1 sequence trace format. Each
Sanger sequence trace le were aligned to the corresponding reference sequence
and analysed by CLCBio Main Workbench (CLC bio, Denmark).
2.5 Targeted next generation sequencing
Next generation sequencing technologies were proceeded to use in 2007. This
technology has not been used to identify a disease causing mutation until the
period of this study. The disease locus contained more than 150 genes and can-
didate gene approaches were limited. Therefore sequencing the entire region was
the best strategy to identify disease causing mutation. For this purpose, two dif-
ferent sequencing platforms, 454 GS FLX and Illumina Genome Analyser, were
used.
2.5.1 Probe design and production
For 454 platform, critical region was targeted by NimbleGen 385K microarrays.
7,437 probes were designed to target the critical region by using the Sequence
Search and Alignment by Hashing Algorithm (SSAHA)[70]. Due to the length
of the region, a Perl script was developed in order to understand if all coding
CHAPTER 2. MATERIALS AND METHODS 34
Figure 2.4: Locations of the probes on the targeted region. Probes were visually
analysed by the Genome Browser (http://genome.ucsc.edu). An exon laying
inside a gap and two exons partially covered in this region are shown.
regions were targeted by designed probe set. For this purpose, exon coordi-
nates (n=1,848) of each alternative transcript variant were obtained from the
ENSEMBL database. Regions within the start-end coordinates and 200 bp ank-
ing sites of each probe were accepted as under coverage. Partially covered exons
and completely non-covered exons were identied with the algorithm summarized
in Figure 2.5. Probe coordinates were converted to BED format to visually anal-
yse the probe locations by Genome Browser. As an example, Genome Broswer
display of Exon 37 of USP6 gene, located in a 1,213bp gap was shown in Fig-
ure 2.4.
It was determined that, a total of 32 exons were located within the gaps. Eight
exons were identied as completely not covered by the probe design (Table 2.2).
Those regions were re-analysed by the SSAHA algorithm using less stringent pa-
rameters. Then, they were added to the chip design. Microarrays were produced
with 7,464 unique probes and a total probe length of 4,853,455 bp targeting a 7.1
Mb region on chromosome 17p.
For Illumina sequencing, a total of 6,184,539 base pair long unique probes
were designed using the SSAHA [70]. Probes were printed on a NimbleGen HD2
2.1M sequence capture microarray which targeted an extended region of 9 Mb
spanning the disease locus.
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Table 2.2: Exons located in the gaps between capture probes
Transcript a prb1_end e_start e_end prb2_start b Gap
Partially covered exons
AC087392.10-201 49 614,728 614,777 614,995 615,017 22 289
GLOD4-202 131 630,543 630,674 630,728 630,746 18 203
METT10D-201 235 2,304,970 2,305,205 2,305,243 2,305,418 175 448
AC015799.23-201 2 2,407,516 2,407,518 2,407,604 2,408,096 492 580
PAFAH1B1-201 140 2,511,868 2,512,008 2,512,036 2,512,100 64 232
ALOX15-001 432 4,487,829 4,488,261 4,488,421 4,488,545 124 716
USP6-203 169 4,969,671 4,969,840 4,969,957 4,970,193 236 522
USP6-206 134 4,971,389 4,971,523 4,971,658 4,971,707 49 318
USP6-205 141 4,977,321 4,977,462 4,977,569 4,977,629 60 308
USP6-206 230 4,980,429 4,980,659 4,980,753 4,980,785 32 356
USP6-201 6 4,985,438 4,985,444 4,985,518 4,985,710 192 272
USP6-204 35 4,989,389 4,989,424 4,989,598 4,990,222 624 833
USP6-206 653 4,989,389 4,990,042 4,990,193 4,990,222 29 833
USP6-206 54 4,991,048 4,991,102 4,991,213 4,991,284 71 236
USP6-205 682 4,991,893 4,992,575 4,992,786 4,992,926 140 1,033
USP6-205 406 5,011,545 5,011,951 5,012,142 5,012,303 161 758
USP6-204 37 5,014,461 5,014,498 5,014,934 5,016,911 1,977 2,450
ZNF594-201 10 5,026,052 5,026,062 5,026,122 5,026,559 437 507
ZNF594-203 12 5,026,052 5,026,064 5,026,142 5,026,559 417 507
ZNF594-203 114 5,026,052 5,026,166 5,026,167 5,026,559 392 507
C17orf87-201 636 5,064,328 5,064,964 5,065,073 5,065,091 18 763
RPAIN-201 5 5,267,809 5,267,814 5,267,818 5,268,446 628 637
AC004148.1-201 10 5,269,389 5,269,399 5,269,524 5,269,667 143 278
RPAIN-202 110 5,271,189 5,271,299 5,271,308 5,271,464 156 275
SLC13A5-201 207 6,539,443 6,539,650 6,539,659 6,539,705 46 262
Completely non-covered exons
AC130689.8-201 230 1,707,746 1,707,976 1,708,188 1,708,436 248 690
PAFAH1B1-202 449 2,509,031 2,509,480 2,509,506 2,509,874 368 843
OR1D4-201 11,489 2,901,224 2,912,713 2,913,705 2,919,998 6,293 18,774
USP6-202 213 4,976,019 4,976,232 4,976,454 4,976,819 365 800
USP6-206 209 4,986,207 4,986,416 4,986,521 4,988,128 1,607 1,921
USP6-201 1,145 5,014,461 5,015,606 5,015,698 5,016,911 1,213 2,450
AC004148.1-201 348 5,273,948 5,274,296 5,274,302 5,274,524 222 576
Abbreviations of the table header are described in Figure 2.5.
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Figure 2.5: Algorithm of the identication of the exons which are not covered by
capture design. Exon-X is covered, exon-G in non-covered and exon-Y is partially
covered in this example.
2.5.2 Sequence capture and sequencing
25µg of DNA sample from each of the two obligate carrier parents (05-981,
05-982) and two aected siblings (05-985, 05-987) were captured with Nim-
bleGen 385K microarrays. Sequence capture was performed by NimbleGen
facility (Roche NimbleGen, WI, USA) according to manufacturer's protocol
(http://www.nimblegen.com/). Captured DNA samples were subjected to stan-
dard procedures for 454 GS FLX sequencing with Titanium series reagents. Four
full 454 GS FLX runs were conducted for each sample. Another aected individ-
ual (05-987) was captured by NimbleGen HD2 2.1M using 5µg DNA. Captured
DNA samples were subjected to standard procedures, and then sequenced by
Illumina Genome Analyser IIx platform (https://icom.illumina.com/).
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2.5.3 Sequence analysis
2.5.3.1 Mapping and annotation
SFF, FNA ve QUAL les were created from 454 GS FLX raw data. The se-
quence fragments obtained from next-generation sequence data is called "read".
FNA le is a FASTA le consists of the each individual sequence read with a
header line containing the code and length of the read. Corresponding qual-
ity score values for each base in the sequence reads are calculated with Phred
basecalling algorithm [71] and are stored in the QUAL les (Figure 2.6). SFF
(Standard Flowgram Format) le is the equivalent of the trace le of Sanger se-
quence data and contains information on the signal strength for each ow. First
level analysis were performed using these les obtained from the sequence data of
four individuals. First, sequence data was mapped to the hg18 reference human
genome sequence by using the gsMapper module of Newbler software (454 Life
Sciences, CT, USA) using standard genomic sequence mapping parameters. Vari-
ants were identied with ALLDis (All Dierences) and more stringent HCDis
(High-Condence Diereneces) approaches by gsMapper.Ref [72] The criteria of
the two approaches are:
 AllDis: There must be at least two non-duplicate reads that
1. show the dierence,
2. have at least 5 bases on both sides of the dierence,
3. have few other isolated sequence dierences in the read.
 HCDis: A dierence is considered High-Condence
1. If at least 3 reads match the conditions listed in AllDis criteria,
2. with at least one aligned in the forward direction and,
3. at least one aligned in the reverse direction.
Annotations were performed using refGene table of UCSC Genome Browser
(NCBI36/hg18) and novel variants were reported based on the SNPs included
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Figure 2.6: Contents of FNA and QUAL les. FNA les are fasta les containing
sequence read and information of each read. The quality scores of each bases are
stored at the QUAL les.
in the reference SNP129 database. Identied variants were saved in the AllD-
i.txt and HCDi.txt les (Figure 2.7). Variant informations were extracted
from AllDi and HCDi les by using UNIX command line tool grep and saved
as tab-delimited text les. Coordinate information data were further used to an-
notate variants by using custom annotation pipeline. Alignments were analysed
visually by a text editor. Sequence statistics for 454 data was provided by New-
bler software. All analysis were repeated with latest version of genome assembly
upon its availability.
Illumina sequence data was mapped to the human genome by using two dif-
ferent aligner. Maq performs ungapped alignment of single-end reads [73] and
was used to align sequence data to reference genome for single nucleotide variant
(SNV) detection. For detection of small insertion and deletions, a gapped global
alignment tool -BWA [74]- was used to align sequence data.
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Figure 2.7: Representation of a variant in a di le. In this gure, a header
line starting with > and alignment of the region is shown. The position of the
variant is chr17:1,577,570. This variant is detected in 97% of 40 the reads.
Analysis of the alignment data and identication of the variants were per-
formed by using Samtools.[75] Annotation of the Illumina variants was performed
by using annotation pipeline of Gunel's group, Yale University.
Alignment data of each platform was converted to tab-delimited IGV les to
analyse visually by using Integrative Genomics Viewer (IGV).[76]
Fold enrichment of the targeted region was calculated with the formulaP REMTrm
STrmP RMG
SG
as described previously (REMTrm: Number of reads mapped to target
region, STrm: size of target region, RMG: number of reads mapped outside of
the target region, SG: size of human genome).[77] Coordinates of the variants
were converted to hg19 genome assembly to re-analyse using updated annotation
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datasets. Mapping analysis were repeated using hg19 version of genome assembly
upon availability.
2.5.3.2 Coverage calculations
To reveal non-covered functional regions and possible deletions, functional cover-
age statistics were calculated by the following steps.
 For 454 data sequence read depths of each base were extracted from align-
ment info les of four individuals.
 For Illumina data, sequence read depths were obtained from alignment les
by using pileup function of Samtools.
 For each base position mean values of the total read depths were calculated
for the sequence data of three aected individuals.
 Bases were classied as non-covered (<2X mean read depth), low-coverage
(2-3X mean read depth) and covered ( 4X).
 Using the start-end coordinates of exons and untranslated regions of each
transcript, non-covered and low-coverage regions were annotated.
 A total statistics indicating the coverage percentages of each functional
genomic unit was calculated.
 To reveal if a non-covered region does actually indicate a pathogenic dele-
tion, alignments of heterozygous parents were analysed.
 Non-covered and low-coverage regions were further analysed by alignment
analysis of the next generation sequence data and Sanger sequencing to
reveal any possible mutations in these gaps.
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2.5.3.3 Genotype calling thresholds
In autosomal recessive disease gene identication studies, determination of the
genotype status of the variants is one of the critical steps for exclusion of the vari-
ants by segregation analysis. Thus, optimization of the heterozygosity thresholds
is crucial. As a rst level genotype designation, a rigid heterozygosity threshold
(30-70%) was used to maximize sensitivity for detection of homozygous variants.
Using this threshold, variants which were detected as more than 70% of the reads
were called as homozygous, and the variants which were detected as between 30-
70% of the reads were classied as heterozygous. A total of 1004 SNPs within
the targeted region were represented on Illumina 300 Duo v2 SNP microarrays.
To optimize genotype calling thresholds, genotypes of the 1004 Illumina SNPs
were compared with the Illumina 300 Duo v2 SNP microarray data and error
rates were calculated in the genotype data obtained by dierent heterozygosity
thresholds.
Mendelian errors (ie. AA x AA = AB) could be another method to optimize
genotype calling parameters. For this purpose, rst, genotypes of individuals
were determined using dierent heterozygosity thresholds (ie: 30-70%, 20-80%,
10-90%, 30-90%) and variants were converted and stored as PED and MAP les.
Then, Mendelian error rates were calculated by using PLINK software for each
threshold.
2.5.3.4 Functional classication
An annotation pipeline was developed to further analyse functional consequences
of the intronic and intergenic variants in terms of hypothetical genes and splicing
variants. ENSEMBL GENES and VARIATION tables for hg18 human genome
assembly were extracted from ENSEMBL54 database by using MartView inter-
face of BIOMART data-mining tool (http://www.ensembl.org) to build a cus-
tom database. A Perl script was developed to annotate the variants using the
custom annotation database. The annotated data were merged with the variant
data annotated by Newbler software using refGene table.
CHAPTER 2. MATERIALS AND METHODS 42
Novel variants were ltered and then, variants in consistent with the
Mendelian transmission of disease allele were selected (ie. variants detected as
heterozygous in parents and homozygous in aected sibling). The selected vari-
ants were binned into 4 groups as i. transcribed and consensus splice site, ii. 5'
& 3'UTRs, iii. intronic and iv. all remaining variants.
SNPs which were detected as homozygous in carrier parents were excluded.
For the remaining SNPs which were compatible with the Mendelian transmission
of disease allele, population frequencies were obtained from public databases.
Variants which have not been detected as homozygous in healthy population
were considered as a potential disease causing mutation.
2.6 Identication of disease causing mutation
2.6.1 Segregation analysis
Each functional novel variant was veried by Sanger sequencing in two aected
and two carrier individuals. To reveal the segregation status, all variants were
genotyped in all family members by using the appropriate genotyping methods
(Table 2.3) as described below.
2.6.2 Population screening
Functional variants were further genotyped in control groups in order to exclude
rare polymorphisms from disease causing mutation. For this purpose, three con-
trol groups were used: i. 214 unrelated healthy controls (428 chromosomes), 50 of
whom were sampled from the same region of Turkey as Family B, ii. independent
series of 400 individuals of various European and Middle Eastern ancestries, iii.
177 members from the kindred of family-B spanning 5 generations. Genotyp-
ing experiments were performed using restriction digestion or allele specic PCR
assays.
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The variants were further analysed in 1000 genomes (http://www.
1000genomes.org) and ESV datasets (http://evs.gs.washington.edu/EVS/).
1000genomes data were downloaded from the ftp server of the project (ftp:
//ftp.1000genomes.ebi.ac.uk/vol1/ftp/). Genotype data were then anal-
ysed by VCF tools[78] and custom Perl scripts.
2.6.2.1 Restriction fragment length polymorphism
Restriction enzymes were determined by using NEBcutter.[79]. The regions con-
taining the variants were amplied using the appropriate primers (Table 2.3) as
described in 2.4.2.2. Restriction enzyme digestion was carried out with 5µL of
PCR products. 2µL of restriction buer, 1 Unit of restriction enzyme (MBI
Fermentas, NY, USA) and 12.80µL of ddH20 were mixed with PCR products.
Restriction digestion reaction mixtures were incubated at 37, for 4 hours or
overnight. 10µL of each digestion product was analysed by 1.0-2.0% agarose gel.
2.6.2.2 Allele specic PCR
For the variants, which were not located inside a restriction enzyme recognition
site, allele specic PCR (AS-PCR) primers were designed for wild-type and mu-
tant alleles (Table 2.3). Standard multiplex PCR reactions were performed with
the addition of a reference primer as internal control. PCR products were then
analysed on 1.0-2.0% agarose gel electrophoresis.
2.7 Screening the candidate genes in disease co-
horts
Candidate genes were further screened in dierent cohorts of patients with neu-
rodevelopmental phenotypes for whom the genetic aetiology is unknown. The
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Table 2.3: Primers and methods for genotyping of candidate variants
Locus Forward Reverse SizeMethod
Sequencing primers
WDR81_V1 TGCCTACTCCACAGGGACA CTGCCACAGAGCAAACACC 429 Sanger
MYBBP1A_V15 AGCCGCACCAAGACCATC CAGCCCACATTCCACTCC 290 Sanger
ZNF594_361 GGTGTGACCTCTGGCTGAA TCATTTGGCGCACAGCTT 426 Sanger
Genotyping primers and methods
WDR81_WT TGTCTCCCAGGGCCTGCC GGACATGAGTGAGAGCACGA 250 AS-PCR
WDR81_MUT TGTCTCCCAGGGCCTGCT GGCAACAGGCTCAAACAGAT 301 AS-PCR
MYBBP1A_V15 AGCCGCACCAAGACCATC CAGCCCACATTCCACTCC 290 HpaII RD
ZNF594_361 GGTGTGACCTCTGGCTGAA TCATTTGGCGCACAGCTT 426 BglII RD
Abbreviations used in this table: RD, Restriction Digestion; AS-PCR, Allele specic polymerase chain reaction.
genes were sequenced in the rst cohort consisted of 58 probands 12 had cere-
bellar hypoplasia (See Appendix A for primer lists). Another cohort consisted of
750 patients with structural cortical malformations or neurodegenerative diseases
with unknown aetiology. In the second cohort, homozygous regions spanning the
linkage interval were examined using the genotype data based on Illumina Human
370 Duo or 610 Quad BeadChips.
2.8 Functional characterization
2.8.1 Evidence of WDR81 transcript
The mutation responsible for the disease was detected in the rst exon of a
predicted transcript of WDR81. To reveal the expression of the transcript and
other possible transcript variants which may contain mutation site, an exon-
spanning RT-PCR approach was performed. For this purpose, cDNA of human
adult cerebellum was amplied using a forward primer 280 bp upstream from the
mutation site and reverse primers for each of the exons (Appendix A).
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2.8.2 Quantitative PCR analysis
The PCR primers anking the mutation site were designed by Primer3 soft-
ware (http://frodo.wi.mit.edu/) and were veried by in-silico PCR (http:
//genome.ucsc.edu/cgi-bin/hgPcr) and BLAT (http://genome.ucsc.edu/
cgi-bin/hgBlat) tools. Primers were purchased from Iontek Inc. (Istan-
bul, Turkey). Primers for WDR81 (WD40 repeat protein 81) were: F-5'-
GCAAGCTGGACCAACTGTTT-3' and R-5'-GGGAAGTAGGGTGGGAAGG-
3'. GAPDH (glyceraldehyde-3-phosphate dehydrogenase) was used as refer-
ence gene and primers were: F-5'-AGGTGAAGGTCGGAGTCAAC-3' and R-
5'-GGGTCATTGATGGCAACA-3'. GAPDH primers were obtained from Dr.
Önder Bozdo§an, Bilkent, Ankara.
Real-time quantitative PCR reactions were performed using SYBR Green Mix
(Bio-Rad, CA, USA) according to the standard protocols. 25µL of PCR reaction
mixtures were prepared by 12.5 µL SYBR Green mix, 0.5 µL of each primer (10
pmol/µL), 6.5µL ddH20 and 5 µL of 1:5 diluted cDNA.
Reactions were performed in triplicate with the following PCR conditions: 10
min initial denaturation at 94, followed by 40 cycles of 94 for 30 sec, 60
for 30 sec and 72 for 30 sec and 5 min nal extension at 72. Melting curve
analysis was performed following amplication step by raising temperature from
55 to 94 with 0:5 increments at each 15 seconds. Data were analysed using
the Pfa method [80] and normalized according to the GAPDH expression. PCR
products were further analysed on 1.5% agarose gel.
2.8.3 In situ hybridization
In order to reveal the expression pattern of the Wdr81 in mouse brain, in situ
hybridization experiments were performed. Experiments were carried out at
Nanobiotechnology labs, UNAM, Turkey. The probes targeting the mutation
region in human patient were prepared from mouse genomic DNA by ampli-
cation of the region. The PCR amplicons cloned into pCR®4-TOPO plasmids
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(Invitrogen, CA, USA) for the antisense probes. To obtain sense probes, the
same region was cloned into a modied pSK vector. Then, riboprobes were syn-
thesized by using digoxigenin labeled NTPs. Mini Quick Spin DNA columns
(Roche, Germany) were used to purify riboprobes.
Procedures were approved by the Animal Ethics Committee of Bilkent Univer-
sity. Animals were group housed in a 12-hour dark, 12-hour light cycle. Animals
were anesthetized by intraperitoneal administration of Ketamine (40-50 mg/kg)
and Xylazine (5 mg/kg). Then, mice were perfused with 4% paraformaldehyde
by injecting into left ventricule. Brains of decapitated animals were removed
and post-xed in 4% paraformaldehyde for 1 hour at 4. The brains were then
placed in sucrose solution at 4. Serial sagittal sections of P7 brain were cut at
20 microns with cryostat (Leica) and directly mounted onto HistoBond (+) slides.
Sections were incubated overnight in hybridization buer at 60. The hybridiza-
tion buer contains 50% formamide, 5xSSC, 5x Denhardt's reagent, 50µg/mL
Heparin, 500µg/mL herring sperm DNA, and 250µg/mL yeast tRNA. Sections
were then washed with 50% formamide and 2X SSC at 60 for 90 min. Then,
anti-Dig Fab fragments conjugated to Alkaline Phosphatase and NBT/BCIP sub-
strate mixture was used to detect the probes.
2.9 Functional prediction
2.9.1 Functional prediction of the variants
Disease causing probability of the variants were predicted by using SIFT[50]
and PolyPhen[53] tools. Coordinates of the variants were converted into lat-
est human genome assembly version (hg19) by using liftOver (http://genome.
ucsc.edu/cgi-bin/hgLiftOver) to analyse in up-to-date versions of predic-
tion software and datasets. Genomic Evolutionary Rate Proling (GERP)[46]
scores were obtained from UCSC Genome Browser allHg19RS_BW track. Do-
mains of the protein product of candidate gene were predicted by using PFAM
protein domain search module of CLCMain Workbench V5.0 (CLCBio, Inc.)
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and ScanProsite[81]. Then, possible eects of the mutation was evaluated.
Membrane spanning domains were predicted using TMpred software (http:
//www.ch.embnet.org/software/TMPRED\_form.html). Homologous proteins
were identied and alignments were done by using CLCMain Workbench using
appropriate modules.
2.9.2 Data mining from published expression datasets
Expression of the candidate gene in fetal brain tissues was evaluated using
the published microarray data sets of E9.5, E11.5 and E13.5 mouse brain tis-
sues (GSE8091)[82] from the GEO database (http://www.ncbi.nlm.nih.gov/
projects/geo/query/acc.cgi). GeneSpring GX V11.1 software (Agilent Tech-
nologies, Inc.) was used to analyse data-sets. First, data were grouped into day
groups. Standard quality control and ltering analysis were performed with ap-
propriate modules of the software (http://www.chem.agilent.com/cag/bsp/
products/gsgx/manuals/GeneSpring-manual.pdf). One-way ANOVA Test
was used to lter dierentially expressed genes within groups (Bonferroni cor-
rected p < 0:001). Genes that correlated highly with the gene of interest (R=0.95-
1.0) was identied by the Find Similar Entity Lists module. Then, functional
annotation clustering of the subset of correlated genes was performed by DAVID
tools [83].
A web-based data-mining engine NextBio[84] was used to further investigate
the dierential expression of the candidate gene in GEO datasets. Signicant
association was found in the analysis of GSE4175[85] dataset.
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2.10 Chemicals, reagents and enzymes
2.10.1 Enzymes
All the restriction digestion enzymes and Thermus aquaticus polymerase enzymes
were purchased from MBI Fermentas (NY, USA).
2.10.2 Solutions and buers
1X TAE (Tris-acetic acid-EDTA): 40mM Tris-acetate,
2 nM EDTA, pH 8.0
Ethidium bromide: 10mg/ml in water
(stock solution)
30 ng/ml (working solution)
Agarose gel loading buer (6X): 15% coll
0.05% bromophenol
0.05% xylene cyanol
Acrylamide:bisacrylamide (30%): 29.5 gr acrylamide
0.44 gr bisacrylamide
ddH2O to 100 ml
SSC (20X): 175.32 gr Sodium Chloride
88.23 gr Sodium Citrate
ddH20 to 1 lt
pH to 7.0
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2.10.3 Chemicals and reagents
Reagent/Chemical Company
Agarose Basica LE, EU
Acetic acid Sigma, MO, USA
Acrylamide Sigma, MO, USA
Ammonium persulfate Carlo Elba, Italy
Bisacrylamide Sigma, MO, USA
Bromophenol blue Sigma, MO, USA
dNTPs Fermentas, NY, USA
EDTA Fermentas, NY, USA
Ethanol Merck, Germany
Ethidium bromide Sigma, MO, USA
TEMED Sigma, MO, USA
Tris-Base Bio-Rad, CA, USA
Trizol reagent Invitrogen, CA, USA
Formamide (Deionized) Ambion, TX, USA
Denhardt's reagent Invitrogen, CA, USA
Tween-20 Sigma, MO, USA
Heparin Sigma, MO, USA
Herring sperm DNA Invitrogen, CA, USA
Bakers yeast RNA Sigma, MO, USA
Anti-Digoxigenin-AP, Fab fragments Roche, Germany
NBT Roche, Germany
BCIP Roche, Germany
CHAPS Sigma, MO, USA
NH4OAc Ambion, TX, USA
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2.11 Reference sequences used in this study
Accession codes for WDR81 orthologs are:
Ailuropoda melanoleuca: XP_002918082
Callithrix jacchus : XP_002747874
Danio rerio: XP_001921778
Equus caballus : XP_001502383
Gallus gallus : XP_415806
Monodelphis domestica: XP_001371487
Mus musculus : NP_620400
Oryctolagus cuniculus : XP_002718930
Pan troglodytes : XP_523527
Pongo abelii : XP_002826860
Rattus norvegicus : NP_001127832
Sus scrofa: XP_003131868
Taeniopygia guttata: XP_002194363
Tetraodon nigroviridis: CAG08933
Xenopus (Silurana) tropicalis : XP_002937192
Chapter 3
Results
3.1 Clinical assessment of the aected family
The aected individuals originated from a consanguineous family in south-eastern
Turkey. Six of the 19 children exhibited mental retardation, dysarthric speech,
truncal ataxia. Five of the aected siblings were exhibited quadrupedal locomo-
tion. One aected male was bipedal but exhibited similar neurological symptoms.
Another aected sibling was deceased at age of 26. However, the phenotype of
the deceased individual was not clear. Quadruped patients were well balanced
and did not show any ataxic movements while walking on all fours (Figure 3.1).
Their ulnar palms make contact with ground. In resting state, patients were
able to stand upright but they quickly returned to the quadrupedal position for
walking. Aected individuals have dysarthric speech with limited vocabulary.
Mini Mental State Examination Test was used to asses their mental abilities
and revealed severe mental retardation. They understood and respond to simple
questions in their own language, but they did not show consciousness on time
and place. Neurological examination of the index case revealed cerebellar ataxia,
intentional tremor without pyramidal signs, bilateral dysmetria, dysdiadochoki-
nesia and mildly decreased muscle tones. Brain imaging using cranial magnetic
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Figure 3.1: Quadrupedal locomotion by a male patient.
Figure 3.2: MRI of a male patient. Coronal (A), sagittal (B), and transverse
(C) sections are shown. A and B arrows shows cerebellar hypoplasia and midline
clefting. Note hypoplasia of the corpus callosum (B) and enlargment of the fourth
ventricle (C). (From Turkmen et al. 2006 [10] by permission)
resonance revealed a number of anatomical abnormalities including, cerebellar hy-
poplasia, complete absence of inferior vermis, enlarged fourth nucleus, and mild
hypoplasia of the corpus callosum (Figure 3.2). Obligate carrier father and an
unaected carrier brother had normal brain.[9, 10]
Further characterization of structural abnormalities of the brain of the af-
fected individuals was carried out by magnetic resonance imaging and morpho-
metric analyses. Volume in the cerebellum, corpus callosum, cortex and white
matter was found to be reduced (Figure 3.3A). There were signicant structural
dierences in motor areas precentral gyrus and BA6, and motor speech areas pars
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opercularis and pars triangularis (Figure 3.3B). There was also moderate to high
atropy in superior, middle and inferior cereballar peduncles revealed by diusion
tensor imaging (DTI).(Figure 3.4)
Figure 3.3: Morphological analysis of brain from aected and unaected individ-
uals. (A) Midsagittal MRI scans of a healthy control individual (left) and aected
relative from Family B (right). The highlighted regions show areas where vol-
umetric dierences are readily visible: corpus callosum (1), third ventricle (2),
fourth ventricle (3), and cerebellum (4). (B) Cortical regions with signicant
dierences in morphometric parameters are displayed on a reference cortex, from
lateral and medial view: BA45 (5), BA44 (6), BA6 (7), precentral (8), superior
temporal (9), superior parietal (10), lateral occipital (11), fusiform (12), isthmus
cingulated (13), posterior cingulated (14), frontal pole (15), medial orbitofrontal
(16), and temporal pole (17).(From Gulsuner et. al. 2011 [11] by permission)
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Figure 3.4: Diusion tensor imaging (DTI) and ber tractography. Fibers of
the inferior middle and superior cerebellar peduncles of 1 female patient and 2
controls are shown. Peduncles of the patient are atrophic compared to healthy
controls; this is most obvious in the middle cerebellar peduncle. (From Gulsuner
et. al. 2011 [11] by permission).
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3.2 Genetic mapping
Pedigree analysis of the family showed autosomal recessive inheritance of the dis-
ease. Previously, disease locus was mapped to a 7.1 Mb region on chromosomes
17p between markers D17S1866 and D17S960.[10] Linkage analysis with autoso-
mal recessive model using Aymetrix 10K Xba GeneChip SNP data conrmed
the previously reported locus on chromosome 17p (Figure 3.5 and Appendix B).
Minimal critical region was further saturated and conrmed by genotyping with
microsatellite markers and haplotype analysis (Figure 3.6).
Figure 3.5: Parametric linkage analysis revealed a single locus on chromosome
17p. See appendix B for the remaining chromosomes.
However, genotype data of chromosomes 1, 2, 5 and 14 was not informative
for linkage analysis and those chromosomes could not be excluded (Appendix B).
In addition, homozygosity mapping analysis using 10K SNP data resulted with
three homozygous loci on chromosomes 8, 14 and 17. The 10K SNP microar-
rays contain low number of SNPs (n=10,204) and do not represent all regions of
human genome. In addition, genotype data of the family contains several miss-
ing genotypes (ie. 05-985: 22%, 05-986: 19%) and had relatively low condence
scores. Thus, analysis was repeated with high resolution Illumina 300 Duo v2
BeadChip (SNP count=318,328) using DNA of two aected individuals (05-984
and 05-987). All chromosomal regions except the minimal critical region on chro-
mosome 17p were excluded by homozygosity mapping analysis using Illumina
data. The minimal critical region was detected between 114,669-6,917,703 base
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pairs (hg19) on chromosome 17 (Figure 3.7).
Figure 3.6: Haplotype analysis of minimal critical region on chromosome 17p.
Haplotypes of the family conrmed the disease locus.
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Figure 3.7: Homozygosity mapping analysis. Genotype data was obtained from
05-984 and 05-987 using Illumina 300 Duo v2 BeadChip microarrays. Only one
single region was detected (chr17:114,669-6,917,703). Analysis was performed by
using HomozygosityMapper software. Y-axis indicates genome-wide homozygos-
ity scores (max=500). Red bars refers to the homozygous regions.
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3.3 Candidate gene sequencing
The minimal critical region on chromosome 17p (D17S1866-D17S960) consisted
of 214 genes (Appendix C.1) including 151 protein coding and 23 RNA genes
(GRCh37.p5) with a total of 482 transcripts. Regarding to the huge number of
genes which segregate with the disease in the family, a candidate gene sequencing
approach was realized and three dierent screening strategies were employed.
CAMRQ is a genetically heterogeneous disease and the rst gene implicated
in CAMRQ is VLDLR.[12] It is suggested that, genetically heterogeneous diseases
could be raised from disruptions of the same or related biological pathways.[86]
Hence, rst an interaction analysis of VLDLR protein was employed. A total of
2139 proteins were found to be interacted with VLDLR up to three connection
levels by APID (Agile Protein Interaction DataAnalyzer). Probably 10 proteins
directly interact with VLDLR which constitutes the rst level. Approximately
an additonal 81 proteins interact with those 10 at the rst level, and nally 2139
proteins found to be interacting with the 81 genes of the second level. Next,
the corresponding genes of those 2139 proteins were merged with those genes in
the 17p13 interval. This analysis yielded 20 genes, of which 16 were known to
have cerebellar expression. Two of them, CRK and LIS1 (PAFAH1B1 ), encode
for proteins that directly interact with DAB1, which is a key protein of Reelin
pathway (Figure 3.8 and Table 3.1) Furthermore, we found an additional protein
(KIF1C) in Reelin Pathway using GeneAssistTM Pathway Atlas.
Next, DGP tool (Disease Gene Prediction)[37] revealed CRK as one of the
most likely candidates (Table 3.2). The second tool, Prospectr (PRiOrization by
Sequence & Phylogenetic Extent of CandidaTe Regions) identied SCARF1 as
the candidate with the highest weight score (Table 3.2).
In conclusion, these combined bioinformatics approaches resulted in the iden-
tication of CRK, LIS1 (PAFAH1B1 ), KIF1C, and SCARF1 as candidate genes.
Exons, exon/intron boundaries and untranslated regions of four candidate
genes were sequenced using 77 primer pairs. 98.7% (76/77) of the sequencing
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Table 3.1: Proteins interacting with VLDLR.
Ensembl Gene ID Location Gene symbol UniProt/Swiss-Prot ID C.Exp
ENSG00000108953 1,194,595 YWHAE 1433E_HUMAN +
ENSG00000167193 1,272,226 CRK CRK_HUMAN +
ENSG00000174238 1,368,037 PITPNA PIPNA_HUMAN +
ENSG00000074660 1,483,903 SCARF1 SREC_HUMAN +
ENSG00000174231 1,500,674 PRPF8 PRP8_HUMAN +
ENSG00000167711 1,593,070 SERPINF2 A2AP_HUMAN +
ENSG00000132383 1,680,095 RPA1 RFA1_HUMAN +
ENSG00000007168 2,443,686 PAFAH1B1 LIS1_HUMAN +
ENSG00000205813 3,128,014 OR3A2 OR3A2_HUMAN 
ENSG00000083457 3,564,672 ITGAE ITAE_HUMAN 
ENSG00000074755 3,854,489 ZZEF1 ZZEF1_HUMAN 
ENSG00000129219 4,657,392 PLD2 PLD2_HUMAN +
ENSG00000141503 4,728,437 MINK1 MINK1_HUMAN +
ENSG00000185245 4,776,680 GP1BA GP1BA_HUMAN +
ENSG00000108518 4,789,723 PFN1 PROF1_HUMAN +
ENSG00000108561 5,276,676 C1QBP C1QBP_HUMAN +
ENSG00000091592 5,345,858 NLRP1 NALP1_HUMAN 
ENSG00000108590 6,487,789 MED31 MED31_HUMAN 
ENSG00000108839 6,840,128 ALOX12 LOX12_HUMAN +
ENSG00000132535 7,033,933 DLG4 DLG4_HUMAN +
Abbreviations used in this table: C.exp, cerebellar expression.
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Table 3.2: Disease gene prediction. Scores calculated using DGP, Prospectr and
Suspects.
Gene VLDLR Ataxia Cerebellar Sum DGP D.P.
SCARF1 63,04 12,86 12,71 88,61 0,34 No
PITPNA 50,3 12,68 17,26 80,24
TRPV1 49,87 15 14,52 79,39 0,66 No
ASGR1 40,39 10,21 10,06 60,66
RABEP1 39,52 12,08 13,4 65 0,62 No
CLEC10A 39,39 9,2 9,05 57,64
TM4SF5 15,18 15,18 15,18 45,54 0,59 No
CHRNE 14,14 17,5 16,62 48,26 0,7 Yes
PRPF8 13,33 13,33 13,33 39,99 0,75 Yes
KIF1C 13,3 11,5 10,2 35 0,5 No
ACADVL 13,24 13,52 13,24 40
C1QBP 13,17 13,17 13,17 39,51 0,6 No
SLC25A11 13,08 16,05 17,85 46,98 0,53 No
CTNS 13,01 13,01 13,01 39,03 0,73 Yes
P2RX5 12,26 11,81 11,84 35,91 0,53 No
RNF167 12,17 12,17 12,17 36,51
PSMB6 12,03 12,68 12,03 36,74 0,54 No
MYO1C 11,88 14,81 11,88 38,57 0,52 No
RPA1 11,87 16,03 14,58 42,48 0,56 No
DVL2 11,81 11,81 11,81 35,43
SKIP_HUMAN 11,48 12,6 12,79 36,87
SLC13A5 11,48 12,44 12,28 36,2 0,6 No
DLG4 11,09 12,03 10,73 33,85
SERPINF1 10,72 10,27 10,3 31,29 0,34 No
SPAG7 10,7 10,7 10,7 32,1 0,41 No
TAX1BP3 10,7 10,7 10,7 32,1
UBE2G1 10,65 10,65 10,65 31,95 0,31 No
PLD2 10,56 15,42 20,73 46,71 0,47 No
ALOX15 10,38 10,66 10,38 31,42 0,54 No
ASPA 10,36 10,36 10,36 31,08 0,67 Yes
ARRB2 10,33 10,33 10,33 30,99 0,5 No
DULLARD 10,33 10,33 10,33 30,99
CAMTA2 10,26 10,26 10,26 30,78 0,52 No
ATP2A3 10,2 14,38 19,99 44,57 0,47 No
MINK1 9,4 14,02 16,61 40,03
CRK 9,38 10,19 10,47 30,04 0,75 No
GABARAP 9,32 12,07 11,43 32,82
ENO3 9,2 10,98 9,2 29,38 0,74 No
PFN1 9,2 9,23 9,2 27,63 0,34 No
NUP88 9,04 9,04 9,04 27,12 0,38 No
SRR 8,94 9,84 8,94 27,72 0,53 No
CAMKK1 8,94 13,1 12,27 34,31 0,57 No
ALOX12 8,86 9,79 8,86 27,51 0,6 No
GP1BA 8,71 10,54 8,71 27,96 0,7 Yes
GPS2 8,29 8,72 9,58 26,59
ABR 7,71 10,91 18,25 36,87 0,55 No
GEMIN4 7,38 7,38 7,38 22,14 0,2 No
PAFAH1B1 7,24 11 10,15 28,39 0,74 Yes
YWHAE 6,65 6,65 6,65 19,95 0,7 Yes
MYBBP1A 6,55 6,55 6,55 19,65 0,4 No
USP6 4,96 4,96 4,96 14,88 0,39 No
ITGAE 0.69 No
Abbreviations used in this table: D.P., disease phenotype.
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Figure 3.8: APID interaction analysis. An example output of interaction analysis
is shown. SCARF1, CRK, LIS1 (PAFAH1B1 ), and KIF1C are located in the
minimal critical region. KIF1C is obtained from GeneAssistTM Pathway Atlas
manually added to the interactome gure.
reactions were successfully realized. Prior to sequencing all PCR products were
analysed using PAGE electrophoresis to identify any possible small insertions
and deletions. PCR amplicons were then sequenced using forward and reverse
primers. However, no mutation that segregated with the disease was detected.
Expansion of several nucleotide repeats are commonly observed in neurological
phenotypes. To rule out this mechanism as the cause of disease in family B, a
nucleotide motif search in minimal critical region was realized. A total of eight
nucleotide repeats were detected in the intragenic regions (Table 3.4). However,
gel electrophoresis following the amplication of the regions did not reveal any
change in the size of the repeats.
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Table 3.3: Candidate gene sequence analysis.
Gene Exon # Total reaction Sanger
KIF1C1 23 26 100%
CRK 3 12 91.6%
SCARF1 11 15 100%
PAFAH1B1 11 24 100%
Table 3.4: Repeat motifs in the minimal critical region.
Gene Repeat type Repeat location
WDR81 GAA * 5 Intron 2-3
HIC1 CGG * 7 Exon 2
RUTBC1 CGG * 7 Exon 1
MNT CAG * 4 Exon 6
PAFAH1B1 CGG * 8 - 49 bp
GARNL4 CGG * 4 - 19 Mb
GARNL4 AGG * 11 - 19 Mb
TRPV1 CTG * 8 Intron 1-2
3.4 Targeted next generation sequencing of the
critical region
The rate limiting step of the disease gene identication is between the identi-
cation of disease locus and nding the disease causing mutation. In most cases,
disease locus contains hundreds of genes and candidate gene approaches fail to
identify the culprit gene. A brute-force approach to sequence all genes in the min-
imal critical region with conventional approaches is very expensive and requires
both extensive human labour and time. The minimal critical region in family B
contains 482 transcripts with a total length of 515,569 bp (GRCh37.p5) which
can be sequenced with at least 1000 PCR primer pairs and 4000 sequencing re-
actions to completely rule out all coding regions. Therefore it was decided that,
using next generation sequencing approaches to sequence the 7.1 Mb region was
the most cost-ecient strategy to nd the culprit gene.
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3.4.1 Capture and sequencing of the locus
Genomic DNA was obtained from blood samples of individuals by phenol-
chloroform and ethanol precipitation method. Quality and quantity of the DNA
samples were measured by spectrophotometry, PicoGreen method and analytical
gel electrophoresis (Figure 3.9, Table 3.5). Then, the minimal critical region at
chr17 (82,514-7,257,922 bp according to hg19) was captured using the DNA of two
aected (05-985, 05-987) siblings and two obligate carrier parents (05-981 father,
05-982 mother) by Nimblegen 385K microarrays. 362 to 403 million base pairs
(46.4X mean haploid coverage) were sequenced from captured DNA of each indi-
vidual with 454 GS FLX using Titanium series reagents. Approximately 78.7% of
the reads from each sample fell within the targeted region, which represents 1,275
to 2,247 fold enrichment. On average, 99.4% of all targeted bases were covered by
at least 4 reads, which is used as the threshold for the detection of homozygous
variants (Table 3.6). The statistics of the 454 sequencing is summarized in Table
3.7. An extended region (chr17:0-9,059,279) was captured by Nimblegen HD2
2.1M sequence capture microarrays using the DNA from another aected sibling
(05-984). Captured DNA was then, sequenced on an Illumina Genome Analyzer
IIx. 2.98 billion bases and 40.3 million reads were obtained. 27.88% of the reads
were mapped to the targeted region. The calculated enrichment was 123 folds.
99.6% of the bases were covered by at least 4 times (Table 3.6).
Table 3.5: DNA concentrations for targeted capture.
Sample Conc. (ng/µL) Total DNA ( µg) 260/280 260/230
05-981 310 34.1 1.90 2.22
05-982 277.4 47.16 1.90 2.17
05-985 349.9 52.49 1.86 2.14
05-987 338.3 40.6 1.90 2.17
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Figure 3.9: Analytic agarose gel electrophoresis. 1% Agarose Gel Electrophoresis
90V, 40 min. M, MassRuler DNA Ladder, Mix as marker; 2-5, DNA samples
diluted 1:10 in TE; 6: 50 ng/ul reference DNA; 7, 05-982 undiluted. 1µL of DNA
and 1µL Loading Buer was loaded into each lane. Gel image was captured with
BioRad Gel Doc 2000 system, DNA quantitation was performed using BioRad
Multi Analyst 1.1 software.
Table 3.6: Coverage of the target region.
Depth 05-981 05-982 05-985 05-987 05-984
0 0.16 0.17 0.17 0.22 0.19
 2 99.73 99.67 99.72 99.64 99.74
 4 99.47 99.35 99.48 99.39 99.59
 10 98.31 97.65 98.28 98.02 99.07
 15 96.72 95.14 96.58 96.26 98.44
 20 94.29 91.23 94.05 93.79 97.67
 30 86.81 78.36 86.07 85.71 95.51
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Table 3.7: Next generation sequencing statistics.
05-981 05-982 05-985 05-987
Mapped bases (Mb) 403.5 362.7 410.2 399.2
% of total bases 99.4 99.1 99.3 99.4
Mapped reads (x106) 1.20 1.78 1.21 1.13
% of total reads 98.3 97.6 98.3 98.3
Target base coverage (%) 96.9 96.6 96.7 96.7
Fold enrichment 1963 1275 1622 2247
Mean coverage 48.4X 40.5X 47.4X 48.9X
All variants 26,751 27,471 24,115 24,690
dbSNP + CEUa 11,674 11,703 8991 9106
Novel variants 15,077 15,768 15,124 15,584
High condence variants 11,942 12,801 9805 9592
dbSNP + CEUa 10,443 10,426 8150 8235
Novel heterozygous 678 1020 421 332
Novel homozygous 821 1355 1234 1025
Novel shared variants 1119
Coding regions (G1) 20
5' and 3' UTR (G2) 15
Intronic (G3) 689
Intergenic (G4) 395
Mendelian compatibility (G1) 3
Population screening 1
a: CEU population of 1000Genomes variants. For a list of missense variants see Appendix D.
3.4.2 Variant calling and error rates
For 454 reads, variants were detected using Roche GSMapper software (Roche
Inc), which uses two dierent approaches.[72] A conservative method was used
to detect high condence variants (HCDi) and a less stringent method (AllDi)
was used to detect all possible sequence variants. Reads mapped to the out-
side of the target region were discarded from analysis. Across all samples 7287
shared and 18,410 total high condence variants were detected (Table 3.7). As
a rst level genotype designation, we used a rigid heterozygosity threshold (30-
70%) to maximize sensitivity for detection of homozygous variants. According to
this threshold variants detected more than 70% of the reads designated as ho-
mozygous. When compared to the Illumine SNP genotyping data, the detection
of alleles was achieved for 99.5% for sample 05-987. Across 1004 SNPs in the
targeted region, ve SNPs (0.49%) were found to be inconsistent with Illumina
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SNP genotyping data (Table 3.8). Analysis of alignments revealed that, two of
the ve SNPs (rs719913, rs231674; 0.2%) were false positives and were found to
be in a homopolymeric region. One SNP (rs8067500, 0.1%) was a false negative
variant and one SNP (rs8068519, 0.1%) was determined as read error with a qual-
ity score of zero. Remaining one SNP (rs314239) was found to be a genotyping
error of Illumina SNP genotyping platform. Alignments of the erroneous SNPs
were given at Appendix E. As expected heterozygous SNPs were negligible in
the aected DNA. 23/25 SNPs were called as heterozygous by both genotyping
and sequencing platforms (Table 3.9). Those SNPs were located in the borders of
homozygous block thus narrowed the homozygous block into 6.74 Mb. Alignment
analysis of remaining 2 SNPs (rs719913, rs231674) which were detected only with
sequencing platform, were identied as variant detection errors (Appendix E).
Table 3.8: Insconsistent SNPs between 454 and Illumina 300Duo V2 genotyping
platformsa
dbSNP id Position Illumina 300 Duo GS FLX Read Percent
rs8068519 1,020,053 TT GG 53 100
rs719913 1,674,048 GG AG 35 69
rs231674 3,137,283 CC TC 27 67
rs314239 6,954,089 GA GG 56 100
rs8067500 7,113,355 CT TT 34 100
a: 5/1004 SNPs were found to be inconsistent with Illumina SNP genotyping data. Alignment analysis reveal
that, 3/5 of the inconsistencies were resulted from variant detection errors (rs719913, rs231674, rs8068519), 1/5
was resulted from sequencing error (rs8068519) of sequencing platform. Remaining one SNP was found to be
an error of genotyping platform (rs314239). See Appendix E for alignments.
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Table 3.9: Heterozygous SNPs in the critical regiona.
Illumina 300Duo V2 454 FLX NGS
dbSNP id Position (hg19) Genotype Score Genotype Read / %
rs7217872 chr17: 88,988 CT 0.63 CT 25 / 68
rs4617924 chr17: 114,669 CA 0.86 CA 84 / 50
rs719913 chr17: 1,727,298 GG 0.88 AG 35 / 69
rs231674 chr17: 3,190,533 CC 0.86 TC 27 / 67
rs7338 chr17: 6,917,703 CT 0.85 CT 27 / 48
rs10521149 chr17: 6,932,140 AC 0.8 AC 46 / 46
rs312456 chr17: 6,938,335 AG 0.81 AG 27 / 63
rs13342692 chr17: 6,946,287 TC 0.82 TC 32 / 34
rs364569 chr17: 6,979,179 AG 0.81 AG 66 / 64
rs444207 chr17: 6,982,444 AG 0.86 AG 47 / 40
rs8078782 chr17: 6,996,653 CA 0.91 CA 26 / 54
rs3760352 chr17: 7,019,878 AG 0.87 AG 52 / 46
rs2062737 chr17: 7,031,638 AG 0.45 AG 46 / 46
rs12150124 chr17: 7,036,251 TC 0.93 TC 33 / 42
rs314245 chr17: 7,040,878 CT 0.92 CT 51 / 47
rs1237044 chr17: 7,042,246 TC 0.86 TC 23 / 57
rs3826408 chr17: 7,101,292 CT 0.9 CT 60 / 52
rs390200 chr17: 7,109,995 AG 0.71 AG 29 / 38
rs2074222 chr17: 7,129,974 AG 0.86 AG 34 / 38
rs222851 chr17: 7,139,238 GA 0.83 GA 17 / 59
rs222852 chr17: 7,140,606 AG 0.82 AG 61 / 43
rs1215 chr17: 7,163,350 AG 0.83 AG 25 / 64
rs4796407 chr17: 7,245,371 AG 0.91 AG 55 / 51
rs11657406 chr17: 7,249,870 GT 0.75 GT 41 / 37
rs2292068 chr17: 7,253,659 TC 0.89 TC 14 / 57
a: One aected individuals (05-987) DNA was genotyped by Illumina 300Duo V2. 23/25 SNPs were called as
heterozygote by both genotyping and sequencing platforms. 2/25 SNPs were determined as variant detection
error (rs719913, rs231674). See Appendix E for alignments of rs719913 and rs231674.
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Next, Mendelian inconsistencies were calculated in the HCDi variants. 8,308
variants were included into analysis, which were detected in both parent and
at least one ospring. The Mendelian error rate (ie. ABxBB=AA) was 0.39%
(32/8118) at >5X and 0.26% (18/6938) at >15X with 30-70% heterozygosity
threshold. Applying a coverage-dependent genotype calling approach [72] did
not change the overall rate of Mendelian errors. Using dierent cut-o values
between 20-30% as lower threshold and 65-80% as upper threshold, 64 erroneous
variants were observed (Appendix F). It is suggested that, Mendelian errors could
be used as a determinant of genotyping errors.[87] Using both genotyping data
and Mendelian errors, 0.3% error rate was determined on overall sequence data.
3.4.3 Analysis of sequence gaps
To reveal non-covered coding regions and possible deletions, alignment data of
three aected individuals were merged to obtain a mean value of read depth for
each nucleotide position. Then, using the custom annotation pipeline coverage
statistics were calculated for each of the functional genomic element. Combined
sequence data of the 3 aected siblings yielded at least 4-fold coverage of 99.78%
of all coding base pairs, 95.32% of intronic and UTR base pairs, and 91.36% of
intergenic base pairs. The remaining 0.22% of coding regions with less than four-
fold coverage was supposed to be candidate regions for disease causing deletions
(Table 3.10). Those regions were compared to that of heterozygous parents to
detect Mendelian inheritance consistency (Figure 3.10). None of the parents
was detected as a heterozygous carrier for a possible deletion. The regions were
detected as under low coverage in all of the sequenced individuals regardless of
their aection status. Analysis of the regions by Sanger sequencing to detect any
overlooked variants resulted with no mutation.
3.4.4 Variant annotation and ltering
To minimize the risk of erroneously overlooking signicant transcript variants a
custom annotation pipeline was developed using ENSEMBL data sets. A custom
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Table 3.10: Coding regions with limited coverage. Genomic coordinates, gap
sizes, GC percentage, accession code, gene symbol and coverage status of the
coding regions with limited coverage.
Position (hg19) Size GC % Acc. code Gene Statusa
chr17:263352-263385 34 73.5% NM_001013672 C17orf97 L.C.
chr17:882713-882715 3 100% NM_022463 NXN L.C.
chr17:1174341-1174383 43 86% NM_001164405 BHLHA9 L.C.
chr17:2966802-2966821 20 45% NM_014566 OR1D5 L.C.
chr17:2966822-2966893 72 52.8% NM_014566 OR1D5 N.C.
chr17:2966894-2966901 8 50% NM_014566 OR1D5 L.C.
chr17:4402342-4402343 2 50% NM_001124758 SPNS2 N.C.
chr17:4402344-4402351 8 50% NM_001124758 SPNS2 L.C.
chr17:6459704-6459726 23 73.9% NM_001165966 PITPNM3 L.C.
chr17:6459710-6459724 15 86.7% NM_001165966 PITPNM3 N.C.
a: Non-covered: <2X sequence depth. Low coverage: 2-3X sequence depth. Abbreviations used in this table:
L.C., Low coverage; N.C., Non-covered.
Figure 3.10: Segregation of a candidate deletion. Alignment of the depth graphs
of all sequenced individuals for the gap in OR1D5 pseudogene did not reveal any
segregated deletion.
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Figure 3.11: Custom annotation pipeline. Several data sources used to create
a custom annotation database. Variants were identied and annotated by using
custom scripts.
database was created using the genomic coordinates of protein coding genes,
hypothetical genes, processed transcripts, miRNAs and other RNA genes and
pseudogenes. The database also contains the coordinate information of all exons
of all alternative transcripts variants. To annotate previously reported SNPs an
additional database was created using the ENSEMBL Variation table. In addition
variants were compared to 1000genomes variants [88] which were not added to
dbSNP database. All variants were re-analysed using the updated versions of
datasets upon their availability. Pipeline is summarized in Figure 3.11.
3.5 Identication of the disease causing variant
The key challenge of using the next generation sequencing technologies in the
identication of novel disease genes is how to identify the disease causing mutation
CHAPTER 3. RESULTS 71
among the background of neutral polymorphisms and sequencing errors.[44] With
the use of high throughput sequencing, the challenge shift from the prioritization
of the candidate genes to whistling down the list of candidate variants. Several
steps of ltering and stratication approaches were carried out to narrow down
the list of variants into single disease causing mutation. These approaches can be
summarized as:
 Exclusion of the variants which were not compatible with the recessive
inheritance model.
 Screening the novel variants to distinguish the rare polymorphisms from
disease causing mutation.
 Stratication of the novel variants:
Predicted roles of the genes in biological pathways or their interactions
with genes that are known to cause similar phenotypes.
Stratication of the candidate variants on the basis of their impact on
the protein product and their deleteriousness.
Conservation analysis based on the observation that mutations in the
highly conserved regions are likely to be damaging.
3.5.1 Analysis and ltering SNPs
As the rst step of discrete ltering, previously reported SNPs were excluded
as neutral polymorphisms. This method assumes that the set of SNPs in db-
SNP database does not contain any pathogenic alleles. However there are two
possibilities that; i. dbSNP database can contain a small number of pathogenic
allele contaminants, ii. For recessive diseases, carrier status will not result in a
phenotype, thus the disease alleles can be observed in control group and reported
as polymorphisms. To exclude all SNPs as disease causing mutation, segregation
of nonsynonymous SNPs were analysed in the sequence data. Seventeen SNPs
were compatible with the Mendelian transmission of the disease allele -detected
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Table 3.11: Functional SNPs compatible with the Mendelian transmission of the
disease allele.
SNP Gene Pos (hg19) R/V Annot (AA/AB/BB)
rs9905106 MYO1C chr17:1,373,518 T/C Q826R 14.7/38.7/46.6
rs2070862 SERPINF2 chr17:1,648,294 C/T A2V 61.2/34.2/4.7
rs216195 SMG6 chr17:2,203,167 T/G K294Q 42.4/39.6/18.0
rs41333251 OR1E2 chr17:3,337,057 A/G C27R 8.2/33.4/58.4
rs55916885 TRPV1 chr17:3,495,391 T/C Q85R 96.1/3.8/0.1
rs150857 SHPK chr17:3,526,637 C/T E215K 61.2/30.4/8.4
rs2976230 ITGAE chr17:3,631,241 A/G V1019A 57.8/29.3/12.9
rs7214723 CAMKK1 chr17:3,775,848 T/C E375G 44.8/39.2/16.0
rs34457931 SPNS3 chr17:4,352,636 G/A G293R 83.2/15.9/0.8
rs3809849 MYBBP1A chr17:4,458,598 G/C Q8E 61.3/34.6/4.1
rs7216284 GGT6 chr17:4,463,699 G/A R40W 68.2/27.6/4.2
rs1052748 PLD2 chr17:4,720,469 C/T T577I 52.9/35.8/11.3
rs12761 RPAIN chr17:5,326,145 C/G N103K 36.6/40.3/23.1
rs2304977 KIAA0753 chr17:6,513,329 G/A P566L 54.0/37.1/8.9
rs61146770 KIAA0753 chr17:6,524,298 T/A E375D 48.2/42.4/9.4
rs16956264 FBXO39 chr17:6,683,684 A/G Y166C 75.0/22.8/2.2
rs7213731 FBXO39 chr17:6,690,164 A/G I363M 71.9/25.4/2.7
Abbreviations used in this table: R/V, Reference/Variant allele; Annot, Annotation at amino acid level. Fre-
quencies of three dierent genotypes were given in the last column.
as heterozygous in parents and homozygous in aected siblings-. Frequencies of
each allele were obtained from 1000genomes data [88] (October 2011 Intergrated
Variant Set release #ICHG2011). Analysis of 1091 genomes revealed that all
17 SNPs were detected as homozygous state in at least one healthy individual
(Table 3.11).
3.5.2 Functional classication of the variants
After the exclusion of previously reported dbSNP variants, 1119 shared novel
variants were selected and binned into 4 groups (G) using annotation data. G-1
includes all variants in the amino acid coding regions of exons, consensus splices-
site regions, and RNA genes (n=20). G-2 contains changes in 5'UTRs and 3'UTRs
(15). G-3 contains the introns (689). All remaining variants were classied as
G-4 (395). Next, variants which were compatible with the autosomal recessive
inheritance model were selected. In this model variants detected homozygous in
obligate carrier parents were ltered out. All functional and Mendelian compati-
ble variants were conrmed by using Sanger sequencing (Figure 3.13). Please see
Figure 3.12 for the summary of variant classication.
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Figure 3.12: Flow chart of variant classication.
Figure 3.13: Segregation and Sanger conrmation of WDR81 p.P856L variant.
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Table 3.12: Novel UTR variants co-inherited with the disease.
Gene Pos (hg19) Type Ref Var 05-981 05-982 05-985 05-987
ELP2P chr17:656,577 3'UTR C G 11 (0.36) 14 (0.29) 13 (0.62) 9 (1.00)
HIC1 chr17:1,962,684 3'UTR A - 17 (0.53) 9 (0.67) 16 (1.00) 23 (0.96)
USP6 chr17:5,076,345 3'UTR G C 23 (0.35) 21 (0.52) 26 (1.00) 22 (1.00)
ZNF594 chr17:5,083,351 3'UTR A T 18 (0.61) 12 (0.33) 12 (1.00) 12 (1.00)
ZNF594 chr17:5,083,804 3'UTR G C 24 (0.25) 14 (0.57) 19 (1.00) 21 (1.00)
3.5.3 Exclusion of the variants
Five of the 15 UTR variants were compatible with the recessive inheritance in the
family (Table 3.12). They were analysed in detail including evaluation of protein
interactions and regulatory motif searches. None of them was found to interact
with previously identied genes with cerebellar phenotypes including CAMRQ
associated VLDLR and CA8. According to regulatory region analysis, nucleotide
substitutions did not have any signicant eect on the regulatory motifs.
Genotypes of four missense variants (WDR81 p.P856L, MYBBP1A p.R671W,
ZNF594 p.L639F and PELP1 p.T402I) and one silent variant (MYO1C p.E932E)
were co-segregated with the disease in the family. Five variants in coding re-
gions were detected homozygous in parents, and 10 variants were detected as
false positive variants (Table 3.13). Thus, these 15 variants were excluded from
analysis.
Alignment analysis of the silent variant in MYO1C (p.E951) revealed that,
nucleotide change occurs in several species (Opossum, X. tropicalis, and chicken)
without aecting the splicing pattern of the gene (Figure 3.14). PELP p.I401
variant is located in intron 10-11 of PELP1 gene. This intron was retained in the
alternative isoform (ENST00000301396, Q8IZL8-2) of the gene and annotated as
an exon in the ENSEMBL database (Figure 3.15). These data strongly suggested
that these two variants were neutral polymorphisms.
MYBBP1A p.R671W was excluded as the disease causing mutation based
on genotypes of controls (Table 3.14). In 214 unrelated healthy controls, 13 in-
dividuals were heterozygous for the variant with a calculated allele frequency
of 0.016 and homozygous frequency of approximately 1 in 4000, which was far
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Table 3.13: List of novel variants in coding regions.
Gene Pos (hg19) Type Ref Var Annot 05-981 05-982 05-985 05-987
Candidate variants
MYO1C chr17:1,371,325 Silent C T p.E932E 42 (0.55) 24 (0.54) 26 (1.00) 39 (1.00)
WDR81 chr17:1,630,820 Missense C T p.P856L 41 (0.51) 33 (0.52) 40 (0.97) 53 (1.00)
MYBBP1A chr17:4,448,967 Missense G A p.R671W 29 (0.52) 21 (0.48) 32 (0.97) 29 (1.00)
ZNF594 chr17:5,085,637 Missense G A p.L639F 39 (0.54) 50 (0.56) 38 (0.97) 37 (1.00)
Excluded by homozygous parents
C17orf97 chr17: 263,287 Missense A G p.D218G 15 (1.00) 13 (1.00) 9 (1.00) 14 (1.00)
C17orf97 chr17: 263,316 Silent T C p.D228H 13 (0.77) 6 (1.00) 4 (0.75) 8 (0.87)
AC090282.6 chr17:3,132,364 miRNA - C - 39 (0.95) 37 (1.00) 34 (0.97) 39 (0.97)
TRPV1 chr17:3,477,172 Frameshift - G p.A620fs 28 (1.00) 17 (1.00) 21 (1.00) 39 (1.00)
ASGR2 chr17:7,012,080 Frameshift - T p.H65fs 29 (1.00) 35 (0.54) 36 (1.00) 41 (0.54)
Retained intron
PELP1 chr17:4,578,955 Missense G A T402I 46 (0.61) 37 (0.51) 45 (1.00) 60 (1.00)
False positive variants
RPH3AL chr17:169,221 Frameshift T - p.D114fs 46 (0.17) 29 (0.28) 31 (0.23) 51 (0.18)
SLC43A2 chr17:1,479,053 Frameshift C - p.V519fs 41 (0.15) 33 (0.21) 35 (0.23) 38 (0.16)
PRPF8 chr17:1,563,808 Frameshift G - p.T1568fs 83 (0.13) 65 (0.20) 66 (0.17) 85 (0.07)
OR1E2 chr17:3,336,820 Frameshift A - p.Y106fs 75 (0.09) 57 (0.19) 52 (0.12) 74 (0.16)
ITGAE chr17:3,664,330 Frameshift - C p.E192fs 40 (0.15) 29 (0.10) 35 (0.11) 43 (0.07)
USP6 chr17:5,036,205 Missense A C p.K66Q 50 (0.20) 42 (0.17) 42 (0.19) 67 (0.31)
USP6 chr17:5,036,210 Missense T G I68M 50 (0.20) 42 (0.17) 43 (0.23) 68 (0.35)
DHX33 chr17:5,353,585 Frameshift C - p.E383fs 52 (0.15) 39 (0.18) 58 (0.12) 46 (0.09)
NLRP1 chr17:5,418,095 Frameshift T - p.G1467fs 75 (0.19) 54 (0.22) 50 (0.20) 77 (0.16)
KIAA0753 chr17:6,513,435 Frameshift T - p.K531fs 47 (0.17) 32 (0.22) 37 (0.16) 41 (0.15)
Abbreviations used in this table: Annot, protein level annotation.
Figure 3.14: Alignment analysis of MYO1C variant.
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Figure 3.15: Retained intron of PELP1.
Table 3.14: Allele frequencies of MYBBP1A p.R671W variant.
Population A B MAF Ind(#)
Turkish 1213 15 1.22 614
1000genomes 2182 2 0.09 1092
European American 2609 11 0.42 1310
African American 2090 2 0.09 1046
Abbreviations used in this table: MAF, minor allele frequency; Ind (#), Number of individuals genotyped.
higher than the frequency of CAMRQ2. In an additional series of 400 individ-
uals of various European and Middle Eastern ancestries, two were homozygous
for MYBBP1A p.R671W. Neither of these two homozygotes had any signs con-
sistent with CAMRQ2. The variant was further analysed in publicly available
exome sequence datasets. In 2620 healthy controls of European ancestries, 11 of
them was heterozygous for the minor allele (NHLBI Exome Sequencing Project).
Therefore, MYBBP1A p.R671W variant was excluded as the allele responsible
for the disease.
ZNF594 p.L639F was excluded as the causal mutation based on population
screening and conservation considerations. The variant was genotyped in 1098
chromosomes (549 healthy individuals) and detected as heterozygous state in four
individuals with an allele frequency of 0.364%. Analysis of various exome and
whole genome data (n=4550) revealed that, the variant was present in the dier-
ent populations (0.183% in HapMap populations, 0.737% in European American
NHLBI Exomes, 0.310% in African American NHLBI Exomes). The ZNF594
p.L639F allele was observed with minor allele frequency of 0.415% in 5099 in-
dividuals. The Hardy-Weinberg consistency of the variant and the frequency in
European American individuals strongly suggested that the variant could be a
rare polymorphism. Furthermore, the variant was present in three of 17 species,
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Table 3.15: Allele frequencies of ZNF594 p.L639F variant.
Population A B MAF Ind(#)
Turkish 1094 4 0,364 549
1000genomes 2180 4 0,183 1092
European American 2154 16 0,737 2170
African American 1284 4 0,310 1288
Total 6712 28 0,415 5099
Abbreviations used in this table: MAF, minor allele frequency; Ind (#), number of individuals genotyped.
Figure 3.16: Alignment analysis of ZNF594 variant.
which is also suggesting that phenylalanine at this site would also not be dam-
aging in humans (Figure 3.16). A negative GERP score (-0.665) for the mutated
nucleotide indicates that this site is probably evolving neutrally. The eect of
amino acid change was evolved by using SIFT [50] and PolyPhen [53] tools and
predicted as benign (PSIC score dierence: 0.301) by PolyPhen and damaging
low condence (SIFT Score: 0.04) by SIFT. In addition, human ZNF594 har-
bors nonsense mutation at site near the ZNF594 p.L639F variant in the HapMap
series. rs116878311 at residue 681 (ZNF594 p.Q681X) appeared in one of the
120 CEU controls and rs114754534 at residue 684 (ZNF594 p.E684X) observed
in four of 118 Yoruban controls with an allele frequency of 0.034. Considering
the genotyping data together with conservation data, exome sequence data and
mutation load, ZNF594 p.L639F variant was excluded as the cause of disease
(Table 3.15).
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3.5.4 WDR81 p.P856L as the disease causing mutation
The remaining variant, which was segregated in the family (Figure 3.13 and 3.17,
WDR81 p.P856L, was not observed among the 549 individuals of the control
group. The variant is identied in a predicted alternative transcript of WDR81.
The region containing the mutation was not completely represented in any exome
capture array or library. Thus, the region can not be thoroughly analysed using
exome sequencing datasets.
To exclude the possibility of homozygous individuals for WDR81 variant, an
extended genealogy of Family B was constructed revealing high levels of consan-
guinity in a large subset of individuals. Genotyping of WDR81 p.P856L in 177 in-
dividuals ruled out the presence of homozygotes (Figure 3.18A). However, 27/177
carriers were identied (Figure 3.18B) and genetic counseling is in progress. A
carrier frequency of 14.8% and a mutation frequency of 10.7% were observed in
this large genealogy. It was noted that the parents of the aected individuals
are the only carrier members married to each other. Genotyping of neighbouring
ZNF594 p.L639F and MYBBP1A p.R671W variant in the same genealogy sug-
gested a single ancestral founder haplotype carrying the mutation (Figure 3.18C).
The status of WDR81 was evaluated in 2 dierent cohorts of patients with
neurodevelopmental/cerebellar phenotypes in which the causative mutations are
not known. The rst cohort consisted of 750 individuals aicted by cortical mal-
formations of the brain or degenerative neurological phenotypes. According to
the genotyping data based on Illumina Human 370 Duo or 610K Quad Bead-
Chips, none of the patients with cerebellar or ataxia phenotypes harboured a
homozygous region ( 2:5 cM) surrounding the WDR81 locus. Exome sequenc-
ing data of these individuals did not reveal any mutations in the sequenced regions
of WDR81 gene. The second cohort consisted of 58 probands of which 12 had
cerebellar phenotype with or without quadrupedal locomotion. Analysis of the
coding regions of the WDR81 in these patients by using Sanger sequencing did
not reveal any mutations.
WDR81 is highly conserved protein throughout vertebrates. Particularly the
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Figure 3.17: NGS coverage statistics and conservation of WDR81. GC content,
NGS read depths, Nimblegen target probes, exon-intron structure and GERP
conservation scores are shown in (A). Alignments of sequence reads for aected
individual 05-985
CHAPTER 3. RESULTS 80
Figure 3.18: Genotyping WDR81 p.P856L in the extended pedigree.(A) Fam-
ily B with aected individuals indicated by lled symbols and genotypes shown
for WDR81 p.P856L (From Gulsuner et. al. 2011 [11] by permission).(B) 1.5%
agarose gel electrophoresis of AS-PCR genotyping poducts of WDR81 p.P856L
variant carriers.(C) Lower gure show the genotypes of three variants in all indi-
viduals, which suggests a single ancestral founder gaplotype carrying the muta-
tion.
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mutated proline residue is completely conserved (Figure 3.20). The gene has no
nonsense polymorphisms in any sequenced species. WDR81 p.P856L was pre-
dicted to be damaging (SIFT score: 0) by SIFT, probably damaging (PSIC
score dierence: 2.724) by PolyPhen, and under evolutionary constraint (GERP
score: 5.68) by GERP (Figure 3.17). Together with the population data, con-
servation considerations and the exclusion of the remaining variants, WDR81
p.P856L is concluded as the mutation responsible for the disease.
3.6 Characterization of WDR81
WDR81 p.P856L mutation (chr17:1,630,820 [hg19]) is located in the rst
exon of the longest isoform of WDR81 (ENST00000409644, NM_001163809.1,
NP_001157281.1). The isoform consisted of 10 exons (Figure 3.19). The protein
product of WDR81 is highly conserved throughout vertebrates. In particular
the proline residue is completely conserved in all known sequences, including the
most distantly related ortholog Tetraodon nigroviridis WDR81 which is 47.8%
identical, 57.2% similar, and has a distance score of 0.76 compared to the human
protein (Figure 3.20). Human WDR81 isoform 1 encodes 1941 amino acids. The
protein consisted of a BEACH domain at amino acids 352-607, a major facilita-
tor superfamily (MFS) domain, and six WD-repeats. The WDR81 p.P856L lies
in the MFS domain. According to membrane spanning domain prediction anal-
ysis, WDR81 is transmembrane protein with six membrane spanning domains.
The most N-terminal domain is located at residues 45-66 and the remaining ve
domains are located at the C-terminus of the protein (residues 980-1815) (Fig-
ure 3.19).
At present, the biological function of WDR81 is not known and a knock out
mouse model is not available. However some clues about its function can be
derived from its protein domains. BEACH (Beige and Chédiac Higashi) domain
containing proteins have been implicated in membrane tracking [89], synapse
morphogenesis [90] and lysosomal axon transport [91].
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Figure 3.19: Exon-intron structure, protein domains and membrane spanning
domains of WDR81. (From Gulsuner et. al. 2011 [11] by permission).
Figure 3.20: Conservation of WDR81 among several species
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Figure 3.21: Proteins with BEACH domain and WD repeats.
The protein show similarity with a group of proteins with BEACH domain
and WD40 repeats such as NSMAF (neutral sphyngomyelinase activation associ-
ated factor), NBEA (neurobeachin) and LYST (lysosomal tracking regulator)
(Figure 3.21). LYST gene contains a BEACH domain, seven WD40 repeats and
additional HEAT/ARM repeats [92]. Nearly all LYST mutations lead to protein
truncation and cause Chediak-Higashi syndrome (CHS), which is characterized
by accumulation of giant intracellular vesicles leading to defects in the immune
and blood systems [93]. Two missense LYST mutations was reported so far [94].
Interestingly, these patients did not represent any immunological involvement but
neurological symptoms. A mouse mutant model (LystIng3618/LystIng3618) harbour
a missense mutation in WD40 domain of LYST gene. Purkinje cell degeneration
and age dependent impairment of motor coordination without signs of lysosomal
defects and immunological symptoms were characteristics of these animals [93].
3.6.1 Expression of WDR81
To reveal the full length transcript of the gene and to analyse its unpredicted tran-
script isoforms containing the mutation site, an exon spanning RT-PCR approach
was conducted. Each exon was analysed by amplication of human cerebellar
cDNA using a forward primer targeting the mutation site (280 bp upstream) and
reverse primers targeting each of the exons. Single bands with appropriate sizes
to the gene structure was obtained for all exons (Figure 3.22).
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Figure 3.22: Evidences of predicted transcript of WDR81. (A) Evidences are
based on EST and cDNA level libraries. Full length transcript containing exon
1 was not observed in any libraries (http://www.ensembl.org). Blue bar at the
top of the gure is shown the evidences found by RT-PCR experiments. (B)
Exon spanning RT-PCR strategy revealed the presence of the isoform in human
cerebellum. Mutation site is shown with a blue box.
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Expression of the ENST00000409644 transcript of WDR81 was analysed by
real-time reverse transcriptase PCR (RT-PCR) in a multiple human tissue panel.
The anking region containing the mutation in exon 1 was amplied in expres-
sion analysis. Human WDR81 was detected in all human tissues, with the high-
est levels of expression in cerebellum and corpus callosum (Figure 3.23). Main
anatomical abnormalities were shown in these two brain regions.
Figure 3.23: Expression of WDR81 in dierent tissues. The region containing
the mutation was expressed in all tissues(A,B). The highest expression levels in
brain tissues were observed in corpus callosum and cerebellum. Multiple tissue
panel Agarose gel electrophoresis of qPCR product shows no correspanding band
in DNAseI digested -RT samples (C). (WDR81V1: 429bp, GAPDH 143bp).
3.6.1.1 In-situ hybridization analysis of WDR81 in mouse brain
Alignment of human and mouse WD repeat domain 81 proteins (1,941 and 1,934
predicted residues, respectively) showed 87.5% identity and 90.7% similarity.
Mouse Wdr81 maps to chromosome 11 within conserved synteny of a part of
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Figure 3.24: (A) Physical location of WDR81/Wdr81 in human and mouse chro-
mosomes. (B) In situ hybridization of mouse embryonic brain revealing increased
expression of Wdr81 in purkinje cells and molecular layer of cerebellum (left). No
hybridization was observed with the sense probe (right). ML: Molecular Layer,
GL: Granular Layer. (From Gulsuner et. al. 2011 [11] by permission).
human chromosome 17p, which also includes the 6.9 Mb CAMRQ 2 linkage inter-
val (Figure 3.24A). Based on the similarity of sequences and conserved synteny,
probes that contain the mutation site in human patients were prepared from
mouse genomic DNA and specic expression pattern of Wdr81 gene in mouse
brain was analyzed. At P7, Wdr81 expression was observed in Purkinje cell layer
in the cerebellum (Figure 3.24B). No hybridization was observed with the sense
probe. These results are consistent with the proposed function of WDR81 protein
in mediating motor behavior.
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3.6.1.2 Western blot analysis of human WDR81
ENST00000409644 transcript encodes a 212 kDa protein. Anti-WDR81 antibody
recognizes exon-7 of the transcript and is predicted to target 212, 96, 77, 75, and
63 kDa splice variants of the gene. Western blot analysis using protein medley
from adult brain showed bands approximately corresponds to the 75, 77 and
possibly 96 kDa protein variants with additional bands present (Figure 3.25).
However no bands was observed at 212 kDa sizes with current antibody. This
results suggested the possibility that protein level expression of WDR81 could
be specic to fetal tissues and additional biochemical studies are required to
characterize the protein product of WDR81.
Figure 3.25: Western blot analysis of WDR81 protein products.
3.6.2 Eect of the mutation in gene expression
The eect of the mutation in expression levels of the gene was investigated by
comparing the expression levels between aected individuals, mutation carriers
and wild type allele carriers. However, no signicant change was observed (Fig-
ure 3.26). It could be due the fact that, WDR81 expression levels were vary
among healthy individuals.
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Figure 3.26: Eect of the mutation on WDR81 expression levels.
3.6.3 Annotation clustering of developing mouse brain ex-
pression proles
As a rst step to decipher the function of WDR81, expression data set of early
embryonic mouse brain tissues (GSE8091)[82] were evolved. Data were grouped
by embryonic days, then dierentially expressed genes within day groups were
ltered (One-way ANOVA Test Bonferroni corrected p<0.001, n=3,611). A total
of 670 genes were identied whose expression proles were signicantly correlated
with that of WDR81 (R=0.95-1.0). DAVID functional annotation clustering tool
[83] was used evaluate the predicted functions of those genes. Functional anno-
tation (Appendix G suggested that positively correlated genes were enriched for
those neuron projection proteins (Benferroni adjusted P = 2.3E-11), axonogen-
esis proteins (Benferroni adjusted P = 1.3E-9) and cell morphogenesis proteins
involved in neuron dierentiation (Benferroni adjusted P = 3.7E-9). Several
genes linked to human diseases with neuronal phenotypes, such as PRNP, DCX
and EL1CAM were found in these enrichment sets (Table 3.16). WDR81 was
co-expressed with mental retardation, quadrupedal gait and cerebellar hypopla-
sia associated gene ATP8A2 gene (unpublished) suggesting that two genes could
represent similar developmental pathways.
Furthermore a data mining analysis was performed to obtain clues to under-
stand possible roles of WDR81. In a study that aims genome scale identication
of membrane-associated human mRNAs (GSE4175) [85], WDR81 transcript was
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Table 3.16: Neuronal phenotype genes with correlated expression proles with
WDR81.
Symbol Name Disease OMIM R
LTM2B integral
membrane
protein 2B
Cerebral Amyloid Angiopathy,
Itm2b-Related, 1
176500 0.981
PRNP prion protein Gerstmann-Straussler Disease;
GSD
137440 0.993
LOX lysyl oxidase Menkes Disease 309400 0.995
DCX Doublecortin Lissencephaly 1; LIS1 607432 0.982
L1CAM L1 cell
adhesion
molecule
MASA Syndrome 303350 0.984
found to be increased in membrane associated RNA in contrast to cytoplasmic
RNA (4.14 folds [p=0.03] and 1.78 folds [p=0.0002] in two dierent datasets),
raising the possibility that WDR81 may encode a membrane-associated protein.
Chapter 4
Discussion
Human disease gene identication has been greatly facilitated with the targeted
enrichment of the genome and next-generation sequencing.[41] However, nding
a causative mutation in the absence of 2 or more independent cases remains a
challenge. This is particularly true when, there are multiple variants without any
obvious eect on protein and the candidate mutation is identied in an unchar-
acterised gene.
Cerebellar ataxia, mental retardation, and dysequilibrium syndrome
(CAMRQ) is a genetically heterogeneous and extremely rare disease character-
ized by congenital cerebellar hypoplasia, cerebellar ataxia and mental retardation
with or without quadrupedal locomotion.[9, 10] CAMRQ was rst described in
a unique consanguineous family. In the context of this study, we describe the
identication of a missense mutation in family B associated with CAMRQ2. The
minimal critical region, which consisted of approximately 192 genes, was cap-
tured and sequenced using the DNA samples of three aected and two carrier
individuals. The coverage analysis revealed that more then 99% of the coding
bases were sequenced. Approximately 26,000 variants were detected by map-
ping the sequence data to the human reference genome. Variants were anno-
tated by using a custom annotation pipeline. Three functional variants (WDR81
p.P856L, MYBBP1A p.R671W, ZNF594 p.L639F), which are consistent with
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the Mendelian inheritance of the disease allele, was found by segregation analy-
sis. High quality targeted next generation sequencing excluded the possibility of
other disease related variants in the minimal critical region.
The causative mutation was identied by using several ltering steps. Af-
ter segregation analysis, previously unreported rare polymorphisms were ltered
out by population screening, analysis of the exome data of control populations,
analysis of conservation at candidate variant sites and presence of polymorphic
nonsense variants near the mutation site. In addition, an extended kinred of the
family spanning ve generations was constructed.
We conclude that, the WDR81-P856L mutation is the cause of CAMRQ2 in
Family B. The p.P856L mutation was identied in the rst exon of the longest
isoform of WDR81 gene. Expression of this hypothetical transcript variant was
conrmed by RT-PCR analysis. Expression pattern of the transcript was analysed
by quantitative RT-PCR experiments in a multiple human tissue panel and by in
situ hybridization of mouse brain sections. Expression of Wdr81 was observed in
the Purkinje cell layer of the mouse cerebellum. Highest levels of expression in
brain was detected in the cerebellum and corpus callosum, where major structural
abnormalities was observed.
At present, the biological function of WDR81 is not known and a knock out
mouse model is not available. But the function of the protein can be predicted
from its protein domains. Bioinformatics tools predicted that the WDR81 protein
is a membrane protein and composed of a BEACH domain, 6 WD40-repeats and
a major facilitator superfamily domain in which the mutation resides.
WD repeats are short, approximately 40 amino acid motifs, which typically
contain Trp-Asp (WD) dipeptide at the C-terminus. WD repeats are present
in approximately 122 dierent genes (http://www.genenames.org) and are im-
plicated in a variety of functions ranging from transcription regulation to cell
cycle. They are thought to form a beta-propeller structure that serves as a plat-
form for the assembly of protein complexes. Specic functions of the proteins
are determined by the remaining sequence.[95, 96, 97] Some WD-repeat proteins
(SEC13 and RACK1 ) consisted of only WD-repeat domain[98]. According to
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experimental data, WD repeat domains themselves have important functions.
[99] There are several WD-repeat genes implicated in inherited diseases. The
rst WD-repeat gene identied as a cause of human disease is lissencephaly-1
(LIS1/PAFAH1B1 ). Mutations in LIS1 gene appears to cause lissencephaly in
humans.[100] Recently, mutations in WD repeat-containing protein 62 (WDR62 )
were identied as the cause of a wide spectrum of cerebral cortical malformations
including microcephaly [41] and hypoplasia of the corpus callosum[101].
BEACH domain is found in eukaryotic proteins with diverse cellular func-
tions ranging from membrane tracking [89], to synapse morphogenesis [90] and
lysosomal axon transport [91]. The function of the BEACH domain is still to
be identied. The BEACH domain is generally followed by WD40 repeats. The
BEACH domain was rst described in the LYST (CHS ) gene encoding lysoso-
mal tracking regulator protein. The mouse homologous of the LYST protein
is Beige. The name for BEACH stands for the mouse Beige and human CHS
(Chediak-Higashi syndrome) proteins.
LYST gene contains a BEACH domain followed by seven WD40 repeats and
additional HEAT/ARM repeats [92]. Nearly all LYST mutations cause protein
truncation and lead to CHS. CHS is an autosomal recessive condition charac-
terized by accumulation of giant intracellular vesicles leading to defects in the
immune and blood systems [93]. Consequently patients exhibit recurrent infec-
tions, albinism and progressive neuropathy.[92, 102] Two missense mutations in
the LYST (R1563H and V1999D) have been reported so far.[94] The aected indi-
viduals had various neurological symptoms but did not have an infection history.
The LystIng3618=LystIng3618 mice which harbours a missense mutation in WD40 do-
main, presents purkinje cell degeneration and impairment of motor coordination
without signs of immunological symptoms. [93].
Subsequently, several proteins with BEACH domain and WD40 repeats were
identied including NSMAF (neutral sphyngomyelinase activation associated fac-
tor) and NBEA (neurobeachin). NBEA has a brain specic expression. Mutations
in this gene are implicated in a form of autism.[103]
CAMRQ has been linked to at least three dierent chromosomes. The rst
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gene on chromosome 9p24 was identied as VLDLR and the second mutation was
identied in CA8 gene. In this study, WDR81 was identied as the third gene
responsible for CAMRQ. Highest levels of expression of WDR81 was observed
in human cerebellum and corpus callosum. In mouse brain, Wdr81 transcript
was observed in Purkinje cell layer of cerebellum. These ndings are consistent
with our observations of major structural abnormalities of the patients were in
these regions. These observations suggest a possible role for WDR81 in motor
behaviour. Further work will be required to understand the normal biological
function of WDR81 and the role of the mutation in causing cerebellar hypoplasia
and quadrupedal locomotion. Genomic analysis of Family B demonstrates that
WDR81 is highly likely to be critical to these developmental processes.
Chapter 5
Future prospects
Cerebellar ataxia and mental retardation with or without quadrupedal locomo-
tion (CAMRQ) has linked to three dierent chromosomes with gene identication
studies. After the identication of VLDLR and CA8 mutations as the cause of
CAMRQ, a missense mutation was identied in WDR81. In addition, several
families were identied and their genetic studies are ongoing. In developmental
diseases which show genetic heterogeneity, identication of several genes would
be interesting regarding to reveal a common pathway underlying the same phe-
notype.
In our study, the disease causing mutation was identied in a hypothetical
transcript isoform of an uncharacterised gene. Therefore characterization of the
gene structure and identication of the tissue specic novel transcript isoforms
would be the rst step of further studies. One of the most important approaches
in the functional characterization of a new gene is using animal models. Knocking
down a gene with a human phenotype would provide us to analyse and reveal the
function of the gene in specic developmental processes. Therefore, functional
Zebrash studies have been developed in order to identify the function of the
gene in brain development.
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After the identication of a causative mutation in an inherited disease, DNA-
based diagnostics could become possible. The mutation in WDR81 can be rec-
ognized by AS-PCR method which makes it possible to screen a large number of
individuals in an economical way. Our population screening eorts already indi-
cated several carriers from the extended kindred of Family B. Genetic counselling
is in progress for this large family.
Identication of other mutations in the same gene in similar phenotypes would
also be interesting. For that purpose, the most ecient way is including all regions
of this gene in exome enrichment libraries. By this way, it would be possible to
analyse contributions of other variants of the gene to health and disease.
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Appendix A
Primer List
Table A.1: Primers for STR genotyping.
Exon Direction Sequence Tm Length
D17S849
F CAATTCTGTTCTAAGATTATTTTGG 64 251-261
R CTCTGGCTGAGGAGGC 54
D17S926
F GCAGTGGGCCATCATCA 54 243-260
R CCGCAGAAGGCTGTTGT 54
D17S1840
F GCCTGGGCGACAGAGTGA 60 173-225
R TGGGGCAGACTTGGTCCTT 60
D17S1533
F AGTGGCTCTAGAGTCAGACAGC 68 210-226
R CTGAGGCTCACCTAGGATGA 62
D17S525
F GCCCACTCTTAATGAGTTCCC 64 110
R TCTTGCAGAGGCAGGAAGTCA 64
D17S1798
F CAGTGAAATGCAATGTGATG 56 244-258
R ATGCCCAGCCTGTGTTAG 56
D17S1854
F TTTGGGAGGTCACAGACATTC 62 92-108
R CCTTGCTCTTAGGATTTGAGGA 64
D17S938
F CCGGATTGCTACACCTAAAT 58 164-182
R AACAGTCTCTNCTGGAGCAG 58
108
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Table A.2: Primers for candidate gene sequencing.
Exon Direction Sequence Tm Length
CRK
1_1
F TTTCTCCTCCAATTCTGTCTGG Tm
491
R TACCAGCTACTCCGCTCCTC Tm
1_1A
F CCTTGCCCTTCTCCCAAT Tm
247
R GCTCCTCCGAGTCGAAGTT Tm
1_2
F GCTGCTGTGAAGCTGAAACC Tm
303
R CCGCTGCTGTTGATGATGTAG Tm
1_3
F GAGGAGCGGAGTAGCTGGTA Tm
543
R AGCTCTTTGTCCCCACGTT Tm
2_1
F CAGGAGTTTGTGGTGAGAGGAT Tm
276
R TCTGGAAACTGGTTCTATCAACG Tm
2_2
F CGTTGATAGAACCAGTTTCCAGA Tm
273
R TACCTCCAATCAGAGCCGATAC Tm
2_3
F GATGATTCCAGTCCCTTACGTC Tm
347
R CCATCTACAACATCCCAATGC Tm
3_1
F GTGCCTAACCAGAGAATGGAGT Tm
379
R AAGACTAGGAATGGAGCAGTTCA Tm
3_2
F TGTAATGGCAAACGAGGTCACT Tm
416
R TAACACTCCTTCCTGTCCATCG Tm
3_3
F TAGTGGTCGTGCCTGTGTGTAT Tm
460
R GGTACATCCTGCTTTTCACCTG Tm
3_4
F CCCCAAACCTGTAAGTAGGTGA Tm
343
R AGAATTTGACCCCAAAACCTTC Tm
3_5
F AAGGACCAATCACCTCTGATATTC Tm
352
R CCTCCCAGGTTGAAGCAA Tm
3_6
F AAATTCTGCCCTCTGCATTCT Tm
472
R GCATTACTCTCCCCATGAGAAA Tm
KIF1C
1
F CCGACGTTTCCCTGTTCTT Tm
493
R CAACCCGGCACATTCCTC Tm
2
F GGAACCACAGGTGCCTTCTA Tm
209
R AGCCATATTCCAGCTTGCAG Tm
3
F GTCCCTGCAGTGGTTCTGAC Tm
282
R CCCAGCATTACCCTCCTCTT Tm
4
F AAATTAGCTTTGGTGGCTGGAG Tm
363
R TCCTCCCAATTCACCCTGACTA Tm
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5
F GGGTGGTAAGGACAATGATGAG Tm
471
R GCTTGCAGTCAACCTCTATCTCC Tm
6
F CTGAGGTTGTTTTCCCATCTG Tm
295
R GTCTGATTCCAGCGACAGC Tm
7
F TGCGTTGTCATTGTTTTTGC Tm
297
R ATCCTGCCTCTCACCTTCC Tm
8
F GGAAGGTGAGAGGCAGGAT Tm
320
R TGACGGAAAAACAGGGTAGG Tm
9-10-11
F ACCCGCACCTTATCTCCTG Tm
600
R GATTTGGGATTCTCGGCATA Tm
12
F GACTCCCCTACCTCAGACCA Tm
259
R TCCTGGCACTCTTCCTATGC Tm
13
F CAGGAGTTCAGAGGCGAGTTG Tm
377
R AAAGGCAAGTGAGGAGGGATG Tm
14
F TGGAGTTCAAGTAGAGAGACTGG Tm
538
R GCGTAAGGTGGGTAGGTTTC Tm
15
F GTCCCAGACCATCCTGAAAC Tm
332
R TCCTCACTCACCTTCTTTGGA Tm
16
F ACGGGCAGTGAAGGTAAGAC Tm
259
R GACAGAAATGATGGAGGGACA Tm
17
F GGATGACGATGGGAGGAGTA Tm
466
R GTTGTCTCGCCCTAACCAAA Tm
18
F TCTGGCACATGCTCACAAAC Tm
250
R CCTCTTTATATGGCTGCACTCC Tm
19
F CACCTTCCTCCAGGGTCTAAT Tm
151
R TGCGACACATCTTCTACCTGA Tm
20
F GCTGATGGGAAGCGAGTTTAC Tm
316
R GTATCTGACAAGAGGAGGACACG Tm
21
F TGTCCTCCTCTTGTCAGATACTC Tm
302
R TGGATTCTTCCTGTAGTCACATC Tm
22_1
F TCCCGTCACTATCTCTGTTGTC Tm
532
R ACAGCTCCCGCATCTTGA Tm
22_2
F AAGATGCAGGCGGTGAAG Tm
460
R TGAGATGGAAGGTTCAGACTCC Tm
23_1
F AGGATTCAGCTCTCCTCACATC Tm
241
R AAGACGACCACGACGGAAG Tm
23_2
F GAATGAAGAAGGTGGTGAGGTC Tm
546
R TGGGGATAAGAGTTGTGCTTTT Tm
23_3
F CCCTCACGACTGCAAGCTAC Tm
528
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R CCTACTCGGACCTTCTCTCTCA Tm
23_4
F CTTGCTAGGAGAAGGGAAGACG Tm
240
R AGCAGCGTTTGTGGGACA Tm
23_5
F AGGAGCAAACCAAAGTGAAGAG Tm
427
R AGACCTGTGCCATTGCCTTAT Tm
PAFAH1B1
1
F CTCTTCCTGGCGGGTCTG Tm
481
R GCGGTGGAGGAGACAGAG Tm
2
F GACAAAACAGTATGGTTTTTGACA Tm
485
R AAGAGACCTCCCAAAGCTGTA Tm
3
F TTTCTTCAGAATAGAAATGAGGTCTT Tm
237
R CAAATGACAAAATTGTGCGTAA Tm
4
F TCCCAAAGTGCTGGGATTAC Tm
R CTAGGTCATACTTTTCATGAAGCAC Tm
5
F GGACCAAGACAAATTCACTGC Tm
564
R TCAGCCTCCCGTTAAGTCTG Tm
6
F AAAGGAGTGATGGAGTTGGTG Tm
247
R ACTGTTAAAGCACTATCCTCTACCC Tm
7
F GACTATTTCCTTGTGGGTTGTTG Tm
428
R GGCTGGTCTTCAATTCCTGA Tm
8
F CTGGGAAGTGTCCTGATGATT Tm
380
R TGCATTAACAGCCCTGAAAC Tm
9
F CCGATCGATCATCTGAGGTT Tm
678
R CACCGACTGGCTCTACAGATT Tm
10
F TGAACCACCTAAGAACAAGGA Tm
590
R TGGCAAAGTCCACACGATTA Tm
11_1
F CAGGGTCTTGCTCTGTCACC Tm
-
R GATTCAACTTCTGCCTTCTTAGG Tm
11_10
F AGGAGGAAGCAAGCGTGTC Tm
381
R TTGTCCTTATCCCAGGCAAG Tm
11_11
F CTGTCCTGTTGATGCCCTTT Tm
351
R ACGCGGTGTCTAAACCAGTC Tm
11_12
F TGAAAACAGACATTCCAGTGC Tm
352
R GAAACAGAAAGAGGCGAACG Tm
11_13
F CGTTCGCCTCTTTCTGTTTC Tm
345
R CAGCCGTGACCTGTAAATCC Tm
11_14
F CTCCTGGTAGAGAAGCGACAT Tm
576
R ATCAGCATTTCCCCTGTGC Tm
11_2
F TCCTCCCTCTTTTCCTCTGG Tm
385
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R ACCACCACTTTTCCCCAAAT Tm
11_3
F TGCTATCTGTTGGTGCCTGA Tm
270
R ACCACTAGCCTCTGCGTGAT Tm
11_4
F ATCACGCAGAGGCTAGTGGT Tm
301
R GCACATTGCACATCCCTAAA Tm
11_5
F TCTCCCCATTGAGTGTGTCA Tm
354
R CCCAGGACTAAGGACATGGA Tm
11_6
F GGAGTGGGAGGAATACAGCA Tm
394
R GAGGGGGACATAACGGAAGT Tm
11_7
F CAGCCGAAGGAAAATCACTT Tm
364
R TTTGTCTTTTGCAGGAACCA Tm
11_8
F GGAAAATTGGTTCCTGCAAA Tm
315
R CAGTCAGAAGAGCTAAGGGAAAA Tm
11_9
F TATTGCCTCACAACCCTGCT Tm
354
R CGTTTCCTCCTCCTTTGTCA Tm
SCARF1
1
F CTCAGGAAAAGCCCTGAGAG Tm
294
R GTCTCCTCCTTCCCCTAACG Tm
2
F CTGGGGACCCTAGCTGTAAA Tm
332
R CGTCACAGGAGAAACCCTGA Tm
3
F CTCCCGTCTTTCCAACCTG Tm
353
R GTGCTTTGTGGATGTGGGTA Tm
4
F GACGCAGGGTAAGGGTCTG Tm
654
R CGCCTGCTCACTTGTGTC Tm
4A
F CGGATGTTCTGAGGGTCTGT Tm
891
R CCGCTCACCAGTTTCCAC Tm
5
F CGTGGAGTACAGGGGTAGGA Tm
330
R GTACCCCACCCTGAACAGAA Tm
6
F TCTGTCACCTGCTGGATTTG Tm
377
R TCAGGAAATGCTGCACAGAG Tm
7
F GCCTCTCCATGTCACTCCAT Tm
473
R GGTCAGGAGCTTGAGACCAG Tm
8
F TAGGAGACAGGAAGGCCTGA Tm
400
R GCACTGCCAACTACCTCCAT Tm
9
F ACCAGTGTCCCTACCCTCCT Tm
351
R CCTCATCTGCCTCTCCAGAC Tm
10
F GTCACCGTGGGTCTCATGTA Tm
467
R ACTAAAGAGGGGGTCGTGGT Tm
11_1
F CTCCAGCCAAGCTCTTCTGT Tm
482
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R CCAGCATGTAGATCGTGGTC Tm
11_2
F GAGCACGTGGAAGCCATT Tm
433
R GTTCCTCCTGCCTTTCCTCT Tm
11_3
F GGCAGTCAGACCAGAGGAAG Tm
432
R GGACAGCAGAGCAAAAGTCC Tm
11_4
F GAAAAGGCAAGGCTTCCAG Tm
R ACGAGGTCAGGAGATCGAGA Tm
11_5
F GAGACAGAATCTCCCTCTGTCC Tm
587
R CTCTCTCTTGACCCACAGACG Tm
Table A.3: Primers for nucleotide repeat expansion
screening.
Locus Direction Sequence Tm Length
WDR81
F AGGTTGCAATGAACTGAGATTGT Tm
209
R GTGGGTCTTCTGAAACTCCTTAAC Tm
MNT
F CACCTAAGCTGAGCCATCGT Tm
425
R CACAGTGATGTGCCCAATG Tm
LIS1
F ctcttcctggcgggtctg Tm
405
R CTCTTCCGTCCTTCACTCC Tm
HIC1
F CCTGGTGCTGGACTTCATCT Tm
283
R GTAGCAGGCCTGGATGACC Tm
TRPV1
F TGGAACAGTAATCTCCCTAACTTC Tm
203
R TGTAGAGGTTACAGTGAGCTGAGA Tm
RUTBC1
F ctccggctgtgggaag Tm
308
R ggggttcttgactcgacttt Tm
GARNL4
F ctcaggacccgctgtacc Tm
405
R agcgaagggcacctcagt Tm
Table A.4: Primers for mutation screening in cohorts.
Exon Direction Sequence Tm Length
WDR81
1_1
F AGCCACGTGCGCTTGTTT Tm
570
R GTCCTGACTTCCGCTTCTCC Tm
1_2
F GGGAAGGCGCTCTCAGAA Tm
391
R GAAGCGAGTGAGGGTCTCAG Tm
1_3
F CCACGTGGTGGCCCTAGT Tm
590
R TGAAGGTGACCACGTCATGT Tm
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1_4
F GTGAAACTACCCAATGCCCT Tm
658
R TGCTTATCCCCCTTGTTGAG Tm
1_5
F CGCATCAGCAACTTCCACTA Tm
582
R AAACGTGAGGTCGATCCA Tm
1_6
F TCCCTCTATCTTCCGCTC Tm
856
R AAACACCATCTCTGCCAA Tm
1_7
F TGCCTACTCCACAGGGACA Tm
429
R CTGCCACAGAGCAAACACC Tm
1_8
F TGCACAGATTCATCCTCCTG Tm
512
R AATCTCCTCCCCAAAAGCAC Tm
1_9
F TGCAGGCATTTCTCACTCAC Tm
769
R CTCCCAAAGTGCTGGGAATA Tm
2-3
F GAGCCCCTGTTATCTGAGGA Tm
597
R GGGCAGGTACTGGTAGGTGA Tm
3-4
F CCGGCAACATCTACCAGAAG Tm
559
R TCTTGACACCCAGTCCAGTG Tm
5-6
F GCCTGGATGACAGAGCAA Tm
574
R AACACCTTCTGCAGCTCGTC Tm
6
F TGCCACAGGTGGTCTTCTCT Tm
511
R CAAGGCTGTCTGTCCTCTCC Tm
7_1
F CACAACGGAATGAATCCACA Tm
597
R AAGTGAAAGTGGGCATCCTG Tm
7_2
F GCATTCAGATCCCCAATGAC Tm
580
R AAACTCCGCAGCATTACAGC Tm
8
F CGGTGAGTTGGGGGATTAG Tm
519
R CCACCTTCCCATCTCACACT Tm
9
F AAGCCAGGATGTTGTTCTGG Tm
564
R CTCCCTGCCCAGTTAGTCCT Tm
10_1
F ACTGGGTTACGGATGCTGAG Tm
328
R GCCGTACAGGTCAAAGGTGT Tm
10_2
F AGCCCACCCATCACTACAAG Tm
256
R GCCTCAGTCTATGCCAGGAG Tm
ZNF594
1_1
F CGCTAGTGAAAGCCACATCTC Tm
583
R GGTTTGAACTCCTGTTGAAGG Tm
1_2
F TGCAGGAGAAAGCTCCCATA Tm
578
R GATGTGGGACAAGGTGTGAA Tm
1_3
F CACAGTAGGGGGAAGCCATA Tm
347
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R TCTCCAGCATGCAATCTCTG Tm
1_4
F TCAGGCAGCATTCTCACCTT Tm
676
R GTGCGCCAAATGAAGAGC Tm
1_5
F GCCAGAGGTCACACCTTGTT Tm
204
R GCAGGCTCTGATGTTTGAGG Tm
1_6
F GGTGTGACCTCTGGCTGAA Tm
426
R TCATTTGGCGCACAGCTT Tm
1_7
F GTGGGAAATCTTTTAGGGGT Tm
583
R CCCCACATTTATTGCATACG Tm
Table A.5: Primers for exon skipping RT-PCR.
Exon Direction Primer sequence Tm Size
Exon 1
F ATGGCCCAGGGCAGCGGG 64 1098
R CAGCTGCATGAGGTAGTGGA 62
Exon 1-2
F GTGAAACTACCCAATGCCCT 60 3115
R CAGCGGACCATCTTGCAGGC 66
Exon 1-2
F CTGCAGTGCCTACTCCACAG 64 1406
R CAGCGGACCATCTTGCAGGC 66
Exon 1-3
F GGGTGTCCTATTGGCAGAGA 62 1630
R GGGCAGGTACTGGTAGGTGA 64
Exon 1-4
F GGGTGTCCTATTGGCAGAGA 62 1774
R CAGGATGTCCATGAGTGTGG 62
Exon 1-5
F GGGTGTCCTATTGGCAGAGA 62 1892
R TGAGGCTGATGGTTTTCACA 58
Exon 1-6
F GCAAGCTGGACCAACTGTTT 60 1961
R GGAGAAGGGCACGTAGATTG 62
Exon 1-7
F GGGTGTCCTATTGGCAGAGA 62 2412
R TTCTCAGGCCGAGAGTCATT 60
Exon 1-8
F GGGTGTCCTATTGGCAGAGA 62 2976
R AAGCGCAGGGTAGAGTCAGA 62
Exon 1-9
F GGACACACTCCTGCAGATGA 62 2966
R CCATGAAGCCTGAGGAGAAG 62
Exon 1-10
F GGGTGTCCTATTGGCAGAGA 62 3316
R GCCGTACAGGTCAAAGGTGT 62
Table A.6: Primers for quantitative RT-PCR.
Exon Direction Primer sequence Tm Size
WDR81
F GCAAGCTGGACCAACTGTTT 60.3 115
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R GGGAAGTAGGGTGGGAAGG 60.7
GAPDH
F AGGTGAAGGTCGGAGTCAAC 59.2 100
R GGGTCATTGATGGCAACA 58.8
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Figure A.1: Locations of the primers for exon skipping RT-PCR.
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Figure B.1: Linkage results-1. Chromosome 1-6.
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Figure B.2: Linkage results-2. Chromosome 7-12.
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Figure B.3: Linkage results-3. Chromosome 13-18.
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Figure B.4: Linkage results-4. Chromosome 19-23.
Appendix C
Genes located at the critical region
Table C.1: Genes located at the critical region.
Chr Start End Biotype Status Name Transcripts
17 62293 202888 protein_coding KNOWN RPH3AL 3
17 254332 263814 processed_transcript PUTATIVE AC108004.3 1
17 260118 264367 protein_coding KNOWN C17orf97 2
17 289769 295730 protein_coding KNOWN FAM101B 1
17 411908 618096 protein_coding KNOWN VPS53 6
17 635847 646074 protein_coding KNOWN FAM57A 3
17 647661 655501 protein_coding KNOWN GEMIN4 2
17 655900 658576 processed_transcript NOVEL AC087392.3 2
17 662550 686505 protein_coding KNOWN GLOD4 4
17 685513 695749 protein_coding KNOWN RNMTL1 1
17 702581 883010 protein_coding KNOWN NXN 3
17 900357 905388 protein_coding KNOWN TIMM22 1
17 906758 1090616 protein_coding KNOWN ABR 6
17 1085187 1088380 processed_transcript PUTATIVE AC016292.1 1
17 1173853 1174754 protein_coding KNOWN BHLHA9 1
17 1182957 1204281 protein_coding KNOWN TUSC5 1
17 1247566 1303505 protein_coding KNOWN YWHAE 8
17 1323983 1359552 protein_coding KNOWN CRK 2
17 1367480 1395995 protein_coding KNOWN MYO1C 6
17 1397872 1420182 protein_coding KNOWN INPP5K 16
17 1420225 1421389 processed_transcript NOVEL AC100748.2 1
17 1421287 1466110 protein_coding KNOWN PITPNA 3
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17 1477666 1532180 protein_coding KNOWN SLC43A2 3
17 1519486 1519589 snoRNA NOVEL snoU13 1
17 1537152 1549042 protein_coding KNOWN SCARF1 3
17 1549444 1553352 protein_coding KNOWN RILP 1
17 1553923 1588154 protein_coding KNOWN PRPF8 2
17 1611064 1613651 protein_coding KNOWN TLCD2 1
17 1614805 1619504 lincRNA KNOWN C17orf91 1
17 1617191 1617285 miRNA KNOWN MIR22 1
17 1619817 1641893 protein_coding KNOWN WDR81 15
17 1646130 1658560 protein_coding KNOWN SERPINF2 6
17 1665253 1680859 protein_coding KNOWN SERPINF1 1
17 1682829 1733170 protein_coding KNOWN SMYD4 4
17 1733266 1802848 protein_coding KNOWN RPA1 1
17 1837978 1928178 protein_coding KNOWN RTN4RL1 1
17 1921177 1924000 processed_transcript NOVEL AC099684.1 1
17 1933431 1946724 protein_coding KNOWN DPH1 1
17 1945277 1946479 protein_coding KNOWN OVCA2 1
17 1953202 1953302 miRNA KNOWN MIR132 1
17 1953565 1953674 miRNA KNOWN MIR212 1
17 1958393 1962980 protein_coding KNOWN HIC1 2
17 1963133 2207069 protein_coding KNOWN SMG6 4
17 2116991 2117922 processed_transcript PUTATIVE AC090617.1 1
17 2118776 2119309 processed_transcript PUTATIVE AC130689.5 1
17 2135974 2136904 processed_transcript NOVEL AL450226.2 1
17 2207248 2228554 protein_coding KNOWN SRR 1
17 2225992 2240678 protein_coding KNOWN TSR1 2
17 2232413 2232507 snoRNA KNOWN SNORD91B 1
17 2233570 2233664 snoRNA KNOWN SNORD91A 1
17 2240806 2284344 protein_coding KNOWN SGSM2 2
17 2287354 2304412 protein_coding KNOWN MNT 2
17 2310279 2318731 protein_coding KNOWN AC006435.1 1
17 2319352 2415200 protein_coding KNOWN METTL16 4
17 2496923 2588909 protein_coding KNOWN PAFAH1B1 3
17 2558973 2559076 snoRNA NOVEL snoU13 1
17 2574352 2577029 lincRNA KNOWN AC005696.2 1
17 2592680 2614927 protein_coding KNOWN KIAA0664 3
17 2651372 2651476 miRNA KNOWN MIR1253 1
17 2699732 2941034 protein_coding KNOWN RAP1GAP2 4
17 2995352 2996290 protein_coding KNOWN OR1D2 1
17 3029878 3030875 protein_coding KNOWN OR1G1 1
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17 3100813 3101742 protein_coding KNOWN OR1A2 1
17 3118915 3119844 protein_coding KNOWN OR1A1 1
17 3132283 3132372 miRNA NOVEL AC090282.1 1
17 3143970 3144908 processed_transcript KNOWN OR1D4 2
17 3181193 3182268 protein_coding KNOWN OR3A2 1
17 3194929 3195876 protein_coding KNOWN OR3A1 1
17 3300398 3301704 protein_coding KNOWN OR1E1 1
17 3323862 3324827 protein_coding KNOWN OR3A3 1
17 3336164 3337135 protein_coding KNOWN OR1E2 2
17 3343308 3417146 protein_coding KNOWN SPATA22 4
17 3377404 3406713 protein_coding KNOWN ASPA 2
17 3413796 3461289 protein_coding KNOWN TRPV3 3
17 3468743 3500392 protein_coding KNOWN TRPV1 5
17 3511893 3539616 protein_coding KNOWN SHPK 1
17 3539762 3564836 protein_coding KNOWN CTNS 9
17 3566196 3571976 protein_coding KNOWN TAX1BP3 1
17 3566357 3599488 processed_transcript NOVEL RP11-48B14.2 2
17 3572090 3572962 protein_coding KNOWN TMEM93 2
17 3575748 3599698 protein_coding KNOWN P2RX5 12
17 3617920 3704537 protein_coding KNOWN ITGAE 1
17 3627211 3630067 protein_coding KNOWN GSG2 1
17 3714460 3749540 protein_coding KNOWN C17orf85 2
17 3763609 3796338 protein_coding KNOWN CAMKK1 4
17 3799891 3819960 protein_coding KNOWN P2RX1 1
17 3822869 3867736 protein_coding KNOWN ATP2A3 8
17 3907739 4046314 protein_coding KNOWN ZZEF1 1
17 3960050 3960170 rRNA NOVEL 5S_rRNA 1
17 4017902 4018004 snoRNA NOVEL snoU13 1
17 4046462 4060989 protein_coding KNOWN CYB5D2 1
17 4066665 4167274 protein_coding KNOWN ANKFY1 3
17 4089621 4089719 misc_RNA NOVEL Y_RNA 1
17 4096063 4096160 misc_RNA NOVEL Y_RNA 1
17 4172512 4269969 protein_coding KNOWN UBE2G1 1
17 4337219 4391498 protein_coding KNOWN SPNS3 2
17 4400689 4402969 processed_transcript NOVEL AC118754.4 1
17 4402129 4443228 protein_coding KNOWN SPNS2 1
17 4442192 4458681 protein_coding KNOWN MYBBP1A 3
17 4460224 4463876 protein_coding KNOWN GGT6 3
17 4487294 4511614 protein_coding KNOWN SMTNL2 2
17 4523044 4523147 snRNA NOVEL U6 1
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17 4534214 4545589 protein_coding KNOWN ALOX15 2
17 4574680 4607632 protein_coding KNOWN AC091153.1 3
17 4578674 4600129 processed_transcript NOVEL AC091153.4 1
17 4607525 4608824 processed_transcript NOVEL RP11-314A20.2 1
17 4613784 4624795 protein_coding KNOWN ARRB2 4
17 4634723 4636888 protein_coding KNOWN MED11 1
17 4636828 4643223 protein_coding KNOWN CXCL16 1
17 4643319 4649411 protein_coding KNOWN ZMYND15 2
17 4675187 4686508 protein_coding KNOWN TM4SF5 1
17 4688581 4689729 protein_coding KNOWN VMO1 4
17 4692307 4693591 protein_coding KNOWN GLTPD2 1
17 4699439 4701798 protein_coding KNOWN PSMB6 1
17 4710391 4726727 protein_coding KNOWN PLD2 1
17 4736635 4801355 protein_coding KNOWN MINK1 4
17 4801069 4806369 protein_coding KNOWN CHRNE 1
17 4802713 4806227 protein_coding KNOWN C17orf107 2
17 4835592 4838325 protein_coding KNOWN GP1BA 2
17 4840425 4843463 protein_coding KNOWN SLC25A11 2
17 4843423 4848518 protein_coding KNOWN RNF167 1
17 4848947 4852309 protein_coding KNOWN PFN1 1
17 4851387 4860426 protein_coding KNOWN ENO3 17
17 4862523 4871132 protein_coding KNOWN SPAG7 1
17 4871287 4890960 protein_coding KNOWN CAMTA2 5
17 4876146 4877976 processed_transcript NOVEL AC004771.2 1
17 4891426 4900905 protein_coding KNOWN INCA1 2
17 4901243 4931696 protein_coding KNOWN KIF1C 1
17 4922509 4923388 processed_transcript PUTATIVE AC109333.10 1
17 4935895 4955304 protein_coding KNOWN GPR172B 3
17 4981754 4999668 protein_coding KNOWN ZFP3 1
17 5008930 5026397 protein_coding KNOWN ZNF232 2
17 5015227 5017672 processed_transcript NOVEL AC012146.7 1
17 5019733 5078329 protein_coding KNOWN USP6 5
17 5082830 5095178 protein_coding KNOWN ZNF594 3
17 5113705 5138137 protein_coding KNOWN C17orf87 2
17 5185558 5289129 protein_coding KNOWN RABEP1 6
17 5289346 5323000 protein_coding KNOWN NUP88 2
17 5322961 5336340 protein_coding KNOWN RPAIN 7
17 5328469 5336196 protein_coding KNOWN AC004148.1 1
17 5336099 5342471 protein_coding KNOWN C1QBP 1
17 5344232 5372236 protein_coding KNOWN DHX33 2
APPENDIX C. GENES LOCATED AT THE CRITICAL REGION 127
17 5374571 5389537 protein_coding KNOWN DERL2 1
17 5390247 5394134 protein_coding KNOWN MIS12 1
17 5402748 5487832 protein_coding KNOWN NLRP1 6
17 5402759 5404465 processed_transcript KNOWN AC055839.1 1
17 5417529 5417590 snRNA KNOWN RNU7-31P 1
17 5973934 6027745 protein_coding KNOWN WSCD1 2
17 6110483 6110589 snRNA NOVEL U6 1
17 6327057 6338519 protein_coding KNOWN AIPL1 4
17 6347761 6354382 protein_coding KNOWN FAM64A 2
17 6354583 6459877 protein_coding KNOWN PITPNM3 2
17 6481646 6544247 protein_coding KNOWN KIAA0753 3
17 6504264 6504371 rRNA NOVEL 5S_rRNA 1
17 6544078 6547920 protein_coding KNOWN TXNDC17 1
17 6546635 6554954 protein_coding KNOWN MED31 1
17 6554971 6556593 protein_coding KNOWN C17orf100 1
17 6588032 6616740 protein_coding KNOWN SLC13A5 3
17 6659156 6678962 protein_coding KNOWN XAF1 5
17 6679551 6690965 protein_coding KNOWN FBXO39 1
17 6701312 6735080 protein_coding KNOWN TEKT1 2
17 6888442 6915653 protein_coding NOVEL AC027763.2 2
17 6899384 6914055 protein_coding KNOWN ALOX12 3
17 6915736 6918199 protein_coding KNOWN RNASEK 8
17 6915954 6920839 protein_coding NOVEL C17orf49 5
17 6917814 6920844 protein_coding KNOWN AC040977.1 9
17 6919137 6922949 processed_transcript NOVEL MIR497HG 1
17 6920934 6921020 miRNA KNOWN MIR195 1
17 6921230 6921341 miRNA KNOWN MIR497 1
17 6926369 6933219 protein_coding KNOWN BCL6B 2
17 6939477 6943438 protein_coding KNOWN SLC16A13 1
17 6944949 6947242 protein_coding KNOWN SLC16A11 2
17 6977857 6983600 protein_coding KNOWN CLEC10A 2
17 7004641 7018292 protein_coding KNOWN ASGR2 5
17 7076750 7082883 protein_coding KNOWN ASGR1 2
17 7093209 7123369 protein_coding KNOWN DLG4 14
17 7120444 7128587 protein_coding KNOWN ACADVL 5
17 7126616 7126698 miRNA KNOWN MIR324 1
17 7128660 7137868 protein_coding KNOWN DVL2 1
17 7138350 7142825 protein_coding KNOWN PHF23 3
17 7143333 7145772 protein_coding KNOWN GABARAP 1
17 7146910 7155280 protein_coding KNOWN CTDNEP1 1
APPENDIX C. GENES LOCATED AT THE CRITICAL REGION 128
17 7155372 7163250 protein_coding KNOWN C17orf81 4
17 7163223 7166512 protein_coding KNOWN CLDN7 3
17 7169374 7169485 misc_RNA NOVEL Y_RNA 1
17 7185053 7191576 protein_coding KNOWN SLC2A4 2
17 7191571 7,197876 protein_coding KNOWN YBX2 1
17 7210318 7215782 protein_coding KNOWN EIF5A 5
17 7214643 7222394 protein_coding KNOWN GPS2 4
17 7218951 7232638 protein_coding KNOWN NEURL4 2
17 7239848 7254797 protein_coding KNOWN ACAP1 1
17 7255208 7258258 protein_coding KNOWN KCTD11 1
Appendix D
Missense variants
Table D.1: Missense variants identied in the next gen-
eration sequence data of 05-985.
Chr Pos Ref Var Reads Freq Ref aa Var aa Gene
17 169,221 T - 28 25% D X RPH3AL
17 177,276 T C 39 5% Q R RPH3AL
17 263,359 - G 34 6% S G LOC400566
17 263,463 T C 31 6% R R LOC400566
17 293,199 A G 42 5% L P FAM101B
17 371,634 - C 43 5% K R VPS53
17 401,917 A G 47 4% L P VPS53
17 477,178 - G 47 4% F F VPS53
17 505,868 T C 55 4% N D VPS53
17 505,883 A G 58 5% S P VPS53
17 591,486 A G 69 3% I V FAM57A
17 591,532 A GT 60 3% D G FAM57A
17 594,990 - G 47 4% L L GEMIN4
17 595,007 A G 46 4% L P GEMIN4
17 595,037 T A 48 4% E V GEMIN4
17 595,214 - G 43 7% V A GEMIN4
17 595,278 A G 50 4% F L GEMIN4
17 595,401 - C 55 4% R G GEMIN4
17 595,764 A GAC 44 5% LS LV GEMIN4
17 596,161 A G 48 6% F F GEMIN4
17 596,453 T C 49 4% N S GEMIN4
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17 596,459 TCT ATCC 49 4% ED ED GEMIN4
17 596,626 - C 41 7% R R GEMIN4
17 596,655 - G 47 4% T P GEMIN4
17 596,691 A G 45 4% F L GEMIN4
17 597,213 A G 53 4% S P GEMIN4
17 597,260 - G 50 6% Q P GEMIN4
17 597,487 A G 61 3% F F GEMIN4
17 597,601 A GT 70 3% F L GEMIN4
17 597,698 A G 67 4% L P GEMIN4
17 597,941 A T 76 3% L Q GEMIN4
17 597,974 A G 80 2% L S GEMIN4
17 621,404 A G 37 5% L L GLOD4
17 626,894 A CG 61 3% Y Y GLOD4
17 626,974 A G 67 3% Y H GLOD4
17 632,211 T C 36 6% K R GLOD4
17 632,215 A G 37 5% F L GLOD4
17 641,537 C T 66 3% A A RNMTL1
17 641,605 A G 59 3% E G RNMTL1
17 641,606 A G 59 3% E E RNMTL1
17 669,521 A TG 36 6% F S NXN
17 675,971 A GT 62 3% V D NXN
17 675,983 T C 61 5% N S NXN
17 848,775 T C 47 4% V A TIMM22
17 848,845 T C 40 5% P P TIMM22
17 859,673 T C 18 11% K E ABR
17 861,847 - G 28 7% V A ABR
17 862,678 T AC 44 5% K S ABR
17 863,153 A G 51 4% L P ABR
17 900,116 T C 37 5% K R ABR
17 900,587 A - 37 24% Y X ABR
17 907,029 A G 49 4% L P ABR
17 907,032 T C 46 4% K R ABR
17 907,080 A G 39 5% F S ABR
17 923,622 - G 36 6% V A ABR
17 1,215,084 T C 41 5% K R YWHAE
17 1,286,752 - G 41 7% L P CRK
17 1,318,075 C T 23 96% E E MYO1C
17 1,318,325 A G 36 6% L P MYO1C
17 1,319,627 T C 43 5% K R MYO1C
17 1,320,518 T C 12 17% K R MYO1C
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17 1,320,704 A G 20 10% F L MYO1C
17 1,321,351 - A 41 5% P L MYO1C
17 1,322,194 T CA 48 4% CI CC MYO1C
17 1,322,235 A G 48 4% V A MYO1C
17 1,322,259 A G 53 4% F S MYO1C
17 1,328,736 T C 45 4% D G MYO1C
17 1,332,571 - C 15 20% D G MYO1C
17 1,346,171 T C 36 8% D G SKIP
17 1,346,191 - A 37 8% S S SKIP
17 1,359,381 - T 44 5% V D SKIP
17 1,371,684 T C 35 6% R R PITPNA
17 1,384,244 T C 52 4% N D PITPNA
17 1,385,263 C - 24 37% W X PITPNA
17 1,435,993 T C 35 6% D G SLC43A2
17 1,466,746 G A 41 7% N N SLC43A2
17 1,494,976 A G 32 6% I T SCARF1
17 1,496,653 A G 36 6% W R RILP
17 1,501,166 T C 30 7% N S PRPF8
17 1,503,612 T C 57 3% I V PRPF8
17 1,503,890 - C 63 3% E G PRPF8
17 1,504,009 A G 72 3% G G PRPF8
17 1,508,341 T C 54 4% I V PRPF8
17 1,508,595 T C 53 4% N S PRPF8
17 1,510,779 A G 58 3% F S PRPF8
17 1,510,833 T C 66 3% K R PRPF8
17 1,510,847 T C 68 3% E E PRPF8
17 1,511,085 T C 73 3% H R PRPF8
17 1,511,100 T C 74 3% E G PRPF8
17 1,511,426 - C 66 3% E E PRPF8
17 1,511,445 A G 66 3% L P PRPF8
17 1,511,783 G C 72 4% S R PRPF8
17 1,523,533 C T 59 3% V V PRPF8
17 1,525,836 - G 63 3% D D PRPF8
17 1,525,841 T CA 64 3% FM FC PRPF8
17 1,526,294 T C 46 4% K E PRPF8
17 1,526,560 T C 41 5% N D PRPF8
17 1,527,177 T C 48 4% Q R PRPF8
17 1,530,790 - G 68 6% S P PRPF8
17 1,530,845 T C 72 3% K K PRPF8
17 1,531,687 - G 38 5% M T PRPF8
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17 1,531,732 T C 39 5% Y C PRPF8
17 1,531,909 A G 52 4% V A PRPF8
17 1,532,013 AG - 47 21% P X PRPF8
17 1,532,250 - T 64 3% L L PRPF8
17 1,532,270 T C 63 5% I V PRPF8
17 1,534,531 T C 14 14% K E PRPF8
17 1,563,788 T C 46 4% T A C17orf91
17 1,578,176 C G 22 9% A G WDR81
17 1,583,983 T C 31 6% F F WDR81
17 1,584,040 C TA 31 6% CV CS WDR81
17 1,587,473 T C 50 4% L P WDR81
17 1,587,556 G A 47 4% G S WDR81
17 1,595,794 T AC 24 8% C T SERPINF2
17 1,597,465 GA - 25 8% VK XR SERPINF2
17 1,621,123 T C 32 6% L L SERPINF1
17 1,625,160 T C 31 6% D D SERPINF1
17 1,625,226 T CA 28 7% DS DI SERPINF1
17 1,626,679 T C 51 4% F S SERPINF1
17 1,626,694 A G 55 4% D G SERPINF1
17 1,627,243 - C 41 5% L S SERPINF1
17 1,627,453 - C 48 4% L P SERPINF1
17 1,627,456 T C 48 6% F S SERPINF1
17 1,636,877 T C 47 4% N D SMYD4
17 1,637,610 G A 29 17% R C SMYD4
17 1,649,970 C - 50 12% V X SMYD4
17 1,650,001 A G 53 4% P P SMYD4
17 1,650,042 T C 55 4% R G SMYD4
17 1,650,073 T A 53 4% E D SMYD4
17 1,650,104 A G 51 4% L P SMYD4
17 1,650,131 C AT 42 5% S N SMYD4
17 1,650,155 A G 41 5% L P SMYD4
17 1,650,230 T C 35 6% N S SMYD4
17 1,650,246 T C 34 6% S G SMYD4
17 1,650,303 T C 37 5% I V SMYD4
17 1,650,446 T C 51 4% H R SMYD4
17 1,650,563 - T 49 4% G E SMYD4
17 1,650,588 T C 48 4% K E SMYD4
17 1,650,805 A G 52 6% A A SMYD4
17 1,650,837 T C 55 4% K E SMYD4
17 1,650,982 A GT 38 5% C * SMYD4
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17 1,654,753 A G 65 3% S P SMYD4
17 1,662,030 T CA 22 9% A A SMYD4
17 1,722,489 C AG 32 6% P S RPA1
17 1,729,087 T CA 86 2% PL PT RPA1
17 1,729,098 T C 85 2% V A RPA1
17 1,729,271 T C 80 4% S P RPA1
17 1,729,320 A - 85 11% N X RPA1
17 1,729,436 A G 70 3% K E RPA1
17 1,729,648 A TG 57 3% T C RPA1
17 1,729,720 - G 51 4% T A RPA1
17 1,738,723 A TG 73 3% D V RPA1
17 1,747,188 T C 76 3% V A RPA1
17 1,786,883 T - 31 23% E X RTN4RL1
17 1,787,091 A G 50 4% C R RTN4RL1
17 1,787,526 G A 39 5% R W RTN4RL1
17 1,787,771 T C 42 5% Y C RTN4RL1
17 1,787,850 A G 37 5% C R RTN4RL1
17 1,883,600 A G 34 6% K R DPH1
17 1,886,636 A G 31 6% D G DPH1
17 1,890,641 - A 56 4% E E DPH1
17 1,892,846 GT - 41 5% V X OVCA2
17 1,893,116 T C 48 4% Y H OVCA2
17 1,915,149 T - 31 16% D X SMG6
17 1,915,633 T C 63 3% K R SMG6
17 1,918,917 A G 47 4% F S SMG6
17 1,931,965 A G 50 4% D D SMG6
17 1,931,980 - C 51 4% E E SMG6
17 1,935,842 A T 59 3% V E SMG6
17 1,935,852 C - 61 13% G X SMG6
17 1,935,928 G A 62 3% C C SMG6
17 2,022,716 T - 40 15% K X SMG6
17 2,038,519 T C 65 3% Q Q SMG6
17 2,133,754 T C 63 3% Y C SMG6
17 2,147,908 T C 49 4% E G SMG6
17 2,148,055 A G 55 5% I T SMG6
17 2,148,999 A G 48 4% S P SMG6
17 2,149,046 A G 49 4% L P SMG6
17 2,149,355 T C 55 4% D G SMG6
17 2,149,496 A - 50 24% L X SMG6
17 2,149,808 T C 40 5% N S SMG6
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17 2,149,853 A G 44 5% L S SMG6
17 2,149,998 T C 56 4% S G SMG6
17 2,150,294 - G 57 9% V A SMG6
17 2,150,314 A TG 58 3% S S SMG6
17 2,150,505 A G 62 3% C R SMG6
17 2,150,636 - A 61 3% P L SMG6
17 2,165,675 A G 39 5% H R SRR
17 2,171,445 A G 21 10% T T SRR
17 2,173,260 A G 52 4% K K SRR
17 2,173,262 T C 52 4% L P SRR
17 2,173,787 T C 60 3% F S SRR
17 2,173,795 G AC 61 3% V T SRR
17 2,173,809 A TG 59 3% VK VE SRR
17 2,174,808 T C 86 2% R G TSR1
17 2,179,408 - G 65 3% L L TSR1
17 2,180,598 T C 65 3% T T TSR1
17 2,180,624 - G 66 3% V L TSR1
17 2,182,218 T C 70 3% R R TSR1
17 2,182,339 T C 53 4% D G TSR1
17 2,183,691 T C 58 3% R G TSR1
17 2,183,740 - C 64 3% V V TSR1
17 2,184,519 C T 53 4% M I TSR1
17 2,184,655 - C 41 5% Q R TSR1
17 2,185,727 A G 39 5% H H TSR1
17 2,213,045 - TG 31 10% A V SGSM2
17 2,213,094 C - 49 35% P X SGSM2
17 2,214,221 A G 32 6% E G SGSM2
17 2,214,948 T CA 45 4% GG GR SGSM2
17 2,217,448 A G 36 6% K K SGSM2
17 2,221,310 T A 41 5% A A SGSM2
17 2,225,553 T C 38 8% D D SGSM2
17 2,237,259 C T 24 8% V M MNT
17 2,237,967 T C 28 7% I V MNT
17 2,238,070 T C 43 5% E E MNT
17 2,245,321 G - 22 14% A X MNT
17 2,270,142 - C 46 4% N D METT10D
17 2,270,821 A G 44 5% I T METT10D
17 2,270,826 T C 46 4% E E METT10D
17 2,323,639 T C 27 7% E G METT10D
17 2,327,887 A G 69 3% C C METT10D
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17 2,520,311 T C 63 3% C C PAFAH1B1
17 2,520,342 TT CTC 60 3% F L PAFAH1B1
17 2,524,132 A G 36 6% R G PAFAH1B1
17 2,545,081 T C 26 8% Y C KIAA0664
17 2,545,522 G A 28 7% L L KIAA0664
17 2,841,387 - C 32 6% F S GARNL4
17 2,848,325 A G 59 3% T A GARNL4
17 2,848,376 G A 57 3% V I GARNL4
17 2,855,432 A G 41 5% E G GARNL4
17 2,912,824 - T 23 9% M I OR1D4
17 2,912,975 A G 41 5% L P OR1D4
17 2,913,119 - G 52 4% F S OR1D4
17 2,942,262 A G 65 3% L P OR1D2
17 2,942,722 A G 31 6% L L OR1D2
17 2,942,848 T C 34 6% N D OR1D2
17 2,976,708 T C 70 3% E E OR1G1
17 2,976,753 T C 80 2% V V OR1G1
17 2,976,766 A G 80 2% M T OR1G1
17 2,976,767 T A 82 4% M L OR1G1
17 2,976,803 T AC 77 3% ST SV OR1G1
17 2,976,825 - T 79 3% C * OR1G1
17 2,976,828 A G 78 3% F F OR1G1
17 2,976,853 - G 84 2% V A OR1G1
17 2,976,864 - G 85 2% H H OR1G1
17 2,976,971 - G 77 9% I L OR1G1
17 2,977,003 A G 82 2% V A OR1G1
17 2,977,236 A G 70 3% Y Y OR1G1
17 2,977,247 C T 66 3% V I OR1G1
17 2,977,399 A G 51 4% L P OR1G1
17 2,977,433 - A 46 7% L F OR1G1
17 3,048,004 T C 30 7% S P OR1A2
17 3,048,334 T - 53 9% Y X OR1A2
17 3,065,852 T C 33 6% L P OR1A1
17 3,066,106 T - 49 8% S X OR1A1
17 3,066,109 T AC 49 4% W T OR1A1
17 3,066,263 A G 53 4% Y C OR1A1
17 3,066,379 A G 56 4% T A OR1A1
17 3,066,507 A T 45 4% P P OR1A1
17 3,128,065 A G 35 6% D D OR3A2
17 3,141,747 T C 60 5% S G OR3A1
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17 3,141,754 G A 60 3% I I OR3A1
17 3,141,776 - G 52 4% I T OR3A1
17 3,141,916 C AT 47 4% R R OR3A1
17 3,141,956 A GT 46 4% V D OR3A1
17 3,142,010 - AC 42 5% G G OR3A1
17 3,142,033 A T 40 5% N K OR3A1
17 3,142,056 A GG 39 5% LS LP OR3A1
17 3,142,089 A G 37 5% F L OR3A1
17 3,142,100 A G 37 5% V A OR3A1
17 3,142,329 A G 21 10% C R OR3A1
17 3,160,461 - C 55 4% L P OR3A4
17 3,160,674 T C 50 4% F S OR3A4
17 3,160,705 G A 54 4% L L OR3A4
17 3,160,713 T C 54 4% I T OR3A4
17 3,160,763 A G 53 4% S G OR3A4
17 3,160,919 C T 52 4% Q * OR3A4
17 3,248,279 - G 13 15% M T OR1E1
17 3,271,405 T - 37 14% V X OR3A3
17 3,293,249 T C 49 4% K R SPATA22
17 3,319,329 G A 38 5% A V SPATA22
17 3,326,330 - G 55 4% R G ASPA
17 3,326,404 T AC 67 3% CD *R ASPA
17 3,326,419 TTT CTTC 61 3% IF IF ASPA
17 3,368,703 G A 62 6% L F TRPV3
17 3,368,876 - C 52 4% E G TRPV3
17 3,378,110 T C 40 5% M V TRPV3
17 3,382,808 T AC 37 5% RM RV TRPV3
17 3,393,641 T - 49 18% K X TRPV3
17 3,421,667 A T 40 5% W R TRPV1
17 3,423,880 T C 28 7% P P TRPV1
17 3,423,921 - G 28 100% A P TRPV1
17 3,427,767 C T 24 8% L L TRPV1
17 3,439,959 T C 56 5% E G TRPV1
17 3,442,140 T C 33 100% Q R TRPV1
17 3,442,149 A G 33 6% I T TRPV1
17 3,442,302 G A 34 6% S F TRPV1
17 3,471,292 - C 29 7% R G SHPK
17 3,473,501 A G 39 5% G G SHPK
17 3,473,520 T C 38 5% K R SHPK
17 3,474,114 G A 65 3% T T SHPK
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17 3,474,211 A G 65 3% V A SHPK
17 3,474,255 - G 60 10% G G SHPK
17 3,480,249 T C 43 5% Q Q SHPK
17 3,490,304 A G 54 4% K E CTNS
17 3,490,306 A G 54 4% K K CTNS
17 3,497,520 T C 54 4% V A CTNS
17 3,510,386 A G 39 5% R G CTNS
17 3,566,795 A G 54 4% I T ITGAE
17 3,566,821 T C 59 3% K K ITGAE
17 3,573,399 A G 40 5% C R ITGAE
17 3,574,845 A G 35 6% T T GSG2
17 3,575,463 T AC 56 4% FG LR GSG2
17 3,575,536 T C 53 6% L L GSG2
17 3,575,572 A G 55 4% I V GSG2
17 3,595,967 A G 34 6% L P ITGAE
17 3,607,751 CA - 35 11% IG HX ITGAE
17 3,609,577 - C 41 7% Q R ITGAE
17 3,610,226 TT ATA 43 5% EK DI ITGAE
17 3,611,079 - C 23 43% E G ITGAE
17 3,611,090 CTTG TCTCTC 17 12% DK ER ITGAE
17 3,611,097 TC CTCT 18 17% EE ER ITGAE
17 3,613,943 A G 42 5% L L ITGAE
17 3,613,970 T C 43 5% T T ITGAE
17 3,663,160 C AT 37 5% R H C17orf85
17 3,663,278 T C 31 6% K E C17orf85
17 3,664,485 T C 40 5% K E C17orf85
17 3,668,601 GA - 42 5% VP CX C17orf85
17 3,672,066 T C 53 4% R G C17orf85
17 3,679,399 A G 60 3% V A C17orf85
17 3,712,272 T C 17 12% E E CAMKK1
17 3,722,652 AA GAG 37 5% DF DS CAMKK1
17 3,734,427 C TG 42 5% G A CAMKK1
17 3,753,291 T C 39 5% Y C P2RX1
17 3,753,366 A G 37 8% V A P2RX1
17 3,775,472 - C 42 5% P P ATP2A3
17 3,780,450 T C 21 10% N D ATP2A3
17 3,785,278 A G 32 6% F S ATP2A3
17 3,797,866 - T 49 4% G G ATP2A3
17 3,856,965 T C 50 4% K E ZZEF1
17 3,864,411 A G 71 4% W R ZZEF1
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17 3,864,416 T C 72 3% Q R ZZEF1
17 3,867,538 A G 57 3% L P ZZEF1
17 3,867,690 C T 76 3% L L ZZEF1
17 3,867,880 A T 68 4% L * ZZEF1
17 3,869,730 - G 24 8% F S ZZEF1
17 4,986,475 - G 19 11% E G USP6
17 4,992,723 T C 16 12% G G USP6
17 5,025,866 - G 12 17% S P ZNF594
17 5,026,361 G A 13 85% L F ZNF594
Appendix E
Alignments of erroneous SNPs
Description of the header line: Chromosome, start and end coordinates, reference
and variant allele, read depth, percent of the variant reads, gene name and SNP
id.
>chr17 1020053 1020053 G T 44 50% ABR rs8068519
Reads with Difference:
chr17 1020033+ T-GTT-T-GT-GTG-TGTGTGT-G-T--G-G-G-G-G-GGGGG-TG-T-GTTT-GTGTA
***
F0FQDYC02H20MN (2) 314- T-GTT-T-GT-GTGC-GTGTGT-G-T--G--TG-G-G-GGGGG-TG-T-GTTT-GTGTA 274
F0FQDYC02GQH1S (2) 204- T-GTT-T-GT-GTG-TGTGTGT-G-T--G--TG-G-G-GGGGG-TG-T-GTTTTGTGTA 163
F0FQDYC02G8SVX (2) 199- T-GTT---GT-GTG-TGTGTGT-G-TN----TG-G-G-GGGGG-TG-T-GTTTTGTGTA 159
F0FQDYC02JFNUI (2) 282- T-GTT---GT-GTG-TGTGTGT-G-T--G--TG-G-G-GGGGG-TG-T-GTTT-GTGTA 243
F0FQDYC02JH42Z (2) 358- T-GTT-T-GT-GTG-TGTGTGT-G-T--G--TG-G-G-GGGG--TG-T-GTTT-GTGTA 319
F0FQDYC01DO4YY 402- TTGTT---GTTGTG-TGTGTGT-G-T--G--TG-G-G-GGGGG-TG-T-GTTT-GTGTA 361
F0FQDYC01AZ4B0 (2) 220- T-GTT---GT-GTG-TGTGTGT-G-T--G--TG-G-G-GGGGG-TG-T-GTTT-GTGTA 181
F0FQDYC01BL46L (3) 322- T-GTT---GT-GTG-TGTGTGT-G-T--G--TG-G-G-GGGGG-TG-T-GTTT-GTGTA 283
F0FQDYC01EFLQ8 (4) 342- T-GTT---GT-GTG-TGTGTGT-G-T--G--TG-G-G-GGGGG-TG-T-GTTT-GTGTA 303
F0FQDYC02IXIJQ 376- T-GTT-T-GT-GTG-TGTGTGT-G-T--G--TG-G-G-GGGGGC-G-T-GTTT-GTGTA 336
F0FQDYC02HWWYR (4) 316- T-GTT-T-GT-GTG-TGTGTGT-G-T--G--TG-G-G-GGGG--TG-T-GTTT-GTGTA 277
F0FQDYC02FNZWQ (2) 297- TTGTT---GT-GTG-TGTGTGT-G-T--G--TG-G-G-GGGG--TG-T-GTTT-GTGTA 258
F0FQDYC01EV69B 187- TTGTT---GTTGTG-TGTGTGT-G-T--G--TG-G--CGGGGG-TG-T-GTTT-GTGTA 146
F0FQDYC02HU6ZD 427- T-GTT-T-GT-GTGC-GTGTGT-GGT--G--TG-G-G-GGGGG-TG-T-GTTT-GTGTA 386
F0FQDYC01CJB61 (2) 328- T-GTT---GT-GTG-TGTGTGT-G-TN----TG-G-G-GGGGG-TG-T-GTTT-GTGTA 289
F0FQDYC01EGKNI 387- T-GTT-T-GT-GTG-TGTGTGT-G-T--G--TG-G-G-GGGGG-TG-T-GTTT-GTGTA 347
F0FQDYC01ESFUD 104- GT-GTG-TGTGTGT-G-T--G--TG-G-G-GGGGG-TG-T-GTTT-GTGTA 69
F0FQDYC02GSNHH 148- GT-GTG-TGTGTGT-G-TN----TG-G-G-GGGGG-TG-T-GTTT-GTGTA 113
F0FQDYC01EGC72 175- GT-GTG-TGTGTGT-G-TN----TG-G-G-GGGGG-TG-T-GTTT-GTGTA 140
F0FQDYC01CNDMS 203- GTG-TGTGTGT-G-TN----TG-G-G-GGGGG-TG-T-GTTT-GTGTA 170
139
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F0FQDYC01BADXZ 1+ TGT-G-T--G--TG-G-G-GGGG--TG-T-GTTT-GTGTA 26
F0FQDYC02F7QA9 1+ GT-G-T--G--TG-G-G-GGGG--TG-T-GTTT-GTGTA 25
***
Other Reads:
***
F0FQDYC01EJZYE (3) 435+ T-GTT-TTGT-GTG-TGTGTGT-G-T--G-G-G--TG-GGG 462
F0FQDYC02J0ZCM 406+ T-GTT-T-GT-GTG-TGTGTGT-G-T--G-G-G--TG-GGG 432
F0FQDYC02FY9HN 317+ T-GTT-T-GT-GTG-TGTGTGT-G----G-G----TG-GGGG--TG-T-GTT--GTGT 352
F0FQDYC02IIVR8 254+ T-GTT-T-GT-GTG-TGTGTGT-G-T--G-G-G--TG-GGGGG-TG-TTGTT--GTGTA 294
F0FQDYC01BPU42 247+ T-GTT-T-GT-GTG-TGTGTGT-GGT--G-G-G-GTG-GGGG--TG-TTGTT--GTGTA 288
F0FQDYC02IDUBZ 240+ T-GTT-T-GT-GTG-TGTGTGT-G-T--G-G-G--TG-GGGGG-TG-T-GTTT-GTGTA 280
F0FQDYC02H22EG 200+ T-GTT-T-GT-GTG-TGTGTGT-GGT--G-G-G-GTG-GGGG--T 230
F0FQDYC02IBWSQ 168+ T-GTT-T-GT-GTG-TGTGTGT-G-T--G-G-G--TG-GGGG--TG-T-GTTT-GTGTA 207
F0FQDYC01CHGUE (2) 152+ T-GTT-T--T-GTG-TGTGTGT-G-T--G-GTG-G-G-GG 177
F0FQDYC01B3UB6 101+ T-GTT-T-GT-GTG-TGTGTGT-GGT--G-G-G-GTG-GGGGG-TGGTTGTT--GTGTA 144
F0FQDYC01DT0D9 334- T-GTT---GT-GTG-TGTGTGT-G-TNTG-G-G-G-G-GGGG--TG-T-GTTTTGTGTA 293
F0FQDYC01ASE2Z (2) 353- T-GTT---GT-GTG-TGTGTGT-G-TNTG-G-G-G-G-GGGG--TG-T-GTTT-GTGTA 313
F0FQDYC02IG3BI 255- TTGTT---GT-GTG-TGTGTGT-G-T--G-GTG-G-G-GGG---TG-T-GTTT-GTGTA 216
F0FQDYC02JG0C0 335- T-GTT-T-GT-GTG-TGTGTGTN--T--G-G-G-G-G-GGG---TG-T-GTTT-GTGTA 297
F0FQDYC01CIQ3U 414- T-GTTAT-GT-GTG-TGTGTG--G-T--G------TG-GGGGG-TGGT-GTT--GTGTA 376
F0FQDYC02G0YXZ 233- T-GTT---GT-GTG-TGTGTGT-G-T-TG-G-G-G-G-GGGG--TG-T-GTTT-GTGTA 194
F0FQDYC01ARJ01 306- T-GTT-T-GT-GTG-TGTGTGT-G-T--GTG-G-G-G-GGGGG-TG-T-GTTT-GTGTA 265
F0FQDYC01CJCIV (2) 225- TTGTT---GT-GTG-TGTGTGTN--T--G-G-GNG-G-GGGG--TG-T-GTTTTGTGTA 184
F0FQDYC01BBBIL 238- T-GTT---GTTGTG-TGTGTGT-G-TNTG-G-G-G-G-GGGG--TG-T-GTTT-GTGTA 197
F0FQDYC01EJGSP (3) 472- T-GTT---GT-GTG-TGTGTGT-G-TNTG-G-G-G-G-GG----TG-T-GTT--GTGTA 435
F0FQDYC01D3KMU 374- T-GTT-T-GT-GTG-TGTGTGT-GGTNTG-G-G-G-G-GGGG--TG-T-GTTT-GTGTA 332
F0FQDYC01EVGTH 165- T-GTT-T-GT-GTG-TGTGTGT-G-T-TG-G-G-G-G-GGGG--TG-T-GTTT-GTGTA 125
***
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>chr17 1674048 1674048 A G 35 69% SMYD4 rs719913
Reads with Difference:
chr17 1674028+ -CT-AAAAGTTT-C--AT-AC-TTTG-AAGGGGG-TTT-C-TGTTACTTGAAACTGAAGAGT
*******
F0FP3GZ02HTLGU 40- ACTTAAAAGTTT-C--ATTAC-TTTGGA-GGGGGGTTT-C-TGTTAC 1
F0FP3GZ01BS7IC 39- -CT-AAAAGTTT-C--AT-AC-TTTG-A-GGGGGGTTT-C-TGTTACTTG 1
F0FP3GZ01EIGXW (2) 66- -CT-AAAAGTTT-C--AT-AC-TTTG-A-GGGGGGTTT-C-TGTTACTTGAAACTGAAGAGT 16
F0FP3GZ01CPUS7 137- -CT-AAAAGTTT-C--AT-AC-TTTG-A-GGGGGGTTT-C-TGTTACTTGAAACTGAAGAGT 87
F0FP3GZ01B4Z0J (3) 105- -CT-AAAAGTTT-C--AT-AC-TTTG-A-GGGGGGTTT-C-TGTTACTTGAAACTGAAGAGT 55
F0FP3GZ02G43D8 106- -CT-AAAAGTTT-C--AT-AC-TTTG-A-GGGGGGTTT-C-TGTTACTTGAAACTGAAGAGT 56
F0FP3GZ02F97YL 359+ -CT-AAAAGTTTTC--AT-AC-TTTG-A-GGGGGGTTT-C-TGTTACTTGAAACTGAAGAGT 410
F0FP3GZ02G6C28 154- -CT-AAAAGTTT-C--AT-AC-TTTG-A-GGGGGGTTT-C-TGTTACTTGAAACTGAAGAGT 104
F0FP3GZ02FVPX1 173- -CT-AAAAGTTT-C--AT-AC-TTTG-A-GGGGGGTTT-C-TGTTACTTGAAACTGAAGAGT 123
F0FP3GZ02I2STE 82- -CT-AAAAGTTT-C--AT-AC-TTTG-A-GGGGGGTTT-C-TGTTACTTGAAACTGAAGAGT 32
F0FP3GZ01EB5CH 286+ -CT-AAAAGTTT-C--AT-AC-TTTG-A-GGGGGGTTT-C-TGTTACTTGAAACTGAAGAGT 336
F0FP3GZ01AE1AM 250- -CT-AAAAGTTT-C--AT-AC-TTTG-A-GGGGGGTTT-C-TGTTACTTGAAACTGAAGAGT 200
F0FP3GZ02G555J 306- -CT-AAAAGTTT-C--AT-AC-TTTG-A-GGGGGGTTT-C-TGTTACTTGAAACTGAAGAGT 256
F0FP3GZ02GN74R 181+ -CT-AAAAGTTT-C--AT-AC-TTTG-A-GGGGGGTTT-C-TGTTACTTGAAACTGAAGAGT 231
F0FP3GZ02F6CL5 95- ACTTAAAAGTTT-C--ATTAC-TTTGGA-GGGGGGTTTTC-TGTTACTTGAAACTGAAGAGT 40
F0FP3GZ02HOT1Y 323- -CT-AAAAGTTT-C--AT-AC-TTTG-A-GGGGGGTTT-C-TGTTACTTGAAACTGAAGAGT 273
F0FP3GZ02FHOIO 92- -CT-AAAAGTTT-C--AT-AC-TTTG-A-GGGGGGTTT-C-TGTTACTTGAAACTGAAGAGT 42
F0FP3GZ01D3VJT (2) 153+ -CT-AAAAGTTT-C--AT-ACCTT-G-A-GGGGGGTTT-C-TGTTACTTGAAACTGAAGAGT 203
F0FP3GZ02I6H2O (3) 389- -CT-AAAAGTTT-C--AT-AC-TTTG-A-GGGGGGTTT-C-TGTTACTTGAAACTGAAGAGT 339
F0FP3GZ01CCYJ0 320- -CT-AAAAGTTT-C--AT-AC-TTTG-A-GGGGGGTTT-C-TGTTACTTGAAACTGAAGAGT 270
F0FP3GZ02F9G5Y 73+ -CT-AAAAGTTT-C--AT-AC-TTTG-A-GGGGGGTTT-C-TGTTACTTGAAACTGAAGAGT 123
F0FP3GZ01C6OOB (3) 476- -CT-AAAAGTTT-C--AT-AC-TTTG-A-GGGGGGTTT-C-TGTTACTTGAAACTGAAGAGT 426
F0FP3GZ01AH7EU 47+ -CT-AAAAGTTT-C--AT-AC-TTTG-A-GGGGGGTTT-C-TGTTACTTGAAACTGAAGAGT 97
F0FP3GZ01CLLDZ 451- -CT-AAAAGTTT-C-TAT-AC-TTTG-A-GGGGGGTTT-CGTGTTACTTGAAACTGAAGAGT 399
*******
Other Reads:
*******
F0FP3GZ01EFZ3U (3) 421+ -CT-AAAAGTTT-C--AT-AC-TTTG-A-GGGGG-TTT-C-TGTTACTTGAAACTGAAGAGT 470
F0FP3GZ01BC6I3 421+ -CT-AAAAGTTT-C--AT-AC-TTTG-A-GGGGG-TTT-C-TGT 452
F0FP3GZ02GRKMX 418+ -CT-AAAAGTTT-C--AT-AC-TT-G-A-GGGG--TTT-C-TGTTACTTGAAACTG 459
F0FP3GZ02IWH9E 391+ -CT-AAAAGTT--C--AT-AC-TTTG-A-GGGGG-TTT-C-TGTTACTTGAAACTGAAGAGT 439
F0FP3GZ02H2AXO 293+ -CT-AAAAGTTT-C--AT-AC-TTTG-A-GGGGG-TTT-C-TGTTACTTGAAACTGAAGAGT 342
F0FP3GZ01DWJUI 292+ -CT-AAAAGTTT-C--AT-AC-TTTG-A-GGGGG-TTT-C-TGTTACTTGAAACTGAAGAGT 341
F0FP3GZ01EPZTZ 269+ -CT-AAAAGTT--CC-AT-AC-TTTG-A-GGGGG-TTT-C-TGTTACTTGAAACTGAAGAGT 318
F0FP3GZ01EU0W9 260+ -CT-AAAAGTTT-C--AT-AC-TTTG-A-GGGGG-TTT-C-TGTTACTTGAAACTGAAGAGT 309
F0FP3GZ01CPUFG 105+ -CT-AAAAGTTT-C--AT-AC-TTTG-A-GGGGG-TTT-C-TGTTACTTGAAACTGAAGAGT 154
F0FP3GZ01DECCD 67+ -CT-AAAAGTTT-C--AT-AC-TTTG-A-GGGGG-TTT-C-TGTTACTTGAAACTGAAGAGT 116
F0FP3GZ01CLHG3 276- ACTTAAAAGTTT-C--ATTAC-TT-G-A-GGGGG-TTT-C-TGTTACTTGAAACTGAAGAGT 225
*******
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>chr17 3137283 3137283 T C 27 67% rs231674
Reads with Difference:
chr17 3137257+ T-AATTTCTCATCA-TCC-ACCCCCCTCC-TACCCACCCAC-ATTT-CT-GATAC-A-T-C
**
F0FP3GZ01BGBHH 77- T-AATTTCTCATCA-TCC-ACCCCC-TCCC-ACCCACCCAC-ATTT-CT-GATAC-A-T-C 28
F0FP3GZ01B7BUJ (2) 71- T-AATTTCTCATCA-TCC-ACCCCC-TCCC-ACCCACCCAC-ATTT-CT-GATAC-A-T-C 22
F0FP3GZ02J093O 125- T-AATTTCTCATCA-TCC-ACCCCCCTCCC-ACCCACCCAC-ATTT-CT-GATAC-A-T-C 75
F0FP3GZ01B4505 138- T-AATTTCTCATCA-TCCCACCCCC-TCCC-ACCCACCCAC-ATTT-CT-GATAC-A-T-C 88
F0FP3GZ01AS2WA 277+ T-AATTTCTCATCA-TCC-ACCCCCCTCCC-ACCCACCCAC-ATTT-CT-GATAC-A-T-C 327
F0FP3GZ02JK1G0 268+ T-AATTTCTCATCA-TCC-ACCCCCCTCCC-ACCCACCCAC-ATTT-CT-GATAC-A-T-C 318
F0FP3GZ01BU4OI (2) 262+ T-AATTTCTCATCA-TCC-ACCCCCCTCCC-ACCCACCCAC-ATTT-CT-GATAC-A-T-C 312
F0FP3GZ02HFHU9 250+ T-AATTTCTCATCA-TCC-ACCCCCCTCCC-ACCCACCCAC-ATTTTCT-GATAC-A-T-C 301
F0FP3GZ02F8B31 (2) 195+ T-AATTTCTCATCA-TCC-ACCCCCCTCCC-ACCCACCCAC-ATTT-CT-GATAC-A-T-C 245
F0FP3GZ02GGWQX 136+ T-AATTTCTCATCA-TCC-ACCCCCCTCCC-ACCCACCCAC-ATTT-CT-GATAC-A-T-C 186
F0FP3GZ01E3VLU 122+ T-AATTTCTCATCA-TCC-ACCCCCCTCCC-ACCCACCCAC-ATTT-CT-GATAC-A-T-C 172
F0FP3GZ01ECLIR 59- T-AATTTCTCATCA-TCC-ACCCCC-TCCC-ACCCACCCAC-ATTT-CT-GATAC-A-T-C 10
F0FP3GZ02JLMOE 411- T-AATTTCTCATCA-TC--ACCCCC-TCCC-ACCCACCCAC-ATTT-CT-GATAC-AAT-C 362
F0FP3GZ02FTDZB 433- T-AATTTCTCATCA-TCC-ACCCCC-TCCC-ACCCACCCAC-ATTT-CT-GATAC-A-T-C 384
F0FP3GZ01C0LE5 131- TTAATTTCTCATCACTCCCACCCCC-TCCC-ACCCACCCAC-ATTT-CT-GATAC-A-T-C 79
F0FP3GZ02FN8ZA (2) 387- T-AATTTCTCATCA-TC--ACCCCC-TCCC-ACCCACCCAC-ATTT-CT-GATAC-A-T-C 339
F0FP3GZ02JWQF7 339- T-AATTTCTCATCA-TCC-ACCCCCCTCCC-ACCCACCCAC-ATTT-CT-GATACCA-T-C 288
F0FP3GZ01A2HTG 429- T-AATTTCTCATCACTCC-ACCCCCCTCCC-ACCCACCCAC-ATTT-CT-GATAC-A-T-C 378
**
Other Reads:
**
F0FP3GZ02INZFQ 460+ T-AATT-CTCATCA-TCC-ACCCCC-TCC--ACCCACCCAC-ATTT-CT-GATAC-A-T-C 507
F0FP3GZ02HB4IP 448+ T-AATTTCTCATCA-TCC-ACCCCCCTCC--ACCCACC-AC-ATTT-CT-GATAC-A-T-C 496
F0FP3GZ01DU9FN (2) 245+ T-AATTTCTCATCA-TCC-ACCCCC-TCC--ACCCACCCAC-ATTT-CT-GATAC-A-T-C 293
F0FP3GZ01DGCGJ (2) 232+ T-AATTTCTCATCA-TCC-ACCCCC-TCC--ACCCACCCAC-ATT--CTTGATAC-A-T-C 280
F0FP3GZ01CRL5N 318- T-AATTTCTCATCA-TCC-ACCCCC-TCC--ACCCACCCAC-ATTT-CT-GATAC-A-TTC 269
F0FP3GZ02HZ95E 177+ T-AATTTCTCATCA-TCC-ACCCCC-TCC--ACCCACCCAC-ATTT-CT-GATAC-A-T-C 225
F0FP3GZ01A4SLV 179+ T-AATTTCTCATCA-TCC-ACCCCC-TCC--ACCCACCCACCATTT-CT-GATAC-A-T-C 228
F0FP3GZ01EC9G3 (2) 170+ T-AATTTCTCATCA-TCC-ACCCCC-TCC--ACCCACC-AC-ATTT-CT-GATAC-A-T-C 217
F0FP3GZ01A6YLU 140+ T-AATTTCTCATCA-TCC-ACCCCC-TCC--ACCCACCCACCATTT-CTTGATAC-A-T 189
**
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>chr17 6954089 6954089 G A 43 93% ASGR2 rs314239
Reads with Difference:
chr17 6954067+ CTTC-TCA-TTCCT-A-T-C-ACCCCCC--GA-CCC-A-GCAGGACCACAT-CCTGGGGAG
***
F0FQDYC02HJGY9 (2) 31- CTTC-TCA-TTCCT-A-T-C-ACCCCC--A-A-CCC-A-GCAG 1
F0FQDYC01D3YSY 107- CTTC-TCA-TTCCT-A-T-C-ACCCCC--A-A-CCC-A-GCAGGACCACAT-CCTGGGGAG 60
F0FQDYC01AM8HL 338+ CTTC-TCA-TTCCT-A-T-CCACCCCCC-A-A-CCC-A-GCAGGACCACAT-CCTGGGGAG 387
F0FQDYC01EAHI7 (2) 127- CTTC-TCA-TTCCT-A-T-C-ACCCCC--A-A-CCC-A-GCAGGACCACAT-CCTGGGGAG 80
F0FQDYC02HZD0P 139- CTTC-TCA-TTCCT-A-T-C-ACCCCCC-A-A-CCC-A-GCAGGACCACAT-CCTGGGGAG 91
F0FQDYC01BRF9N 270+ CTTC-TCA-TTCCT-A-T-C-ACCCCC--A-A-CC--A-GCAGGACCACAT-CCTGGGGAG 316
F0FQDYC02I070H 252+ CTTC-TCA-TTCCT-A-T-CCACCCCCCTA-A-CC--A-GC 282
F0FQDYC01DZ0B5 (3) 56- CTTC-TCA-TTCCT-A-T-C-ACCCCC--A-A-CCC-A-GCAGGACCACAT-CCTGGGGAG 9
F0FQDYC01AXT1O (3) 58- CTTC-TCA-TTCCT-A-T-C-ACCCCC--A-A-CCC-A-GCAGGACCACAT-CCTGGGGAG 11
F0FQDYC01CD0A4 220+ CTTC-TCA-TTCCT-A-T-C-ACCCCC--A-A-CCC-A-GCAGGACCACAT-CCTGGGGAG 267
F0FQDYC01DU32S 58- CTTC-TCA-TTCCT-A-T-C-ACCCCCC-A-A-CCC-A-GCAGGACCACAT-CCTGGGGAG 10
F0FQDYC01DUOH0 208+ CTTC-TCA-TTCCT-A-T-C-ACCCCC--A-A-CC--A-GCAGGACCACAT-CCTGGGGAG 254
F0FQDYC01BICEF (2) 205+ CTTC-TCA-TTCCT-A-T-CCACCCCCC-A-A-CCC-A-GCAGGACCACAT-CCTGGGGAG 254
F0FQDYC01CZ0UY 197- CTTC-TCA-TTCCT-A-T-C-ACCCCC--A-A-CCC-A-GCAGGACCACAT-CCTGGGGAG 150
F0FQDYC01DX3HQ (2) 296- CTTC-TCA-TTCCT-A-T-C-ACCCCC--A-A-CCC-A-GCAGGACCACAT-CCTGGGGAG 249
F0FQDYC01BMPOI 195- CTTC-TCA-TTCCT-A-T-C-ACCCCCC-A-A-CCC-A-GCAGGACCACAT-CCTGGGGAG 147
F0FQDYC01B9YEG 112- CTTC-TCA-TTCCT-A-T-C-ACCCCCC-A-A-CCC-A-GCAGGACCACAT-CCTGGGGAG 64
F0FQDYC02FORIK 203- CTTC-TCA-TTCCT-A-T-C-ACCCCC--A-A-CCC-A-GCAGGACCACAT-CCTGGGGAG 156
F0FQDYC01CUTDX 141- CTTC-TCA-TTCCT-A---CCACCCCCC-A-A-CCC-A-GCAGGACCACAT-CCTGGGGAG 93
F0FQDYC02F8SV1 226- CTTC-TCA-TTCCT-A-T-C-ACCCCC--A-A-CCC-A-GCAGGACCACAT-CCTGGGGAG 179
F0FQDYC01BF8OJ 77- CTTC-TCA-TTCCT-A-T-C-ACCCCC--A-A-CCC-A-GCAGGACCACAT-CCTGGGGAG 30
F0FQDYC01BQOA7 (3) 113- CTTC-TCA-TTCCT-A-T-C-ACCCCCC-A-A-CCC-A-GCAGGACCACAT-CCTGGGGAG 65
F0FQDYC01DL14J 219- CTTC-TCA-TTCCT-A-T-C-ACCCCC--A-A-CCC-A-GCAGGACCACAT-CCTGGGGAG 172
F0FQDYC02H4BNQ 238- CTTC-TCA-TTCCT-A-T-C-ACCCCC--A-A-CCC-A-GCAGGACCACAT-CCTGGGGAG 191
F0FQDYC01CNS32 (2) 159+ CTTC-TCA-TTCCT-A-T-C-ACCCCC--A-A-CC--A-GCAGGACCACAT-CCTGGGGAG 205
F0FQDYC01C0H0H 43- CTTC-TCA-TTCCT-A-T-C-ACCCCCC-A-A-CCC-A-GCAGGACCACAT-CCT 1
F0FQDYC02GQL72 303- CTTC-TCA-TTCCT-A-T-C-ACCCCC--A-A-CCC-A-GCAGGACCACAT-CCTGGGGAG 256
F0FQDYC02IWTBZ (2) 203- CTTC-TCA-TTCCT-A-T-C-ACCCCCC-A-A-CCC-A-GCAGGACCACAT-CCTGGGGAG 155
F0FQDYC01AXE9S 267- CTTC-TCA-TTCCT-A-T-C-ACCCCCC-A-A-CCC-A-GCAGGACCACAT-CCTGGGGAG 219
F0FQDYC02G9JZQ (2) 355- CTTC-TCA-TTCCT-A-T-C-ACCCCC--A-A-CCC-A-GCAGGACCACAT-CCTGGGGAG 308
F0FQDYC01ALPOZ 127+ CTTC-TCA-TTCCT-A-T-C-ACCCCC--A-A-CCC-A-GCAGGACCACAT-CCTGGGGAG 174
F0FQDYC02HMEG6 128- CTTC-TCAATTCCT-A-T-C-ACCCCC--A-A-CCC-A-GCAGGACCACAT-CCTGGGGAG 80
F0FQDYC01D2TDN 308- CTTC-TCA-TTCCT-A-T-C-ACCCCC--A-A-CCC-A-GCAGGACCACAT-CCTGGGGAG 261
F0FQDYC01AHLKN 75+ CT-CCTCA-TTCCT-A-T-C-ACCCCCC-A-A-CCC-A-GCAGGACCACAT-CCTGGGGAG 123
F0FQDYC02IXD9Z 65+ CTTC-TCA-TTCCT-A-T-C-ACCCCC--A-A-CCC-A-GCAGGACCACAT-CCTGGGGAG 112
F0FQDYC02IGZFV 404- CTTC-TCA-TTCCT-ACT-C-ACCCCC--A-A-CCC-A-GCAGGACCACATAC-TGGGGAG 356
F0FQDYC01A48QN 366- CTTC-TCA-TTCCTTACT-C-ACCCCCC-A-A-CCCCACGCAGGACCACAT-CCTGGGGAG 314
F0FQDYC01CB2WJ 20+ CTTC-TCA-TTCCT-A-T-C-ACCCCCC-A-A-CCC-A-GCAGGACCACAT-CCTGGGGAG 68
F0FQDYC02G69IX (2) 483- CTTC-TCA-TTCCT-ACT-C-ACCCCCC-A-A-CCC-ACGCAGGACCACAT-CCTGGG-AG 434
F0FQDYC02FNMUO 307- CA-TTCCT-A-T-C-ACCCCC--A-A-CCC-A-GCAGGACCACAT-CCTGGGGAG 265
***
Other Reads:
F0FQDYC02IYA6S 37- CTTC-TCA-TTCCT-A-T-C-ACCCCC--AG--CCC-A-GCAGGACCAC 1
F0FQDYC01EBQAE 59+ CTTC-TCA-TTCCT-A-T-C-ACCCCCC-AG--CCC-A-GCAGGACCACAT-CCTGGGGAG 107
F0FQDYC02J1MRN 194- CTTC-TCA-TTCCT-A-TN--ACCCCC----AACCC-A-GCAGGACCACAT-CCTGGGGAG 147
***
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>chr17 7113355 7113355 C T 42 69% rs8067500
Reads with Difference:
chr17 7113328+ TC-TCAA-CCTTGA-CACTGTT-G-AC-ATTTT--CTCCCC-T-GCTATCTCTT-GGG-CT
***
F0FQDYC02IQEPI 392+ TC-TCA-GCCTTGA-CACTGTT-G-AC-ATTTTT--TCCCCN--GCTATCTCTT-GGG-CT 440
F0FQDYC01DZH9J 267+ TC-TCA-GCCTTGA-CACTGTT-G-AC-ATTTTT--TCCCCN--GCTATCTCTT-GGG-CT 315
F0FQDYC02JYP5H 289- TC-TCA-GCCTTGA-CACTGTT-G-AC-ATTTTT--TCCCC-T-GCTATCTCTT-GGG-CT 241
F0FQDYC02F4HB9 345- TC-TCA-GCCTTGA-CACTGTT-G-AC-ATTTTT--TCCCC-T-GCTATCTCTT-GGG-CT 297
F0FQDYC01C0VNZ (2) 171+ TC-TCA-GCCTTGA-CACTGTT-G-AC-ATTTTT--TCCCC-T-GCTATCTCTT-GGG-CT 219
F0FQDYC01EK5KZ 194- TC-TCA-GCCTTGA-CACTGTT-G-AC-ATTTTT--TCCCC-T-GCTATCTCTT-GGG-CT 146
F0FQDYC01DYLVR (2) 264- TC-TCA-GCCTTGA-CACTGTT-G-AC-ATTTTTT-TCCCC-T-GCTATCTCTT-GGG-CT 215
F0FQDYC01DVC3W 158+ TC-TCA-GCCTTGA-CACTGTT-G-AC-ATTTTT--TCCCC-T-GCTATCTCTT-GGG-CT 206
F0FQDYC01CAX1J 188- TC-TCA-GCCTTGA-CACTGTT-G-AC-ATTTTT--TCCCC-T-GCTATCTCTT-GGG-CT 140
F0FQDYC01EKBZV 347- TC-TCA-GCCTTGA-CACTGTT-G-AC-ATTTTT--TCCCC-T-GCTATCTCTT-GGG-CT 299
F0FQDYC01ASREN 125+ TC-TCA-GCCTTGA-CACTGTT-G-AC-ATTTTT--TCCCC-T-GCTATCTCTT-GGG-CT 173
F0FQDYC01EIZCS 243- TC-TCA-GCCTTGA-CACTGTT-G-AC-ATTTTT--TCCCC-T-GCTATCTCTT-GGG-CT 195
F0FQDYC01CAEMP 273- TC-TCA-GCCTTGA-CACTGTT-G-AC-ATTTTT--TCCCC-T-GCTATCTCTT-GGG-CT 225
F0FQDYC01B71EU 312- TC-TCA-GCCTTGA-CACTGTT-G-AC-ATTTTT--TCCCC-T-GCTATCTCTT-GGG-CT 264
F0FQDYC02IIQLM 315- TC-TCA-GCCTTGA-CACTGTT-G-AC-ATTTTT--TCCCC-T-GCTATCTCTT-GGGGCT 266
F0FQDYC01BRYZ6 (3) 110+ TC-TCA-GCCTTGA-CACTGTT-G-AC-ATTTTT--TCCCC-T-GCTATCTCTT-GGG-CT 158
F0FQDYC01B72AL (2) 260- -C-TCA-GCCTTGA-CACTGTT-G-AC-ATTTTT--TCCCC-T-GCTATCTCTT-GGG-CT 213
F0FQDYC02I449V (2) 299- TC-TCA-GCCTTGA-CACTGTT-G-AC-ATTTTT--TCCCC-T-GCTATCTCTT-GGG-CT 251
F0FQDYC01A8JFC 457- TC-TCA-GCCTTGA-CACTGTT-G-AC-ATTTTT--TCCCC-T-GCTATCTCTT-GGG-CT 409
F0FQDYC01EEG05 458- -CC-CA-GCCTTGA-CACTGTT-G-AC-ATTTTT--TCCCC-T-GCTATCTCTT-GGG-CT 411
F0FQDYC01ERC64 340- TC-TCA-GCCTTGA-CACTGTT-G-AC-ATTTTT--TCCCC-T-GCTATCTCTTTGGG-CT 291
F0FQDYC02JJ9KR 8+ TC-TCA-GCCTTGA-CACTGTT-G-AC-ATTTTT--TCCCC-T-GCTATCTCTT-GGG-CT 56
F0FQDYC01BGW21 304- TC-TCA-GCCTTGA-CACTGTTTG-AC-ATTTTT--TCCCC-T-GCTATCTCTT-GGG-CT 255
F0FQDYC01BW8T1 7+ TC-TCA-GCCTTGAACACTGTT-G-AC-ATTTTT--TCCCC-T-GCTATCTCTT-GGG-CT 56
F0FQDYC02J51PV 76- TC-TCA-GCCTTGA-CACTGTT-G-AC-ATTTTT--TCCCC-T-GCTATCTCTT-GGG-CT 28
F0FQDYC01DF2K7 407- C-TCA-GCCTTGA-CACTGTT-G-AC-ATTTTT--TCCCC-T-GCTATCTCTT-GGG-CT 360
F0FQDYC02GVMD1 1+ CCTTGA-CACTGTT-G-AC-ATTTTT--TCCCC-T-GCTATCTCTT-GGG-CT 43
F0FQDYC01DC1W8 462- ACTGTT-GTACCATTTTT--TCCCC-T-GCTATCTCTT-GGG-CT 425
F0FQDYC01ERL9F 172- GTT-G-AC-ATTTTT--TCCCC-T-GCTATCTCTT-GGG-CT 140
***
Other Reads:
F0FQDYC01B36YZ 202- TC-TCA-GCCTTGA-CACTGTT-G-AC-ATTTT---TCCCC-T-GCTATCTCTT-GGG-CT 155
F0FQDYC02G9GPW 231+ TC-TCA-GCCTTGA-CACTGTT-G-AC-ATTTT---TCCCC-T-GCTATCTCTT-GGG-CT 278
F0FQDYC02HDQHG 209- TC-TCA-GCCTTGA-CACTGTT-G-AC-ATTTT---TCCCC-T-GCTATCTCTT-GGG-CT 162
F0FQDYC02J6NK1 153+ TC-TCA-GCCTTGA-CACTGTT-G-AC-ATTTT---TCCCC-T-GCTATCTCTT-GGG-CT 200
F0FQDYC02HRGJ9 119+ TC-TCA-GCCTTGA-CACTGTT-G-AC-ATTTT---TCCCC-T-GCTATCTCTT-GGG-CT 166
F0FQDYC01DYQRG 113+ TC-TCA-GCCTTGA-CACTGTT-G-AC-ATTTT---TCCCC-T-GCTATCTCTT-GGG-CT 160
F0FQDYC01D3GVX 194- TC-TCA-GCCTTGA-CACTGTT-G-AC-ATTTT---TCCCC-T-GCTATCTCTT-GGG-CT 147
F0FQDYC01BEJPW 351- TC-TCA-GCCTTGA-CACTGTT-G-AC-ATTTT---TCCCC-T-GCTATCTCTT-GGG-CT 304
F0FQDYC01AZIAC (2) 434- TC-TCA-GCCTTGA-CACTGTT-G-AC-ATTTT---TCCCC-T-GCTATCTCTT-GGG-CT 387
F0FQDYC01DT9TI 224- TC-TCA-GCCTTGA-CACTGTT-G-AC-ATTTT---TCCCC-T-GCTATCTCTT-GGG-CT 177
F0FQDYC01DWXUC 53+ TC-TCA-GCCTTGA-CACTGTT-G-AC-ATTTT----CCCC-TTGCTATCTCTT-GGG-CT 100
F0FQDYC01B55KO 104- TC-TCA-GCCTTGA-CACTGTT-G-AC-ATTTT---TCCCC-T-GCTATCTCTT-GGG-CT 57
F0FQDYC02I1W94 43+ TC-TCA-GCCTTGA-CACTGTT-G-AC-ATTTT---TCCCC-T-GCTATCTCTT-GGG-CT 90
***
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>chr17 1674048 1674048 A G 31 71% SMYD4 rs719913
Reads with Difference:
chr17 1674023+ CATAG-CT-AAAAGTTTCAT-ACTTT--GAAGGGGG--T-TTCTGTTACTT-GAAACTGAA
*******
F0FQDYC01AVMWN 49- CATAGACTTAAAAGTTTCATTACTTT--GA-GGGGGG-T-TTCTGTTACTT-GAA 1
F0FQDYC01DKDWN 56- CATAG-CT-AAAAGTTTCAT-ACTTT--GA-GGGGGG-T-TTCTGTTACTT-GAAACTGAA 5
F0FQDYC02JXYBK (2) 230+ CATAG-CT-AAAAGTTTCAT-ACTTT--GA-GGGGGG-T-TTCTGTTACT-CGAAACTGAA 281
F0FQDYC01AS3DN 89- CATAG-CT-AAAAGTTTCAT-ACTTT--GA-GGGGGG-T-TTCTGTTACTT-GAAACTGAA 38
F0FQDYC01A3HLJ 91- CATAG-CT-AAAAGTTTCAT-ACTTT--GA-GGGGGG-T-TTCTGTTACTT-GAAACTGAA 40
F0FQDYC01DKPX6 130- CATAG-CT-AAAAGTTTCAT-ACTTT--GA-GGGGGGCT-T-CTGTTACTT-GAAACTGAA 79
F0FQDYC02F5WLR (3) 186- CATAG-CT-AAAAGTTTCAT-ACTTT--GA-GGGGGG-T-TTCTGTTACTT-GAAACTGAA 135
F0FQDYC01CTYKF (2) 195- CATAG-CT-AAAAGTTTCAT-ACTTT--GA-GGGGGG-T-TTCTGTTACTT-GAAACTGAA 144
F0FQDYC01CDEUQ 212- CATAG-CT-AAAAGTTTCAT-ACTTT--GA-GGGGGG-T-TTCTGTTACTT-GAAACTGAA 161
F0FQDYC01B2SGS 234- CATAG-CT-AAAAGTTTCAT-ACTTTN--A-GGGGGG-T-TTCTGTTACTT-GAAACTGAA 183
F0FQDYC01CW50U 297- CATAG-CT-AAAAGTTTCAT-ACTTTN--A-GGGGGG-T-TTCTGTTACTT-GAAACTGAA 246
F0FQDYC01B0CFM (2) 222+ CATAG-CT-AAAAGTTTCAT-ACTTT--GA-GGGGGG-T-TTCTGTTACTT-GAAACTGAA 273
F0FQDYC01B18W1 214+ CATAG-CT-AAAAGTTTCAT-ACTTT--GA-GGGGGG-T-TTCTGTTACTT-GAAACTGAA 265
F0FQDYC01B7OKY 284- CATAG-CT-AAAAGTTTCAT-ACTTTN--A-GGGGGG-T-TTCTGTTACTT-GAAACTGAA 233
F0FQDYC02FOEWJ 330- CATAG-CT-AAAAGTTTCAT-ACTTT--GA-GGGGGG-T-TTCTGTTACTT-GAAACTGAA 279
F0FQDYC01CJCSY 129+ CATAG-CT-AAAAGTTTCAT-ACTTT--GA-GGGGGG-T-TTCTGTTACTT-GAAACTGAA 180
F0FQDYC02JFEIA 85- CATAG-CT-AAAAGTTTCAT-ACTTT--GA-GGGGGG-T-TTCTGTTACTT-GAAACTGAA 34
F0FQDYC01BSFK1 308- CATAG-CT-AAAAGTTTCAT-ACTTT--GA-GGGGGG-T-TTCTGTTACTT-GAAACTGAA 257
F0FQDYC02HRIZF 41+ CATAG-CT-AAAAGTTTCAT-ACTTT--GA-GGGGGG-T-TTCTGTTACTT-GAAACTGAA 92
F0FQDYC02IRR5J 38+ CATAG-CT-AAAAGTTTCAT-ACTTT--GA-GGGGGG-T-TTCTGTTACTT-GAAACTGAA 89
F0FQDYC02HB0P9 (2) 323- CATAG-CT-AAAAGTTTCAT-ACTTT--GA-GGGGGG-T-TTCTGTTACTT-GAAACTGAA 272
F0FQDYC02F9DVI 517- CATAG-CT-AAAAGTTTCAT-ACTTT--GA-GGGGGG-T-TTCTGTTACTT-GAAACTGAA 466
*******
Other Reads:
*******
F0FQDYC02JGU6J 345+ CATAG-CT-AAAAGTTTCAT-ACTTT--GA-GGGGG--TCT-CTGTTACTT-GAAACTGAA 395
F0FQDYC01AX8CD 295+ CATAG-CT-AAAAGTTTCAT-ACTTT--GA-GGGGG--T-TTCTGTTACTT-GAAACTGAA 345
F0FQDYC01CBKKR 262+ CATAG-CT-AAAAGTTTCAT-ACTTT--GA-GGGGG--T-TTCTGTTACTT-GAAACTGAA 312
F0FQDYC01DL1UE 236+ CATAG-CT-AAAAGTTTCAT-ACTTT--GA-GGGGG--T-TTCTGTTACTT-GAAACTGAA 286
F0FQDYC01AND8O (2) 254+ CATAG-CT-AAAAGTTTCAT-ACTTT--GA-GGGGG--T-TTCTGTTACTT-GAA-CTGAA 303
F0FQDYC02FWOXX 167+ CATAG-CT-AAAAGTTTCAT-ACTTT--GA-GGGGG--T-TTCTGTTACTT-GAAACTGAA 217
F0FQDYC02FPKQL (3) 339- CATAG-CT-AAAAGTTTCAT-ACTTTN--A-GGGGG--T-TTCTGTTACTT-GAAACTGAA 289
F0FQDYC02HRLTH 61+ CATAG-CT-AAAAGTTTCAT-ACTTT--GA-GGGGG--T-TTCTGTTACTT-GAAACTGAA 111
F0FQDYC01DCGDP 405- CATAG-CT-AAAAGTTTCAT-ACTTT-TGA-GGGGG--T-TTCTGTTACTT-GAAACTGAA 354
*******
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>chr17 3137283 3137283 T C 23 74% rs231674
Reads with Difference:
chr17 3137255+ AGTAATTTCTCATC-ATCCACCCCCCTCC--TACCC-ACCCACATTT-CTGAT-AC-AT
***
F0FQDYC02GWKGT (2) 71- AGTAATTTCTCATC-ATCCACCCCC-TCCCC-ACCC-ACCCACATTT-CTGAT-AC-AT 20
F0FQDYC01DRMOP 64- AGTAATTTCTCATC-ATCCACCCCCCTCCC--ACCC-ACCCACATTT-CTGAT-AC-AT 13
F0FQDYC02GM4GA 310+ AGTAATTTCTCATC-ATCCACCCCCCTCCC--ACCC-ACCCACATTT-CTGAT-AC-AT 361
F0FQDYC02HP5FW 61- AGTAATTTCTCATC-ATCCACCCCCCTCCCC-ACCC-ACCCACATTT-CTGAT-AC-AT 9
F0FQDYC02FUDMH 142- AGTAATTTCTCATC-ATCCACCCCCCTCCCC-ACCCCACCCACATTT-CTGAT-AC-AT 89
F0FQDYC02F4B40 286+ AGTAATTTCTCATC-ATCCACCCCCCTCCC--ACCC-ACCCACATTT-CTGAT-AC-AT 337
F0FQDYC01EHPPY 207- AGTAATTTCTCATCG-TC-ACCCCC-TCCC--ACCC-ACCCACATTT-CTGAT-AC-AT 158
F0FQDYC01DS55U 284- -GTAATTTCTCATC-ATCCACCCCCCTCCC--ACCC-ACCCACATTT-CTGAT-AC-AT 234
F0FQDYC01D7A67 (2) 209+ AGTAATTTCTCATC-ATCCACCCCCCTCCC--ACCC-ACCCACATTT-CTGAT-AC-AT 260
F0FQDYC01CNKJ5 154+ AGTAATTTCTCATC-ATCCACCCCCCTCCC--ACCC-ACCCACATTT-CTGAT-AC-AT 205
F0FQDYC02JA5X6 113+ AGTAATTTCTCATC-ATCCACCCCCCTCCC--ACCC-ACCCACATTT-CTGAT-AC-AT 164
F0FQDYC02FP69L 62+ AGTAATTTCTCATC-ATCCACCCCCCTCCC--ACCC-ACCCACATTT-CTGAT-AC-AT 113
F0FQDYC01AZGHI 418- AGTAATTTCTCATC-ATCCACCCCC-TCCC--ACCC-ACCCACATTT-CTGAT-AC-AT 368
F0FQDYC02GRQA3 (2) 219- AGTAATTTCTCATC-ATC-ACCCCC-TCCC--ACCC-ACCCACATTT-CTGAT-AC-AT 170
F0FQDYC02FKXF2 15+ AGTAATTTCTCATC-ATCCACCCCCCTCCC--ACCC-ACCCACATTT-CTGAT-AC-AT 66
F0FQDYC01BSQ2D 357- GTAATTTCTCATC-ATCCACCCCC-TCCC--ACCC-ACCCACATTT-CTGAT-AC-AT 308
F0FQDYC02G8M9K 429- CCACCCCC-TCCC--ACCC-ACCCACATTT-CTGAT-AC-AT 395
***
Other Reads:
***
F0FQDYC02GBTUK 348+ AGTAATTTCTCATC-ATCCACCCCCCTCC---ACCC-ACCCACATTTTCTGAT-AC-AT 399
F0FQDYC01DY22T 220- AGTAATTTCTCATC-ATC-ACCCCC-TCC---ACCC-ACCCACATTT-CTGAT-AC-AT 172
F0FQDYC02HPK3P 208+ AGTAATTTCTCATC-ATCCACCCCC-TCC---ACCC-ACC-ACATTTTCTGATTACCAT 259
F0FQDYC01D86AX 197+ AGTAATTTCTCATC-ATCCACCCCC-TCC---ACCC-ACC-ACATTT-CTGATTAC-AT 246
F0FQDYC01DIP65 (2) 165+ AGTAATTTCTCATC-ATCCACCCCC-TCC---ACCC-A 196
F0FQDYC01A4J86 242- AGTAATTTCTCATC-ATC-ACCCCC-TCC---ACCC-ACCCACATTT-CTGAT-AC-AT 194
***
Appendix F
Mendelian errors
Table F.1: Mendelian errors with dierent cut-o valuesa
05-981 05-982 05-985 05-987
Pos. G. D. F. G. D. F. G. D. F. G. D. F.
83,173 2 57 100 2 41 100 2 51 100 1 48 52
122,807 2 29 72 2 37 81 1 19 63 1 32 69
122,813 2 29 72 2 36 83 1 19 63 2 32 72
123,233 2 4 75 2 5 80 1 6 50 2 14 71
123,234 2 6 83 2 5 80 1 6 50 2 15 73
134,431 2 35 89 2 19 89 2 33 79 2 37 95
157,037 2 15 87 2 8 100 2 11 82 1 13 69
164,514 1 30 67 1 29 69 1 20 65 1 23 57
165,403 1 29 69 2 18 78 1 21 52 1 33 52
166,814 2 10 90 2 6 100 2 5 80 2 10 90
182,990 2 36 83 2 39 82 2 31 71
203,333 1 40 67 2 30 73 1 35 49 1 30 63
237,217 2 12 92 2 18 83 2 10 80 2 16 81
251,752 1 47 66 2 40 72 1 41 59 1 56 48
566,592 2 41 85 2 33 82 1 49 69 2 46 78
678,908 2 42 100 2 42 100 1 38 66 2 47 100
691,574 2 23 96 2 18 83 2 7 100 2 25 76
691,576 1 22 68 2 18 72 2 7 86 1 26 54
1,023,057 2 11 91 1 10 70 1 17 59 2 7 86
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1,132,247 2 6 100 2 7 86 2 9 78 2 10 90
1,324,628 2 42 88 2 33 97 2 44 80 2 35 86
1,705,407 1 33 70 1 29 69 2 25 76 1 29 62
1,849,505 1 41 66 2 37 76 1 36 61 2 47 77
1,885,471 1 21 67 2 12 83 1 14 57 1 17 53
2,154,360 2 12 92 2 20 90 1 20 70 1 22 64
2,154,377 2 10 90 2 19 89 1 20 65 1 23 57
2,154,381 2 10 90 2 19 84 1 19 58 1 24 54
2,154,388 2 11 73 2 18 83 1 19 53 1 24 50
2,154,391 2 11 82 2 18 83 1 19 63 1 24 50
2,154,419 2 7 71 2 14 79 1 21 48 1 24 46
2,502,102 2 38 100 2 26 92 1 31 68 2 39 92
2,523,841 2 46 83 2 41 83 2 46 78 1 39 69
2,801,993 2 17 94 2 19 89 2 12 75 2 17 100
2,869,983 2 42 71 2 24 71 1 35 63 2 42 81
3,138,363 2 22 82 2 28 82 1 21 67 2 20 95
3,150,616 2 13 85 2 8 100 2 11 91 2 8 75
3,154,197 2 30 87 2 20 95 2 22 100 2 27 74
3,204,089 2 12 83 2 14 93 2 15 100 2 9 78
3,407,986 2 42 83 2 31 97 2 44 75 2 35 77
3,422,735 2 22 82 2 20 95 2 25 76 1 22 68
3,745,996 2 15 80 2 13 85 1 16 56
3,992,558 2 29 72 2 21 90 2 38 71 1 39 69
3,995,787 1 52 67 1 47 70 1 45 62 2 48 71
4,445,431 2 55 82 2 22 86 2 36 83 2 35 80
4,522,032 2 29 86 2 11 91 1 23 70 2 31 94
4,533,315 2 14 86 2 9 100 2 12 92 2 13 77
4,565,544 2 20 85 2 20 80 2 24 83 1 18 56
4,677,997 2 21 81 2 18 72 1 22 68 1 22 59
5,016,562 2 10 100 2 10 90 2 10 80 2 16 94
5,085,205 2 16 94 2 14 79 1 20 60 2 30 83
5,102,912 2 45 91 2 42 90 2 35 80 2 37 92
5,508,616 2 17 71 2 14 93 2 16 100 1 22 68
5,631,114 2 53 91 2 41 88 2 50 88 1 50 70
5,686,057 2 4 75 2 4 100 2 7 71 1 8 62
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5,690,146 2 19 95 2 17 100 2 16 100 1 19 68
5,690,164 2 20 90 2 21 86 2 16 100 1 20 70
5,690,173 1 16 69 1 18 67 1 16 56 1 15 53
5,713,997 2 40 92 2 31 84 1 38 66 1 42 69
5,752,670 2 17 94 2 7 100 2 6 100 2 9 78
5,756,144 1 16 69 1 27 67 1 17 53 1 26 69
5,982,779 2 39 79 2 25 80 1 52 65 2 48 77
6,297,160 2 17 88 2 12 92 1 25 68 2 20 80
6,581,945 2 17 100 2 13 92 1 13 62 2 17 100
6,629,270 2 14 79 2 9 89 1 13 69 2 11 100
6,915,766 2 20 95 2 19 100 2 35 97 2 19 100
a: Genotypes: 0, AA; 1, AB; 2, BB. G. Abbreviations: D., Depth; F., Freq
Appendix G
Functional annotation clusters
Table G.1: Top seven functional annotation clusters
Cluster 1 E. Score: 10.09 Count P Benjamini
GOTERM_BP_FAT axonogenesis 29 6.3E-13 1.3E-9
GOTERM_BP_FAT cell morphogenesis in-
volved in neuron di.
30 1.7E-12 1.8E-9
GOTERM_BP_FAT cell morphogenesis in-
volved in di.
32 3.0E-12 2.1E-9
GOTERM_BP_FAT neuron projection mor-
phogenesis
29 4.4E-12 2.3E-9
GOTERM_BP_FAT cell projection morpho-
genesis
31 4.5E-12 1.9E-9
GOTERM_BP_FAT neuron projection devel-
opment
32 6.4E-12 2.2E-9
GOTERM_BP_FAT cell part morphogenesis 31 1.6E-11 4.8E-9
GOTERM_BP_FAT cell morphogenesis 37 4.6E-11 1.2E-8
GOTERM_BP_FAT cell projection organiza-
tion
37 1.2E-10 2.7E-8
GOTERM_BP_FAT neuron development 35 1.7E-10 3.5E-8
GOTERM_BP_FAT neuron dierentiation 41 3.8E-10 7.4E-8
GOTERM_BP_FAT cellular component mor-
phogenesis
38 4.4E-10 7.8E-8
GOTERM_BP_FAT axon guidance 17 1.3E-7 1.4E-5
GOTERM_BP_FAT cell motion 31 4.9E-6 4.5E-4
Cluster 2 E. Score: 9.76 Count P Benjamini
150
APPENDIX G. FUNCTIONAL ANNOTATION CLUSTERS 151
GOTERM_CC_FAT neuron projection 38 7.2E-14 2.3E-11
GOTERM_CC_FAT axon 20 6.4E-9 2.9E-7
GOTERM_CC_FAT cell projection 50 1.2E-8 4.0E-7
Cluster 3 E. Score: 7.64 Count P Benjamini
GOTERM_BP_FAT cell adhesion 50 4.7E-10 7.7E-8
GOTERM_BP_FAT biological adhesion 50 4.9E-10 7.5E-8
SP_PIR_KEYWO. cell adhesion 38 1.1E-8 1.4E-6
GOTERM_BP_FAT cell-cell adhesion 21 1.2E-4 8.7E-3
Cluster 4 E. Score: 5.76 Count P Benjamini
SP_PIR_KEYWO. signal 160 1.2E-9 2.3E-7
SP_PIR_KEYWO. glycoprotein 178 6.2E-8 4.9E-6
UP_SEQ_FEATURE signal peptide 160 6.1E-7 6.6E-4
SP_PIR_KEYWO. disulde bond 126 2.5E-6 1.1E-4
UP_SEQ_FEATURE glycosylation site:N-linked
(GlcNAc...)
167 1.7E-4 3.1E-2
UP_SEQ_FEATURE disulde bond 117 1.5E-3 1.6E-1
Cluster 5 E. Score: 5.57 Count P Benjamini
GOTERM_CC_FAT synapse 41 3.3E-12 5.3E-10
GOTERM_CC_FAT synapse part 32 1.9E-11 1.2E-9
SP_PIR_KEYWO. synapse 27 1.9E-8 1.9E-6
GOTERM_CC_FAT synaptic vesicle 15 9.3E-8 2.9E-6
SP_PIR_KEYWO. cell junction 36 2.2E-7 1.3E-5
GOTERM_CC_FAT cell junction 41 2.9E-7 8.4E-6
GOTERM_CC_FAT clathrin-coated vesicle 16 3.9E-6 1.0E-4
GOTERM_CC_FAT coated vesicle 16 3.4E-5 8.3E-4
GOTERM_CC_FAT cytoplasmic vesicle 33 1.3E-3 1.8E-2
GOTERM_CC_FAT vesicle 33 1.8E-3 2.1E-2
SP_PIR_KEYWO. cytoplasmic vesicle 18 2.6E-3 4.3E-2
GOTERM_CC_FAT cytoplasmic membrane-
bounded vesicle
26 7.2E-3 6.2E-2
GOTERM_CC_FAT membrane-bounded vesi-
cle
26 8.6E-3 7.1E-2
Cluster 6 E. Score: 5.05 Count P Benjamini
GOTERM_CC_FAT extracellular matrix 35 4.9E-9 2.6E-7
GOTERM_CC_FAT proteinaceous extracellu-
lar matrix
34 6.5E-9 2.5E-7
SP_PIR_KEYWO. extracellular matrix 26 7.7E-8 5.1E-6
GOTERM_CC_FAT extracellular region part 49 1.2E-4 2.1E-3
SP_PIR_KEYWO. Secreted 75 1.6E-4 3.8E-3
GOTERM_CC_FAT extracellular matrix part 12 4.2E-4 6.6E-3
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SP_PIR_KEYWO. collagen 11 5.6E-4 1.1E-2
GOTERM_CC_FAT extracellular region 81 3.7E-3 3.6E-2
Cluster 7 E. Score: 4.22 Count P Benjamini
GOTERM_BP_FAT vesicle-mediated trans-
port
37 2.1E-6 2.0E-4
GOTERM_BP_FAT endocytosis 20 1.5E-5 1.3E-3
GOTERM_BP_FAT membrane invagination 20 1.5E-5 1.3E-3
GOTERM_BP_FAT membrane organization 23 1.1E-4 8.3E-3
SP_PIR_KEYWO. Endocytosis 9 1.4E-2 1.4E-1
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Quadrupedal gait in humans, also known as Unertan syndrome, is
a rare phenotype associated with dysarthric speech, mental retar-
dation, and varying degrees of cerebrocerebellar hypoplasia. Four
large consanguineous kindreds from Turkey manifest this pheno-
type. In two families (A and D), shared homozygosity among
affected relatives mapped the trait to a 1.3-Mb region of chromo-
some 9p24. This genomic region includes the VLDLR gene, which
encodes the very low-density lipoprotein receptor, a component of
the reelin signaling pathway involved in neuroblast migration in
the cerebral cortex and cerebellum. Sequence analysis of VLDLR
revealed nonsense mutation R257X in family A and single-
nucleotide deletion c2339delT in family D. Both these mutations
are predicted to lead to truncated proteins lacking transmembrane
and signaling domains. In two other families (B and C), the
phenotype is not linked to chromosome 9p. Our data indicate that
mutations in VLDLR impair cerebrocerebellar function, conferring
in these families a dramatic influence on gait, and that hereditary
disorders associated with quadrupedal gait in humans are genet-
ically heterogeneous.
genetics  Unertan syndrome
Obligatory bipedal locomotion and upright posture of mod-ern humans are unique among living primates. Studies of
fossil hominids have contributed significantly to modern under-
standing of the evolution of posture and locomotion (1–5), but
little is known about the underlying molecular pathways for
development of these traits. Evaluation of changes in brain
activity during voluntary walking in normal subjects suggests that
the cerebral cortices controlling motor functions, visual cortex,
basal ganglia, and the cerebellum might be involved in bipedal
locomotor activities (6). The cerebellum is particularly impor-
tant for movement control and plays a critical role in balance and
locomotion (7).
Neurodevelopmental disorders associated with cerebellar hy-
poplasias are rare and often accompanied by additional neuro-
pathology. These clinical phenotypes vary from predominantly
cerebellar syndromes to sensorimotor neuropathology, ophthal-
mological disturbances, involuntary movements, seizures, cog-
nitive dysfunction, skeletal abnormalities, and cutaneous disor-
ders, among others (8). Quadrupedal locomotion was first
reported when Tan (9, 10) described a large consanguineous
family exhibiting Unertan syndrome, an autosomal recessive
neurodevelopmental condition with cerebellar and cortical hy-
poplasia accompanied by mental retardation, primitive and
dysarthric speech, and, most notably, quadrupedal locomotion.
Subsequent homozygosity mapping indicated that the phenotype
of this family was linked to chromosome 17p (11). Thereafter,
three additional families from Turkey (12–14) and another from
Brazil (15) with similar phenotypes have been described, and
video recordings illustrating the quadrupedal gait have been
made (10–12). Here, we report that VLDLR is the gene respon-
sible for the syndrome in two of these four Turkish families and
report additional genemapping studies that indicate the disorder
to be highly genetically heterogeneous.
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Fig. 1. Phenotypic (A) and cranial radiologic (B) presentation of quadrupe-
dal gait in families A and D. (A) Affected brothers VI:20 and VI:18 and cousin
VI:25 in family A (Upper) and the proband II:2 in family D (Lower) display
palmigrate walking. This is different from quadrupedal knuckle-walking of
the great apes (2). The hands make contact with the ground at the ulnar palm,
and consequently this area is heavily callused as exemplified by VI:20. Stra-
bismus was observed in all affected individuals. (B) Coronal and midsagittal
MRI sections of VI:20, demonstrating vermial hypoplasia, with the inferior
vermial portion being completely absent. Inferior cerebellar hypoplasia and a
moderate simplification of the cerebral cortical gyri are noted. The brainstem
and the pons are particularly small (Left and Center). Similar findings are
observed for II:2 (Right).
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Results
The proband of Family A (12) is a 37-year-old male with habitual
quadrupedal gait (Fig. 1A Upper Left and Fig. 2A, VI:20). He did
not make the transition to bipedality during his childhood
despite the efforts of his healthy parents. He has dysarthric
speech with a limited vocabulary, truncal ataxia, and profound
mental retardation. He was not aware of place or of the year,
month, or day. His MRI brain scan revealed inferior cerebellar
and vermial hypoplasia, with the inferior vermial portion being
completely absent. Whereas corpus callosum appeared normal,
a moderate simplification of the cerebral cortical gyri accom-
panied by a particularly small brainstem and the pons was
observed (Fig. 1 B Left andCenter). Subsequently, we studied the
proband’s affected brother and cousin (Fig. 1AUpper Center and
Fig. 2. Homozygosity mapping of cerebellar hypoplasia and quadrupedal locomotion to chromosome 9p24 (A) and identification of the VLDLR c769C 3 T
mutation in family A (B) and of theVLDLR c2339delT mutation in family D (C). (A) Pedigree of family A; filled symbols represent the affected individuals. Squares
indicate males, and circles indicate females. Black bars represent the haplotype coinherited with the quadrupedal phenotype in the family. Recombination events
in individuals VI:16 (obligate carrier) and VII:4 (normal sibling) positioned the disease gene between markers rs7847373 and rs10968723. Physical positions and
pairwise lod scores for each marker are shown on the upper left. Zmax represents the maximum lod score obtained at  0.00 cM. (B and C) Sequences of critical
regions of VLDLR for wild-type and homozygous mutant genotypes.
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Upper Right and Fig. 2A, VI:18 and VI:25) and other branches
of the family living in nearby villages in southeastern Turkey. All
affected individuals were offspring of consanguineous marriages
(Fig. 2A). With the exception of one female (VII:1), who was an
occasional biped with ataxic gait, all affected persons in family
A had quadrupedal locomotion.
The proband of family D (14) is a 38-year-old male (Fig. 1A
Lower Left and Center). Like all other quadrupedal individuals
in these families, he did not make the transition to bipedality
during his early childhood. He is profoundly retarded and
exhibits dysarthric speech along with truncal ataxia. His MRI
brain scan images are consistent with moderate cerebral cortical
simplification and inferior cerebellar and vermial hypoplasia
(Fig. 1BRight). The 65-year-old aunt and 63-year-old uncle of the
proband are both mentally retarded and continue to walk on
their wrists and feet despite their advanced ages. The family is
consanguineous; all relatives were raised in neighboring villages
on the western tip of the Anatolian peninsula.
All patients in these four families had significant developmen-
tal delay noted in infancy (Table 1). They sat unsupported
between 9 and 18months, and began to crawl on hands and knees
or feet. Whereas normal infants make the transition to bipedal
walking in a short period, the affected individuals continued to
move on their palms and feet and never walked upright. All
patients had severe truncal ataxia affecting their walking pat-
terns. They can stand from a sitting position and maintain the
upright position with flexed hips and knees. However, they
virtually never initiate bipedal walking on their own and instead
ambulate efficiently in a quadrupedal fashion. All patients had
hyperactive lower leg and vivid upper extremity reflexes. Normal
tone and power were observed in motor examination. All
affected persons were mentally retarded to the degree that
consciousness of place, time, or other experience appeared to be
absent. However, no autistic features were expressed. The
affected individuals all had good interpersonal skills, were
friendly and curious to visitors, and followed very simple ques-
tions and commands. Additional clinical information on families
A and D is provided in supporting information (SI) Table 2.
To identify the chromosomal locale of the gene or genes
responsible for this phenotype, we carried out genome-wide
linkage analysis and homozygosity mapping in families A–C (see
Materials and Methods below). Although the families lived in
isolated villages 200–300 km apart and reported no ancestral
relationship, the rarity of the quadrupedal gait in humans led us
to expect a single locus shared by affected individuals in all
families. Instead, the trait mapped to three different chromo-
somal locales. In family A, linkage analysis and homozygosity
mapping positioned the critical gene on chromosome 9p24
between rs7847373 and rs10968723 in a 1.032-Mb region (Fig.
2A and SI Fig. 4). In family B, the trait mapped to chromosome
17p13, confirming a previous study (11). In family C, highly
negative logarithm of odds (lod) scores were obtained for both
chromosomes 9p24 and 17p13 (SI Figs. 5 and 6); gene mapping
in this family is ongoing. In family D, polymorphic markers from
the critical intervals of chromosomes 9p24 and 17p13 were
genotyped, and homozygosity was detected with markers on
9p24. Together, these results indicate that the syndrome includ-
ing quadrupedal gait, dysarthric speech, mental retardation, and
cerebrocerebellar hypoplasia is genetically heterogeneous.
The chromosome 9p24 region linked to the trait in families A
and D includes VLDLR, the very low-density lipoprotein recep-
tor. We hypothesized that a gene involved in neural develop-
ment, cell positioning in brain, and cerebellar maturation could
be involved in the pathogenesis of quadrupedal gait. In addition,
cerebellar hypoplasia with cerebral gyral simplification was
shown to be associated with a genomic deletion that includes
VLDLR (16). We therefore considered VLDLR (17) to be a
prime positional candidate for our phenotype and sequenced the
gene in genomic DNA from probands of the four families (SI
Table 3). The VLDLR sequence of affected members of family
A was homozygous for a nonsense mutation in exon 5 (c769C3
T; R257X) (Fig. 2B). The VLDLR sequence of the proband of
family D was homozygous for a single-nucleotide deletion in
exon 17 resulting in a stop codon (c2339delT; I780TfsX3) (Fig.
2C). VLDLR sequences excluded the possibility of compound
heterozygosity in families B and C (SI Fig. 7). In families A and
D, homozygosity for the VLDLR mutations was perfectly coin-
herited with quadrupedal gait (SI Figs. 8 and 9). Both mutations
were absent from 100 unaffected individuals who live in the same
local areas of southeastern and western Turkey as families A and
D (SI Fig. 10).
Table 1. Physical, radiological, and genetic characteristics of the Turkish families in this study and of Hutterite family DES-H (27)
Characteristic Family A Family B Family C Family D DES-H
Chromosomal location 9p24 17p Not 9p or 17p 9p24 9p24
Gene and mutation VLDLR
(c769C3 T)
Unknown Unknown VLDLR
(c2339delT)
Deletion including VLDLR
and LOC401491
Gait Quadrupedal Quadrupedal Quadrupedal Quadrupedal Bipedal
Speech Dysarthric Dysarthric Dysarthric Dysarthric Dysarthric
Hypotonia Absent Absent Absent Absent Present
Barany caloric nystagmus Normal Cvs defect Pvs defect Not done Not done
Mental retardation Profound Severe to profound Profound Profound Moderate to profound
Ambulation Delayed Delayed Delayed Delayed Delayed
Truncal ataxia Severe Severe Severe Severe Severe
Lower leg reflexes Hyperactive Hyperactive Hyperactive Hyperactive Hyperactive
Upper extremity reflexes Vivid Vivid Vivid Vivid Vivid
Tremor Very rare Mild Present Absent Present
Pes-planus Present Present Present Present Present
Seizures Very rare Rare Rare Absent Observed in 40% of cases
Strabismus Present Present Present Present Present
Inferior cerebellum Hypoplasia Hypoplasia Mild hypoplasia Hypoplasia Hypoplasia
Inferior vermis Absent Absent Normal Absent Absent
Cortical gyri Mild simplification Mild simplification Mild simplification Mild simplification Mild simplification
Corpus callosum Normal Reduced Normal Normal Normal
Cvs, central vestibular system; Pvs, peripheral vestibular system.
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VLDLRR257X is in the ligand-binding domain, and
VLDLRI780TfsX3 is in the O-linked sugar domain of the
VLDLR protein (Fig. 3 A and B). Mutant VLDLR transcripts
were expressed in endothelial cells from blood of affected
individuals (Fig. 3C), and in these cells, levels of mutant and
wild-type transcript expression appeared approximately equal
(Fig. 3D; please also see SI Text). Because the stop codons of
both mutations are located in the extracellular domain of
VLDLR (Fig. 3B), the encoded mutant proteins could not be
inserted into the membrane and could not function as receptors
for reelin.
We propose VLDLR-associated Quadrupedal Locomotion
(VLDLR-QL) or Unertan Syndrome Type 1 to describe the
phenotype of families A and D.
Discussion
The identification of these VLDLR mutations provides molec-
ular insight into the pathogenesis of neurodevelopmental move-
ment disorders and expands the scope of diseases caused by
mutations in components of the reelin pathway (18). Reelin is a
secreted glycoprotein that regulates neuronal positioning in
cortical brain structures and the migration of neurons along the
radial glial fiber network by binding to lipoprotein receptors
VLDLR and APOER2 and the adapter protein DAB1 (19). In
the cerebellum, reelin regulates Purkinje cell alignment (20),
which is necessary for the formation of a well defined cortical
plate through which postmitotic granual cells migrate to form the
internal granular layer (21). Homozygous mutations in the reelin
gene (RELN) cause the Norman–Roberts type lissencephaly
syndrome, associated with severe abnormalities of the cerebel-
lum, hippocampus, and brainstem (OMIM 257320) (22). Muta-
tion of Reln in the mouse results in the reeler phenotype and
disrupts neuronal migration in several brain regions and gives
rise to functional deficits such as ataxic gait and trembling (23).
In contrast, mice deficient forVldlr appear neurologically normal
(24), but the cerebellae of these mice are small, with reduced
foliation and heterotopic Purkinje cells (17).
In humans, homozygosity for either of two VLDLR truncating
mutations leads to cerebrocerebellar hypoplasia, specifically
vermial hypoplasia, accompanied by mental retardation, dysar-
thric speech, and quadrupedal gait. In the Hutterite population
of North America, homozygosity for a 199-kb deletion encom-
passing the VLDLR gene leads to a form of Disequilibrium
Syndrome (DES-H, OMIM 224050), characterized by nonpro-
gressive cerebellar hypoplasia with moderate-to-profound men-
tal retardation, cerebral gyral simplification, truncal ataxia, and
delayed ambulation (16). The designation Disequilibrium Syn-
drome was originally given to cerebral palsy characterized by a
variety of congenital abnormalities, including mental retarda-
tion, disturbed equilibrium, severely retarded motor develop-
ment, muscular hypotonia, and perceptual abnormalities (25,
26). Neither DES-H nor other disequilibrium syndromes have
been reported to include quadrupedal gait. The movement of
most DES-H patients was so severely affected that independent
walking was not possible. Those who could walk had a wide-
based, nontandem gait (27).
The neurological phenotypes in the Turkish families and in the
Hutterite families appear similar, with the most striking differ-
ence being the consistent adoption of efficient quadrupedal
locomotion by the affected Turkish individuals (Table 1). In our
view, the movement disorder described for the Hutterite patients
may be a more profound deficit, with the patients perhaps
lacking the motor skills for quadrupedal locomotion. The 199-kb
deletion in DES-H encompasses the entire VLDLR gene and
part of a hypothetical gene. LOC401491, the hypothetical gene,
is an apparently noncoding RNA that shares a CpG island and
likely promoter with VLDLR, and is represented by multiple
alternative transcripts expressed in brain. It has been suggested
that the DES-H phenotype could be the result of deletion of
VLDLR or both VLDLR and the neighboring gene (16).
Fig. 3. Functional domains of VLDLR with positions of the mutations relative to the exons (A), domains (B), and the analysis of VLDLR transcript (C and D).
(A) The gene consists of 19 exons. Arrows indicate the locations of the mutations. (B) VLDLR consists of ligand-binding type repeat (LBTR), epidermal growth
factor repeat (EGFR) I–III, YWTD -propeller (YWTD), O-linked sugar domain (OLSD), transmembrane domain (TD), and cytoplasmic domain (CD) (34)
(www.expasy.org/uniprot/P98155). (C) Restriction-based analysis with HphI revealed the presence of only the mutant (347 bp) and both the mutant and wild type
(396 and 347 bp; please note that the 49-bp fragment is not visible) VLDLR transcripts in patient VI:20 and carrier V:18 (both from family A), respectively. M is
a DNA size marker. (D) Quantitative RT-PCR analysis of VLDLR transcript from peripheral blood samples of all probands in families A and D and controls was
performed. Relative expression ratios were normalized according to the housekeeping gene GAPDH (glyceraldehyde-3-phosphate dehydrogenase) and the
endothelial marker KDR (kinase insert domain receptor). Ct values were calculated from duplicate samples and were converted to linear scale (35). Control
denotes ‘‘VLDLR expression in controls,’’ VLDLR-GAPDH denotes ‘‘VLDLR expression in patients normalized to GAPDH,’’ and finally VLDLR-KDR denotes ‘‘VLDLR
expression in patients normalized to KDR.’’
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It has been suggested that in the Turkish families, lack of
access to proper medical care exacerbated the effects of cere-
bellar hypoplasia, leading to quadrupedality. Although it may be
true that family B lacked proper medical care, families A and D
had consistent access to medical attention, and both families
actively sought a correction of quadrupedal locomotion in their
affected children. An unaffected individual in family A is a
physician who was actively involved in the medical interventions.
In family D, the proband’s mother sought a definitive diagnosis
and correction of the proband’s quadrupedal locomotion from
private medical practices and from two major academic medical
centers. The parents in family A discouraged quadrupedal
walking of their affected children, but without success. We
conclude that social factors were highly unlikely to contribute to
the quadrupedal locomotion of the affected individuals.
In conclusion, we suggest that VLDLR-deficiency in the brain
at a key stage of development leads to abnormal formation of the
neural structures that are critical for gait. Given the heteroge-
neity of causes of quadrupedal gait, identification of the genes in
families B and C promises to offer insights into neurodevelop-
mental mechanisms mediating gait in humans.
Materials and Methods
Study Subjects. Parents of patients and other unaffected individuals gave
consent to the study by signing the informed consent forms prepared accord-
ing to the guidelines of the Ministry of Health in Turkey. The Ethics Commit-
tees of Baskent and Cukurova Universities approved the study (decision
KA07/47, 02.04.2007 and 21/3, 08.11.2005, respectively).
Genome-Wide Linkage Analysis. Linkage analysis was performed by SNP geno-
typing with the commercial release of the GeneChip 250K (NspI digest) or 10K
Affymetrix arrays as described (28). In addition, genotype data were analyzed
by hand to identify regions of homozygosity. The parametric component of
the Merlin package v1.01 was used for the multipoint linkage analysis assum-
ing autosomal recessive mode of inheritance with full penetrance (29, 30). The
analysis was carried out along a grid of locations equally spaced at 1 cM.
Haplotype analysis was performed on chromosomal regions with positive lod
scores (Fig. 2A and SI Figs. 4–6). Pairwise linkage was analyzed by using the
MLINK component of the LINKAGE program (FASTLINK, version 3) (31–33).
Markers D17S1298 (3.51 Mb) and D9S1779 (0.4 Mb), D9S1871 (3.7 Mb) were
used to test for homozygosity to chromosomes 17p13 and 9p24, respectively.
Mutation Search. Sequencing primers were designed for each VLDLR exon by
using Primer3, BLAST, and the sequence of NC000009. DNA from all of the
probands was sequenced in both directions by using standard methods. The
mutations in exons 5 (c769C 3 T) and 17 (c2339delT) were detected in all
affected (homozygous) and carrier (heterozygous) individuals of families A
and D, respectively. The c769C3 T mutation creates a restriction site for the
enzyme HphI (5-GGTGA(N)82 3), and the c2339delT mutation abolishes a
restriction site for the enzyme MboI (5-G2 ATC-3). Assays using these
restriction enzymes were developed to test for the mutations in all four
families and in 200 healthy controls from the Turkish population. Restriction
based mutation and quantitative RT-PCR analyses of VLDLR transcript in
patients and controls was also performed (please see SI Text relating to Fig. 3
C and D).
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LETTER
Reply to Herz et al. and Humphrey
et al.: Genetic heterogeneity of
cerebellar hypoplasia with
quadrupedal locomotion
Mutations in the very low-density lipoprotein receptor
VLDLR are responsible for cerebellar hypoplasia with qua-
drupedal gait (1). The most likely mechanism leading to this
phenotype is that VLDLR deficiency in the brain at a key
stage of development precludes the normal formation of neu-
ral structures critical for gait. Quadrupedal gait is an integral
part of VLDLR-associated cerebellar hypoplasia syndrome in
these families (1, 2). It is not necessary to invoke an ‘‘epiphe-
nomenon’’ or ‘‘unfavorable environmental conditions’’ to ex-
plain the phenotype (3), but rather simply considering clinical
heterogeneity in the context of genomic understanding of
complex traits is sufficient.
Disequilibrium syndrome was first described by the Swedish
neuropediatrician Bengt Hagberg and colleagues (4) as a
form of cerebral palsy characterized by a variety of congenital
abnormalities. Subsequently, Schurig et al. (5) described, in
the North American Hutterite population, inherited cerebellar
disorder with mental retardation, the genetic basis of which
proved to be homozygous deletion of the VLDLR gene and
the adjacent noncoding LOC401491 sequence (6). Based on
the phenotypic similarities of the Swedish and Hutterite pa-
tients, the acronym DES-H [disequilibrium syndrome-
Hutterites, Online Mendelian Inheritance in Man (OMIM)
accession no. 224050] was adopted for this syndrome (6).
Our results (1) and those of others (7) extend these find-
ings to different VLDLR mutations leading to cerebellar hyp-
oplasia and related disequilibrium features, including in some
families bipedal gait (5, 6), in other families quadrupedal gait
(1, 8), and in another family ‘‘gait ataxia’’ (7). Additional kin-
dreds with disequilibrium syndrome and quadrupedal gait
have been described in Brazil (9) and Iraq (10). It will be in-
teresting to know whether mutations responsible for the phe-
notype in these families lie in the VLDLR gene or in one
of the other loci linked to this genetically heterogeneous
phenotype (1).
The comments of Humphrey et al. (11) address three fun-
damental features of genomic analysis of human traits: allelic
heterogeneity, genotype–phenotype correlations, and variable
expression.
Allelic heterogeneity—the expression of the same pheno-
type due to different mutations in a gene—is characteristic of
virtually all human genetic disease. For example, homozygos-
ity for any of 300 different mutations in the LDL receptor
leads to hypercholesterolemia. It was to be expected, there-
fore, that in different families different mutations in VLDLR
would lead to a phenotype comprising cerebellar hypoplasia
with quadrupedal gait. It would not be expected that quadru-
pedalism would be present only in the presence of one ‘‘spe-
cific mutation.’’
The converse observation, of a correlation between geno-
type and phenotype, is also characteristic of inherited human
disease. Different mutations in the same gene frequently lead
to different clinical phenotypes. Contrary to the statement of
Humphrey et al. (11), the Hutterite families in North America
and families A and D in Turkey do not carry ‘‘the same ho-
mozygous mutation.’’ The Hutterite mutation is a complete
genomic deletion of VLDLR; the mutations in Turkish fami-
lies A and D are, respectively, a nonsense mutation and a
single-base-pair deletion leading to a frame shift in VLDLR.
It is not surprising, therefore, that features of the cerebellar
hypoplasia syndrome, including presence or absence of qua-
drupedal walking, differ among families with different muta-
tions in the gene.
Third, variable expression of a phenotype is frequently ob-
served even among persons with the same mutation in a criti-
cal gene. Variable expression may be due to differences in
genetic background of the individual, to differences in envi-
ronmental exposures, or to chance. Among affected individu-
als in families A and D, none displays exclusively bipedal
locomotion; two affected individuals can walk bipedally for
short distances but prefer quadrupedal locomotion (1, 8).
Finally, the use of a walking frame to assist bipedalism in
affected individuals (12) does not demonstrate that the cause
of quadrupedalism was ‘‘local cultural environment.’’ Wear-
ing eyeglasses assists persons with myopia. Should we then
conclude that near-sightedness is caused by ‘‘local cultural
environment’’?
Some descriptions by the press of Turkish families with cer-
ebellar hypoplasia and quadrupedal gait have portrayed the
affected individuals as doomed to quadrupedal gait by the
religious beliefs of their parents (13). We hope that future
descriptions of these families will conform to standards re-
f lected in recent genomic analyses of their disorder.
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Research
Homozygosity mapping and targeted genomic
sequencing reveal the gene responsible for cerebellar
hypoplasia and quadrupedal locomotion
in a consanguineous kindred
Suleyman Gulsuner,1 Ayse Begum Tekinay,2 Katja Doerschner,3,4 Huseyin Boyaci,3,4
Kaya Bilguvar,5,6,7 Hilal Unal,2 Aslihan Ors,4 O. Emre Onat,1 Ergin Atalar,4,8
A. Nazli Basak,9 Haluk Topaloglu,10 Tulay Kansu,11 Meliha Tan,12 Uner Tan,13
Murat Gunel,5,6,7 and Tayfun Ozcelik1,2,14
1Department of Molecular Biology and Genetics, Faculty of Science, Bilkent University, Ankara 06800, Turkey; 2Institute of Materials
Science and Nanotechnology, Bilkent University, Ankara 06800, Turkey; 3Department of Psychology, Faculty of Economics,
Administrative and Social Sciences, Bilkent University, Ankara 06800, Turkey; 4National Research Center for Magnetic Resonance,
Bilkent University, Ankara 06800 Turkey; 5Department of Neurosurgery, Yale University School of Medicine, New Haven, Connecticut
06510, USA; 6Department of Neurobiology, Yale University School of Medicine, New Haven, Connecticut 06510, USA; 7Department of
Genetics, Center for Human Genetics and Genomics and Program on Neurogenetics, Yale University School of Medicine, New Haven,
Connecticut 06510, USA; 8Department of Electrical and Electronics Engineering, Faculty of Engineering, Bilkent University, Ankara
06800, Turkey; 9NDAL Laboratory, School of Arts and Sciences, Bogazici University, Istanbul 34342, Turkey; 10Department of Pediatric
Neurology, Ihsan Dogramaci Children’s Hospital, Ankara 06100, Turkey; 11Department of Neurology, Hacettepe University Faculty of
Medicine, Ankara 06100, Turkey; 12Department of Neurology, Baskent University Faculty of Medicine, Ankara 06490, Turkey;
13Department of Physiology, Cukurova University Faculty of Medicine, Adana 01330, Turkey
The biological basis for the development of the cerebro-cerebellar structures required for posture and gait in humans is
poorly understood. We investigated a large consanguineous family from Turkey exhibiting an extremely rare phenotype
associated with quadrupedal locomotion, mental retardation, and cerebro-cerebellar hypoplasia, linked to a 7.1-Mb region
of homozygosity on chromosome 17p13.1–13.3. Diffusion weighted imaging and fiber tractography of the patients’ brains
revealed morphological abnormalities in the cerebellum and corpus callosum, in particular atrophy of superior, middle,
and inferior peduncles of the cerebellum. Structural magnetic resonance imaging showed additional morphometric ab-
normalities in several cortical areas, including the corpus callosum, precentral gyrus, and Brodmann areas BA6, BA44,
and BA45. Targeted sequencing of the entire homozygous region in three affected individuals and two obligate carriers
uncovered a private missense mutation, WDR81 p.P856L, which cosegregated with the condition in the extended family.
The mutation lies in a highly conserved region of WDR81, flanked by an N-terminal BEACH domain and C-terminal
WD40 beta-propeller domains. WDR81 is predicted to be a transmembrane protein. It is highly expressed in the cere-
bellum and corpus callosum, in particular in the Purkinje cell layer of the cerebellum. WDR81 represents the third gene,
after VLDLR and CA8, implicated in quadrupedal locomotion in humans.
[Supplemental material is available for this article.]
Developmental abnormalities of the cerebellum are a rare and ge-
netically heterogeneous group of disorders characterized by loss of
balance and coordination. Identification of the genes responsible
for these disorders providesmechanistic insights into the regulation
of neuronal development, differentiation, morphogenesis, migra-
tion, and organization (Fogel and Perlman 2007). These genes can
be identified by exploiting targeted genomic sequencing in com-
bination with linkage analysis and homozygosity mapping (Ropers
2007; Bilguvar et al. 2010).We applied this approach to the analysis
of cerebellar hypoplasia and quadrupedal locomotion in an ex-
tended consanguineous family from southern Turkey.
Multiple families have been reported with cerebellar ataxia,
mental retardation, and disequilibrium syndrome (CAMRQ) (Tan
2006; Turkmen et al. 2006, 2009; Moheb et al. 2008; Ozcelik et al.
2008; Kolb et al. 2010). All the reported CAMRQ families are con-
sanguineous with recessive inheritance of their condition. Clinical
characteristics vary slightly among the families. In four families
from Turkey and Iran, the condition is due to homozygosity for
mutations in the VLDLR gene encoding the very low density lipo-
protein receptor (CAMRQ1 [MIM 224050]). Each of these four
families harbors a different VLDLRmutation. In a fifth family, from
Iraq, the condition is due to homozygosity for a missense mutation
in theCA8 gene encoding carbonic anhydrase VIII (CAMRQ3 [MIM
613227]). In Family B, the first family described in the literature
14Corresponding author.
E-mail tozcelik@bilkent.edu.tr.
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and also referred to as Uner Tan syndrome (Tan 2006), homozy-
gosity mapping revealed a 7.1-Mb interval on chromosome 17p13,
containing 192 genes and at least 20 pseudogenes, that segre-
gates with the disease (CAMRQ2 [MIM 610185]) (Turkmen et al.
2006; Ozcelik et al. 2008). In order to identify the mutation re-
sponsible for CAMRQ2 in Family B, we targeted and fully se-
quenced the 7.1-Mb genomic interval and evaluated all variation
in the region.
Results
Description of the affected family
Family B came to medical attention because of the unusual form of
locomotion in five of the 19 siblings. A detailed clinical description,
including video recordings and genetic mapping, was published
elsewhere (Tan 2006; Turkmen et al. 2006; Ozcelik et al. 2008).
Pedigree analysis suggested autosomal recessive inheritance. Link-
age analysis and homozygosity mapping revealed a single locus on
chromosome 17p between D17S1866 and D17S960. Illumina 300
Duo v2 BeadChip SNP genotype data of two of the affected in-
dividuals (05-984 and 05-987) revealed a single 6.8-Mb homozy-
gous stretch between markers rs4617924–rs7338 (chr17: 114,669–
6,917,703) and confirmed that chromosome 17p is the only region
of interest (Supplemental Fig. 1).
The phenotype was further characterized by magnetic reso-
nance imaging (MRI) and morphometric analyses (Fig. 1). The
most dramatic morphological differences were significant re-
ductions in volume in the cerebellum and corpus callosum of the
patient’s brain (Fig. 1A). Both the cortex and the white matter of
the cerebellum were significantly smaller in the patients. In con-
trast, the volume occupied by the caudate nucleus was signifi-
cantly larger. Significant structural differences were also detected
in the motor areas precentral gyrus and BA6 (increased mean
curvature and gray matter volume) and motor speech areas pars
opercularis and pars triangularis (increased cortical thickness and
mean curvature) (Fig. 1B). A detailed account of themorphometric
analyses is presented in Supplemental Figure 2 and Supplemental
Table 1. Diffusion tensor imaging (DTI) and fiber tractography
revealed moderate to high atrophy in superior, middle, and in-
ferior cerebellar peduncles (Supplemental Fig. 3).
Targeted next-generation sequencing of the critical region
The critical region at chr17: 82,514–7,257,922 (hg19)was captured
by NimbleGen 385K microarrays and sequenced with 454 Life
Sciences (Roche) GS FLX in DNA of two of the affected individuals
(05-985, 05-987) and two of the unaffected obligate carrier parents
(05-981 father, 05-982 mother). An average of ;400 Mb, yielding
46.33 haploid coverage, was sequenced from the captured DNA of
each individual. An average of 79% of all reads from each sample
mapped to the target region, representing 1275-fold to 2247-fold
enrichment (Supplemental Table 2).Onaverage, 99.4%of all targeted
bases were covered by at least four reads (Supplemental Table 3).
In a parallel experiment, the same region from the DNA of
another affected sibling (05-984) was captured with NimbleGen
HD2 2.1M sequence capture microarrays and sequenced on an
Illumina Genome Analyzer IIx. The captured region was enriched
123-fold, with 2.98 billion bases and 40.3 million reads obtained
and 28% of reads mapped to the targeted region; 99.6% of targeted
bases were covered by at least four reads. Combined sequence data
for the three affected siblings yielded at least a fourfold coverage of
99.78% of all coding base pairs, 95.32% of intronic and UTR base
pairs, and 91.36%of intergenic base pairs. The remaining 0.22% of
coding regions with less than fourfold coverage was analyzed by
Sanger sequencing (Supplemental Table 4).
With the 454 GS FLX platform, a total of 18,410 different
variants were detected at high confidence (defined as in Hedges
et al. 2009) in at least one sample (Supplemental Table 2). No ad-
ditional functional variants were detected with the Illumina se-
quencing platform. Comparison of the sequence data from both
platforms with Illumina 300 Duo v2 SNP genotype data indicated
that the alleles were detectedwith sensitivity and specificity >99%.
Heterozygous SNPs detected at the borders of the homozygous
blocks of the affected individuals narrowed the region of homo-
zygosity to 6.74 Mb (Supplemental Table 5). The Mendelian error
rate, an indicator of call errors (Hedges et al. 2009), was calculated
as 0.3%.
Of the 18,410 high-confidence variants, 17,281 were reported
by dbSNP. For each nonsynonymous SNP compatible with the
Mendelian transmission of the disease allele, the frequencies of
homozygotes for each allele were accessed from public databases.
With one exception, homozygosity at both alleles had been reported
in control populations. The one exception, rs55916885, was at a
nonconserved site and was predicted as tolerated by SIFT (Ng and
Henikoff 2001) and Polyphen-2 (Sunyaev et al. 2001). Based on
these observations, all previously reported nonsynonymous vari-
ants were excluded (Supplemental Table 6).
Of the 18,410 high-confidence variants, 1119 variants were
both novel vis-a´-vis dbSNP132 and present in both the affected
siblings and their obligate carrier parents. These 1119 novel shared
variants were classified by genomic context: coding sequence or
flanking splice junctions (n = 20), 59 UTR or 39 UTR (n = 15),
intronic (n = 689), or intergenic (n = 395). The 20 variants in the
Figure 1. MRI-based morphological analysis of brain from affected and
unaffected individuals. (A) Midsagittal MRI scans of a healthy control in-
dividual (left) and affected relative from Family B (right). The highlighted
regions show areas where volumetric differences are readily visible: corpus
callosum (1), third ventricle (2), fourth ventricle (3), and cerebellum (4).
(B) Cortical regions with significant differences in morphometric param-
eters are displayed on a reference cortex, from lateral and medial view:
BA45 (5), BA44 (6), BA6 (7), precentral (8), superior temporal (9), superior
parietal (10), lateral occipital (11), fusiform (12), isthmus cingulated (13),
posterior cingulated (14), frontal pole (15), medial orbitofrontal (16), and
temporal pole (17). Additional details are provided in Supplemental
Figure 2 and Supplemental Table 1.
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coding sequence or flanking splice junctions were genotyped in the
family to evaluate cosegregationwith the phenotype (Supplemental
Table 7). Genotypes of three missense variants were consistent with
the recessive inheritance of the disease allele in Family B: WDR81
p.P856L,MYBBP1A p.R671W, and ZNF594 p.L639F (Table 1). Of the
15 59/39UTR variants, five cosegregatedwith the disease phenotype.
Therefore, they were carried to a more detailed analysis, including
evaluation of the protein interactions. None was found to interact
with previously identified genes with cerebellar phenotypes, in-
cludingCAMRQ-associatedVLDLR andCA8 (Supplemental Table 8).
Identification of disease causing variant
MYBBP1Ap.R671Wcould be excludedas the causalmutation for the
disorder of Family B based on the genotypes of controls (Supple-
mental Table 9). In 214 unrelated healthy controls (428 chromo-
somes), 50 of whomwere sampled from the same region of Turkey as
Family B, 13 individuals were heterozygous for MYBBP1A p.R671W.
This carrier frequency yields an allele frequency of 0.016 and an
expected frequency of homozygotes of about one in 4000, far higher
than the frequency of CAMRQ2, which occurs in only one extended
family. In a second, independent series of 400 individuals of various
European and Middle Eastern ancestries, MYBBP1A was fully se-
quenced in the context of whole-exome sequencing. Of these 400
individuals, two were homozygous for MYBBP1A p.R671W. Neither
of these two homozygotes had any signs consistent with CAMRQ2.
MYBBP1A p.R671Wwas therefore excluded as the allele responsible
for the disorder of Family B.
ZNF594 p.L639F could be excluded as the causal mutation for
the disorder based on conservation considerations. Residue 639 of
ZNF594 is not well conserved: Two of 16 species sequenced have
phenylalanine (F) at the orthologous site, strongly suggesting that
phenylalanine at this site would also not be damaging in humans. A
negative GERP score (0.665) for the mutated nucleotide indicates
that this site is probably evolving neutrally (Davydov et al. 2010).
The variant is predicted as ‘‘benign’’ (PSIC score difference, 0.301) by
PolyPhen (Sunyaev et al. 2001) and ‘‘damaging low confidence’’
(SIFT score, 0.04) by SIFT (Supplemental Table 10; Ng and Henikoff
2001). In addition, the human ZNF594 gene harbors polymorphic
nonsense mutations at sites near the missense at L639F. ZNF594
p.E684X appeared in four of 118 Yoruban controls (rs114754534;
allele frequency, 0.034), and ZNF594 p.Q681X appeared in one of
120 CEU controls (rs116878311; allele frequency, 0.0083) in the
HapMap series.
In contrast, WDR81 p.P856L (Fig. 2A,B; Supplemental Fig. 4) is
both rare and alters a highly conserved site. This missense did not
appear in any of the 549 individuals of the control series. WDR81 is
a highly conserved protein throughout vertebrates, with no poly-
morphic stops in any sequenced species. In particular, proline at
residue 856 is completely conserved in all known sequences of the
WDR81 protein (Fig. 2C).
The extended genealogy of Family B revealed consanguinity
in several branches of the kindred (Fig. 2D), whose ancestors have
migrated from a village on the Syrian side of the border withHatay,
Turkey, in the early 1950s. Approximately 240 individuals span-
ning seven generation could be ascertained. WDR81 p.P856L was
genotyped in 177 members of the kindred spanning five genera-
tions. A single union of heterozygous carriers, 05-981 3 05-982,
was observed whose children include the affected individuals of
this study. None of the 172 unaffected individuals in the kindred is
homozygous for WDR81 p.P856L. Genetic counseling is in prog-
ress for the 27members of the familywho are heterozygous carriers
of the mutation. The status of WDR81 was evaluated in two dif-
ferent cohorts of the patients with neurodevelopmental/cerebellar
phenotypes for whom the underlying genetic cause is still un-
known. The first cohort consisted of 750 patients with structural
cortical malformations or degenerative neurological disorders. By
using the whole-genome genotyping data based on Illumina Hu-
man 370 Duo or 610K Quad BeadChips, we did not identify any
patient with a cerebellar phenotype or ataxia phenotype to harbor
a homozygous interval ($2.5 cM) surrounding the WDR81 locus.
Exome sequencing of the same group did not reveal any muta-
tions, including compound heterozygous substitutions. In the
second cohort of 58 probands, 12 had cerebellar hypoplasiawith or
without quadrupedal gait. No additional mutations in WDR81
were identified by Sanger sequencing of the entire coding regions.
Characterization of WDR81
WDR81 p.P856L at chr17: 1,630,820 (hg19) lies in exon 1 of
WDR81 isoform 1 (ENST00000409644, NM_001163809.1, NP_
001157281.1), the longest isoform of WDR81, containing 10
exons and encoding 1941 amino acids (Fig. 2A). Proline at this site
was present in all species analyzed (Fig. 2C), including the most
distantly related sequenced ortholog, the Tetraodon nigroviridis
WDR81 protein, which is 47.8% identical and 57.2% similar and
has a distance score of 0.76 compared with the human protein.
WDR81 p.P856L was predicted to be ‘‘damaging’’ (SIFT score, 0) by
SIFT (Ng and Henikoff 2001), ‘‘probably damaging’’ (PSIC score
difference, 2.724) by PolyPhen (Sunyaev et al. 2001), and ‘‘under
evolutionary constraint’’ (GERP score, 5.68) by GERP (Davydov
et al. 2010).
The function ofWDR81 is unknown, but clues can be derived
from its structure. The conserved region of WDR81 that includes
P856 is flanked on the N-terminal side by a BEACH (Beige and
Chediak-Higashi) domain at amino acids 352–607. BEACH proteins
Table 1. Missense variants co-inherited with cerebellar hypoplasia and quadrupedal locomotion in Family Ba
No. and percentage of variant reads
Gene Position (hg19) Ref Var Effect 05-981b 05-982b 05-985c 05-987c
WDR81 chr17: 1,630,820 C T P856L 41 (51%) 33 (52%) 40 (97%) 53 (100%)
MYBBP1A chr17: 4,448,967 G A R671W 29 (52%) 21 (48%) 32 (97%) 29 (100%)
ZNF594 chr17: 5,085,637 G A L639F 39 (54%) 50 (56%) 38 (97%) 37 (100%)
Ref indicates reference nucleotide; Var, variant nucleotide.
aCoding regions, consensus splices-sites, and RNA genes.
bCarrier.
cAffected individual.
WDR81 is associated with CAMRQ2
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have been implicated in membrane trafficking (Wang et al. 2000),
synapse morphogenesis (Khodosh et al. 2006), and lysosomal axon
transport (Lim and Kraut 2009). A BEACH domain is the major
structural feature of neurobeachin, a scaffoldingprotein disrupted in
a patient with autism (Volders et al. 2011). WDR81 p.P856L lies in
amajor facilitator superfamily (MFS) domain, a region characteristic
of solute carrier transport proteins (Saier et al. 1999). The C terminus
ofWDR81 is composedof sixWD-repeats that are likely constituents
of a beta-propeller. Based on analysis by TMpred (www.ch.embnet.
org/software/TMPRED_form.html), WDR81 is a transmembrane
proteinwith sixmembrane-spanningdomains, themostN-terminal
at amino acids 45–66 and the other five at the C terminus of the
protein, between amino acids 980 and 1815 (Fig. 2A). Supporting
the likelihood that WDR81 is a transmembrane protein is the
observation that WDR81 transcript expression is increased in
membrane-associated RNA in contrast to cytoplasmic RNA (4.14
folds, P = 0.03, and 1.78 folds, P = 0.0002 in Gene Expression Om-
nibus [GEO] [http://www.ncbi.nlm.nih.gov/geo/] data setGSE4175)
(Diehn et al. 2006).
In order to assess a possible role for WDR81 in regulating
motor behavior, we evaluated the expression profiles of human
andmouseWDR81/Wdr81 isoform 1 in the brain. HumanWDR81
isoform 1 transcript was expressed in all the tissues evaluated
(Supplemental Fig. 5). In particular, all the brain tissues were pos-
itive for the transcript, with highest levels of expression in the
cerebellum and corpus callosum (Fig. 3A). In the mouse brain at
post-partum day P7, Wdr81 expression was observed in Purkinje
cell layer in the cerebellum (Fig. 3B,C). The cerebellum is a crucial
regulatory center for motor function.
We examined the expression of WDR81 in the context of ex-
pression profiles of the early embryonic mouse brain (GSE8091)
(Hartl et al. 2008). Differentially expressed genes within the day
groups were filtered (one-way ANOVA test Bonferroni-corrected P <
0.001, n = 3611). From these profiles, we identified the subset of
genes whose expression was highly correlated with that ofWDR81
(R > 0.95, n = 670) and then usedDAVID tools (Huang et al. 2009) to
evaluate the predicted functions of this subset of genes. The subset
of genes coexpressed withWDR81 was enriched for those involved
in neuronal differentiation and neuronal projection, axonogenesis,
and cell morphogenesis (Bonferroni-corrected P-values 2.3 3
1011, 1.33 109, and 3.73 109, respectively). Among the genes
coexpressed with WDR81 were those encoding prion protein,
doublecortin (responsible for lissencephaly), and L1CAM (re-
sponsible for MASA syndrome) (Supplemental Table 11).WDR81
is not coexpressed with VLDLR and CA8, raising the possibility
that WDR81 represents a different developmental regulatory
pathway.
Discussion
The identification of genes responsible for human disease has been
greatly facilitated with new technologies, particularly the targeted
enrichment of the genome by solution capture, followed by geno-
mic sequencing (Bilguvar et al. 2010). Despite these advances,
demonstrating the causality for a mutation in the absence of two or
more independent cases remains a challenge. This is particularly
true when multiple variants, none of them with obvious effect on
protein function, cosegregate with the phenotype in the family; the
candidate gene encodes a previously uncharacterized protein with
multiple isoforms, ofwhich the criticalmutation is ononlyone; and
the candidatemutation is amissense. However, unique families and
uncharacterized proteins exist, and precisely because of this reason,
it becomes imperative to fully exploit genetics and genomics ap-
proaches to distinguish the causative mutation.
We describe here the discovery of a mutation associated with
an extremely rare and genetically heterogeneous autosomal re-
cessive phenotype in a unique consanguineous family (Tan 2006).
The putative causative mutation could be distinguished from pre-
viously unknown rare polymorphisms in the same genomic region
by analysis of conservation at all candidate variant sites, by the
presence of polymorphic stops in the critical region of another
candidate gene, and by genotyping ethnically matched unaffected
individuals who would not be expected to carry homozygous mu-
tations at the mutant site. We conclude that the WDR81 p.P856L
mutation is the cause of cerebellar hypoplasia associated with qua-
drupedal locomotion in Family B.
WDR81 is an uncharacterized gene. It shows similarity with
a host of genes, including NSMAF (neutral sphyngomyelinase ac-
tivation associated factor), NBEA (neurobeachin), and LYST (lyso-
somal trafficking regulator). The LYST gene contains HEAT/ARM
repeats, a BEACH domain, and seven WD40 repeats (Ward et al.
2000). Nearly all reported LYST mutations result in protein trun-
cation and lead to Chediak-Higashi syndrome (CHS), which is
characterized by accumulation of giant intracellular vesicles lead-
ing to defects in the immune and blood systems (Rudelius et al.
2006). Two patients with missense LYST mutations have been
reported (Karim et al. 2002). Interestingly, these patients presented
with neurological symptoms without immunological involvement.
The LystIng3618/LystIng3618 mutant mouse harbors a missense mu-
tation in the WD40 domain. Purkinje cell degeneration accom-
paniedby age-dependent impairmentofmotor coordinationwithout
Figure 3. Expression pattern of WDR81 in brain. (A) Expression in hu-
man brain with highest levels in cerebellum and corpus callosum. (B) In
situ hybridization of mouse embryonic brain revealing increased expres-
sion of Wdr81 in purkinje cells and molecular layer of cerebellum. (C ) No
hybridization was observed with the sense probe. (ML) Molecular layer,
(GL) granular layer.
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signs of lysosomal deficiency in immunological organs were charac-
teristics of these animals (Rudelius et al. 2006).
Expression ofWDR81 at high levels in the human cerebellum
and corpus callosum and in the Purkinje cell layer of the mouse
cerebellum is consistent with our observations of major structural
abnormalities in these regions of the brain of affected individuals.
Together, these observations suggest a possible role for WDR81 in
motor behavior. Further work will be required to understand the
normal biological function ofWDR81 and the role of themutation
in causing cerebellar hypoplasia and quadrupedal locomotion.
Genomic analysis of Family B demonstrates that WDR81 is highly
likely to be critical to these developmental processes.
Methods
Human subjects
The institutional review boards of Bilkent, Hacettepe, Baskent,
and Cukurova Universities approved the study (decisions: BEK02,
28.08.2008; TBK08/4, 22.04.2008; KA07/47, 02.04.2007; and21/3,
08.11.2005, respectively). Written informed consent, prepared
according to the guidelines of theMinistry ofHealth in Turkey, was
obtained from all familymembers and control group subjects prior
to the study. A total of 18 subjects participated in MRI scans. Six of
themwere from Family B, including four affected siblings (05-984,
05-986, 05-987, 05-988), one normal female sibling homozygous
for the wild-type allele of the WDR81 p.P856L variant (10-033),
and their carrier father (05-981). The remaining 14 participants
were age- and sex-matched healthy controls. The two male pa-
tients (age,mean6 SD = 37.006 4.24) werematched to sevenmale
controls (age, mean 6 SD = 35.14 6 5.76), and the two female
patients (age, mean 6 SD=27.00 6 4.24) were matched to seven
female controls (age, mean 6 SD = 28.57 6 3.64). Family B mem-
bers were scanned under sedation. For the healthy controls, no
sedation was performed. Sedation was achieved by initial admin-
istration of midazolam (2 mg per subject), which was followed by
propofol (120 mg) and fentanyl (50 mcg) administration in-
travenously. Hypnosis level was adjusted by 20 mg injections
of propofol approximately every 10 min to eliminate somatic re-
sponses such as slight movements. Blood oxygen level and heart
rate were monitored during the entire procedure. Eyelash reflexes
were absent at all times. Neuromuscular blockade was not used.
Next-generation sequencing
NimbleGen 385K microarrays were produced to capture the criti-
cal region at chr17: 82,514–7,257,922 (hg19) using 7464 unique
probes with a total probe length of 4,853,455 bp. Sequence Search
and Alignment by Hashing Algorithm (SSAHA) (Ning et al. 2001)
was used to determine probe uniqueness by NimbleGen (Roche
NimbleGen). Sequence capture was conducted by the NimbleGen
facility using 25 mg of input DNA. Captured DNA samples were
subjected to standard sample preparation procedures for 454 GS
FLX sequencing with Titanium series reagents. Four full 454 GS
FLX runs were conducted for two affected individuals (05-985, 05-
987) and their unaffected obligate carrier parents (05-981 father,
05-982 mother). Sequence data were initially mapped to human
genome reference sequence and annotated using the GSMapper
software package (Roche). Fold enrichment of the target regionwas
calculated with the formula +REMTrm/STrm: +RMG/SG as de-
scribed previously (REMTrm, number of reads mapped to target
region; STrm, size of target region; RMG, number of reads mapped
outside of the target region; SG, size of human genome) (Rehman
et al. 2010). Variants were identified with ALLDiff and more strin-
gentHCDiff approaches (Hedges et al. 2009). Annotation of variants
was made by GSMapper software using the refGene table of the
University of California, Santa Cruz (UCSC) Genome Browser
(Fujita et al. 2010). Ensembl 62 genome annotation data for hg19
human genome assemblywere extracted using the BIOMARTdata-
mining tool for further analysis of intronic and intergenic variants
in terms of hypothetical genes and splicing variants (Flicek et al.
2011). Novel variants were reported based on the SNPs included
in the reference SNP database. For Illumina sequencing, a total of
6,184,539-bp-long unique probes were designed to target a 9-Mb
genomic region spanning the disease locus (chr17:0–9,059,276;
hg19) using a custom NimbleGen HD2 2.1M sequence capture
microarray. Another affected individual was sequenced with the
Illumina Genome Analyzer IIx. Illumina sequence data were map-
ped to the reference genome using MAQ tools (Li et al. 2008), and
single nucleotide variants were determined with Samtools (Li et al.
2009). To determine indels, data were mapped with BWA (Li and
Durbin 2010) and analyzed with Samtools. Sequence data were
visually analyzed using the Integrative Genomics Viewer (IGV)
(Robinson et al. 2011).
Array based genotyping
We conducted Illumina 300 Duo v2 BeadChip for two affected
individuals (05-984, 05-987) according to the manufacturer’s rec-
ommendations (Illumina). The image data were normalized, and
the genotypes were called using data analysis software (Bead Stu-
dio, Illumina). Sex, inbreeding, and sibship were confirmed.
The Mendelian compatibility of sequence variants was analyzed
with PLINK (Purcell et al. 2007).
DNA sequencing
Confirmation of novel variants identified by next-generation se-
quencing was done with conventional capillary sequencing. The
Primer3 software (Rozen and Skaletsky 2000) was used to design
PCR primers for the amplification of candidate variants (Supple-
mental Table 12). Products were analyzed via gel electrophoresis
and were sequenced using forward and reverse primers on an ABI
3130 XL capillary sequencing instrument (Applied Biosystems).
Sanger sequence trace files were analyzed with the CLCBio Main
Workbench software package (CLCBio Inc.).
Population screening
To distinguish the disease-causing variant from novel polymor-
phisms, a population screening approach was conducted for each
candidate variant. Allele-specific PCR (AS-PCR) and restriction frag-
ment length polymorphism (RFLP) analyses were performed (Sup-
plemental Table 12) on 1098 chromosomes from a healthy control
population. In addition, the first-, second-, and third-degree rela-
tives of the affected family, amounting to 177 individuals, were
sampled for genotype analysis. Sanger sequencingwas performed to
confirm all of the variants detected in the normal population using
the above-mentioned methods. Racial distribution of the control
groupwas100%Caucasian, including22%fromsoutheasternTurkey.
Quantitative real-time RT-PCR analysis of WDR81 expression
First-strand cDNA was prepared from multi-tissue RNA panels
(Clontech: 636567, 636643; Agilent: 540007, 540117, 540137,
540157, 540053, 540005, 540143, 540135) with RevertAid kit and
random hexamer primers (Fermentas; K1622) after DNase I (Fer-
mentas; EN0521) digestion. The PCR primers located in exon 1
and flanking the mutation site were designed using Primer3 soft-
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ware (Supplemental Table 13; Rozen and Skaletsky 2000). SYBR
Green real-time PCR were realized according to standard protocols
(BioRad; 170-8882) with 100% PCR efficiency. Each assay included
minus RT and nontemplate controls. Ct values were normalized to
GAPDH as an internal control. The data were analyzed using the
Pfaffl method (Pfaffl 2001).
In situ hybridization
In order to examine the specific expression pattern ofWdr81 gene
in the mouse brain, probes that contain the mutated region in
human patients were prepared by PCR amplification of the region
frommouse genomic DNA and subsequent cloning into plasmids.
The riboprobes were synthesized by using Dig-labeled NTPs, and
in situ hybridization experiments were performed as described
(Tekinay et al. 2009). The Animal Ethics Committee of Bilkent
University approved procedures for the tissue extraction and for in
situ hybridization tests. Animals were group housed in a 12-h dark,
12-h light cycle. Embryo and P7 brain sections were prepared as
described (Gong et al. 2003). Twenty-micrometer sagittal sections
were takenwith a cryostat (Leica). The antisense probewas prepared
by PCR amplification from the mouse genomic DNA and sub-
sequent cloning into pCR4-TOPO vector (Invitrogen). A modified
version of pSK vector was used for cloning the sense probe of the
same region. Digoxigenin (Dig)-labeled riboprobe was transcribed
using Dig-NTP in the transcription reaction. Riboprobes were pu-
rified with Mini Quick Spin DNA columns (Roche) prior to hy-
bridization. Sections were incubated at 60°C overnight in hybrid-
ization buffer containing 50% formamide, 53 SSC, 53Denhardt’s
reagent, 50 mg/mL heparin, 500 mg/mL herring sperm DNA, and
250mg/mLyeast tRNA.Hybridized sectionswerewashed for 90min
with 50% formamide and 23 SSC at 60°C. Probes were detected
with anti-Dig Fab fragments conjugated to alkaline phosphatase
and NBT/BCIP substrate mixture (Tekinay et al. 2009).
Bioinformatics analyses
Homozygosity mapping analysis was performed using Homo-
zygosityMapper software (Seelow et al. 2009). SIFT (Ng andHenikoff
2001) and PolyPhen (Sunyaev et al. 2001) tools were used to pre-
dict the functional impact of the variants. Genomic Evolutionary
Rate Profiling (GERP) scores for each variant were obtained from
the UCSC Genome Browser allHg19RS_BW track (Davydov et al.
2010). The PFAM protein domain search module of CLCMain
Workbench V5.0 (CLCBio, Inc.) and ScanProsite (Gattiker et al.
2002) toolswere used to predict domains and possible effects of the
variant on protein product. Membrane spanning domains were
predicted using TMpred software (www.ch.embnet.org/software/
TMPRED_form.html). Homology searches were performed with
CLCMain Workbench using appropriate modules (reference se-
quence accession codes for WDR81 orthologs are Ailuropoda
melanoleuca, XP_002918082; Callithrix jacchus, XP_002747874;Danio
rerio, XP_001921778; Equus caballus, XP_001502383; Gallus gallus,
XP_415806;Monodelphis domestica, XP_001371487;Mus musculus,
NP_620400; Oryctolagus cuniculus, XP_002718930; Pan troglodytes,
XP_523527; Pongo abelii, XP_002826860; Rattus norvegicus, NP_
001127832; Sus scrofa, XP_003131868; Taeniopygia guttata, XP_
002194363; Tetraodon nigroviridis, CAG08933; Xenopus [Silurana]
tropicalis, XP_002937192). Published microarray data sets of E9.5,
E11.5, and E13.5 mouse brain tissue (GSE8091) were downloaded
from the GEO database (http://www.ncbi.nlm.nih.gov/projects/
geo/query/acc.cgi) (Hartl et al. 2008) and processed with GeneSpring
GX V11.1 software (Agilent Technologies). Data sets were grouped
within day groups, and standard quality control and filtering
analysis were performed (http://www.chem.agilent.com/cag/bsp/
products/gsgx/manuals/GeneSpring-manual.pdf). Differentially ex-
pressed genes within the day groups were filtered using a one-way
ANOVA test (Bonferroni-corrected P < 0.001). Genes that corre-
lated with Wdr81 (R = 0.95  1.0) were obtained using the ‘‘Find
Similar Entity Lists’’ module of the software. Functional annota-
tion clustering was performed using the obtained gene list by
DAVID tools (Huang et al. 2009).WDR81differential expression in the
GEO data sets was further investigated using the NextBio System,
a web-based data-mining engine (Kupershmidt et al. 2010), and the
GSE4175 (Diehn et al. 2006) data set was selected as a significant dif-
ference in membrane-associated RNA versus cytoplasmic RNA com-
parisons. Ensembl identifiers of the candidate genes and transcripts
are as follows: WDR81 [ENSG00000167716; ENST00000409644],
MYBBP1A [ENSG00000132382; ENST00000254718], and ZNF594
[ENSG00000180626; ENST00000399604].
MRI data acquisition and structural analysis procedures
MRI data were acquired using a three Tesla scanner (Magnetom
Trio, Siemens AG)with a 12-channel phase-array head coil. A high-
resolution T1-weighted three-dimensional (3D) anatomical-vol-
ume scan was acquired for each participant (single-shot turbo
flash; voxel size = 13 13 1mm3; repetition time [TR] = 2600msec;
echo time[TE]= 3.02msec; flip angle = 8°; field of view [FOV] = 2563
224 mm2; slice orientation = sagittal; phase encode direction =
anterior-posterior; number of slices = 176; acceleration factor
[GRAPPA] = 2). DTI datawere acquired using a single-shot spin-echo
EPI with a parallel imaging technique GRAPPA (acceleration factor
2). The sequencewasperformedwith30 gradient directions, and the
diffusion weighting b-factor was set to 800 sec/mm2 (TR, 6400
msec; TE, 88 msec; in-plane resolution, 1 mm 3 1 mm; slice thick-
ness, 3.0 mm; 50 transverse slices; base resolution, 128 3 128).
Structural analyses were performed with the Freesurfer image anal-
ysis package (http://surfer.nmr.mgh.harvard.edu/). The analyses
involved intensity normalization, removal of nonbrain tissue, sub-
cortical segmentation (Fischl et al. 2002), and identification of the
white matter/gray matter boundary upon which cortical re-
construction and volumetric parcellation were performed. The
cortexwas then registered to a spherical atlas andparceled into units
according to the gyral and sulcal structure based on the Desikan-
Kilinay Atlas (Desikan et al. 2006) and theDestrieuxAtlas (Destrieux
et al. 2010). Next, using the same software, we performed mor-
phometric analyses of cortical thickness, mean curvature, surface
area, and volume for each unit of parcellation and computed the
group differences. Significant differences between the groups are
determined using two-tailed unpaired t-tests at an alpha level of
0.05. Fiber tracking was performed in MedINRIA (Toussaint et al.
2007). Fibers with FA < 0.3 were excluded from the analysis. Region
of interests (ROIs) were drawn manually over cross-sections of su-
perior, middle, and inferior cerebellar peduncles, using the MRI
Atlas of HumanWhiteMatter as a reference (Oishi et al. 2010). ROIs
were drawn at approximately corresponding locations for the pa-
tients and healthy controls. Fiber tracts were first limited to pass
through these ROIs and were then subsequently refined using a re-
cursive tracking technique (Toussaint et al. 2007). T1-weighted
images were coregistered with DWI data using FSL (Smith et al.
2004;Woolrich et al. 2009). Final tractsweremanuallyoverlaidonto
high-resolution T1-weighted images for illustration purposes.
Data access
Sequence data of the homozygous region has been deposited at the
DNAData Bank of Japan (DDBJ; http://www.ddbj.nig.ac.jp/) under
accession no. DRA000432. SNP genotype data have been deposited
at the European Genome-Phenome Archive (EGA; http://www.
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ebi.ac.uk/ega/), which is hosted at the EBI, under accession no.
EGAS00000000099.
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